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This thesis work was centered on detecting cervical precancer using near-infrared (NIR) 
Raman spectroscopy. A rapid and portable NIR Raman spectroscopy system coupled 
with a specially designed ball lens fiber-optic Raman probe was successfully 
developed for in vivo tissue diagnosis and characterization. Firstly, Raman 
measurement was conducted on biopsied cervical tissues to test the feasibility of NIR 
Raman spectroscopy for the detection of cervical precancer. A good classification with 
an accuracy of 92.5% between benign and dysplasia (i.e., LGSILs and HGSILs) tissues 
was achieved ex vivo, encouraging the extension of our ex vivo work to in vivo study. 
Monte Carlo simulation method was employed to evaluate the performance (i.e., 
collection efficiency and depth-selectivity) of the ball lens fiber-optic Raman probe 
designs with various configurations (i.e., the diameter and refractive index of the ball 
lens). We demonstrated that the ball-lens NIR Raman spectroscopy developed is able 
to acquire good-quality Raman spectra of cervix in vivo. We demonstrated for the first 
time that NIR Raman spectroscopy in the high wavenumber (HW) region has the 
potential for the diagnosis of cervical precancer using our in-house developed Raman 
system and exhibits comparable diagnostic performance as Raman spectroscopy in 
fingerprint region. We also demonstrated that combining NIR autofluorescence and 
Raman spectroscopy can further improve the diagnosis of cervical precancer. We also 
evaluated the performance of ultraviolet/visible autofluorescence and diffuse 
reflectance spectroscopy in the characterization of cervical dysplasia and finally 
combined them with NIR Raman spectroscopy. It was found that optimal diagnosis of 
cervical precancer could be achieved by combining all these three different 
spectroscopic techniques together. The work completed in this thesis promotes some 
future directions to further optimize the diagnosis and detection of cervical precancer 
  vii
in vivo using Raman spectroscopy. One of the major directions is to develop robust 
software integrated with Raman spectral data preprocessing, statistical modeling for 
real-time in vivo tissue diagnosis and characterization. Another major direction is to 
develop fluorescence image-guided Raman spectroscopic diagnosis system to further 

















List of Figures 
Figure 1.1 Energy transition diagram of vibrational spectroscopy. V is the vibrational 
quantum number. ...................................................................................................... 4 
Figure 2.1 Schematic of the NIR Raman spectroscopy system. BPF: Band Pass Filter; 
LPF: Long Pass Filter. ............................................................................................ 42 
Figure 2.2 The interface of Raman data acquisition program developed using 
LabVIEW and Matlab. ........................................................................................... 43 
Figure 2.3 The averaged Raman spectra±1SD of: (a) benign=24, (b) LGSILs=34, and 
(c) HGSILs=22. Line: averaged spectrum; Grey band: ±1SD. .............................. 47 
Figure 2.4 The averaged normalized Raman spectra of: (a) benign and LGSILs, (c) 
benign and HGSILs and (e) LGSILs and HGSILs. The corresponding difference 
spectra are: (b) LGSILs−benign, (d) HGSILs−benign, and (f) HGSILs−LGSILs. 48 
Figure 2.5 Scatter plots of the intensity ratio of Raman bands: (a) benign vs LGSILs, 
I849/I1004; (b) benign vs HGSILs, I932/I1449 vs I1339/I1658; (c) benign vs HGSILs, 
I932/I1449 vs I1449/I1658; (d) LGSILs vs HGSILs, I932/I1254 vs I932/I1658; (e) LGSILs vs 
HGSILs, I932/I1449 vs I1004/I1658; Simple straight-line diagnostic function can 
achieve sensitivities and specificities of: (a) 73.5% (25/34) and 79.2% (19/24); (b) 
100.0% (22/22) and 66.7% (16/24); (c) 100.0% (22/22) and 70.8% (17/24); (d) 
68.2% (15/22) and 97.1% (33/34); (e) 63.6% (14/22) and 100.0% (34/34), 
respectively. Key: (○ in black) benign; (Δ in blue) LGSILs; (☆ in red) HGSILs.. 49 
Figure 2.6 Examples of the first six diagnostically significant PCs with p-value<0.1: (a) 
PC1, (b) PC2, (c) PC4, (d) PC5, (e) PC6 and (f) PC11. ........................................ 51 
Figure 2.7 Scatter plots of the diagnostically significant PC scores for benign and 
LGSILs tissues: (a) PC2 vs PC5, (b) PC2 vs PC11 (c) PC4 vs PC5, (d) PC5 vs 
PC11. LGSILs can be discriminated from benign tissues by straight-line diagnostic 
functions: (a) PC5 = −0.61×PC2+0.2, (b) PC11 = 2.1×PC2+0.41, (c) PC5 = 
0.76×PC4+0.95 and (d) PC11 = −1.68×PC5+0.29. The corresponding sensitivities 
and specificities are: (a) 79.4% (27/34) and 75.0% (18/24), (b) 76.5% (26/34) and 
70.8% (17/24), (c) 85.3% (29/34) and 70.8% (17/24), and (d) 79.4 % (27/34) and 
75.0 % (18/24), respectively. Key: (○ in black) benign; (Δ in blue) LGSILs. ....... 52 
Figure 2.8 Scatter plots of the diagnostically significant PC scores for benign and 
HGSILs tissues: (a) PC1 vs PC11, (b) PC2 vs PC4 (c) PC2 vs PC11, (d) PC4 vs 
PC5. HGSILs can be discriminated from benign tissues by straight-line diagnostic 
functions: (a) PC11 = 1.39×PC1+0.31, (b) PC4 = −0.19×PC2+0.14, (c) PC11 = 
1.11×PC2−0.34 and (d) PC5 = 1.03×PC4+0.6. The corresponding sensitivities and 
specificities are: (a) 81.8% (18/22) and 70.8% (17/24), (b) 72.7% (16/22) and 
79.2% (19/24), (c) 86.4% (19/22) and 70.8% (17/24), and (d) 81.8% (18/22) and 
66.7% (16/24), respectively. Key: ( ☆○ in black) benign; (  in red) HGSILs. ........ 53 
Figure 2.9 Scatter plots of the diagnostically significant PC scores for LGSILs and 
HGSILs tissues: (a) PC2 vs PC5, (b) PC2 vs PC11 (c) PC4 vs PC5, (d) PC4 vs 
PC11. HGSILs can be discriminated from LGSILs by straight-line diagnostic 
functions: (a) PC5 = −2.5×PC2−0.08, (b) PC11 = 1.09×PC2−0.14, (c) PC5 = 
−0.78×PC4+0.53 and (d) PC11 = 1.24×PC4−0.21. The corresponding sensitivities 
and specificities are: (a) 86.4% (19/22) and 79.4% (27/34), (b) 86.4% (19/22) and 
79.4% (27/34), (c) 63.6% (14/22) and % 85.3(29/34), and (d) 86.4% (19/22) and 
79.4% (27/34), respectively. Key: (Δ in blue) LGSILs; (☆ in red) HGSILs. ........ 53 
Figure 2.10 Scatter plot of two LD function weights for benign, LGSILs and HGSILs 
tissues tested with leave-one-out cross-validation. Key: (○ in black) benign; (Δ in 
  ix
blue) LGSILs; (☆ in red) HGSILs. ........................................................................ 55 
Figure 2.11 Two-dimensional ternary plot of the posterior probabilities belonging to 
benign, LGSILs and HGSILs, respectively, using the PCA-LDA-based spectral 
classification with leave-one spectrum-out, cross-validation method. Each vertex 
of the triangle represents a 100% confidence that the tissue is benign, LGSILs or 
HGSILs. Key: (○ in black) benign; (Δ in blue) LGSILs; (☆ in red) HGSILs. ...... 55 
Figure 2.12 Three-dimensional view of the ROC surface calculated from the posterior 
probabilities belonging to benign, LGSILs and HGSILs with a VUS of 0.815. ... 56 
Figure 2.13 Reference Raman spectra of glycogen, collagen, DNA, oleic acid and 
cholesterol. ............................................................................................................. 57 
Figure 2.14 Comparison of tissue spectrum and fitted spectrum with reference spectra: 
(a) benign and (b) dysplasia. Residue is produced by subtracting fitted spectrum 
from tissue spectrum. ............................................................................................. 58 
Figure 2.15 Mean normalized fitting coefficients with 1±SD for component 
biochemicals, including glycogen, collagen, oleic acid, DNA and cholesterol for 
benign and dysplasia tissues. ................................................................................. 59 
Figure 3.1 Schematic of the developed dispersive Raman spectroscopy. .................... 69 
Figure 3.2 Raman spectra of human biopsied samples under different excitation lights 
(reprinted from Ref. [4]). ....................................................................................... 72 
Figure 3.3 System schematic of dispersive spectrographs: (a) Czerny-Turner 
configuration; (b) Holographic transmission grating-based configuration. ........... 75 
Figure 3.4 Schema of: (a) FI-CCD and (b) BI-CCD .................................................... 76 
Figure 3.5 Spectral response function of front-illuminated CCD and Back-thinned 
CCD (back-illuminated) (reprinted from Ref. [210]). ........................................... 77 
Figure 3.6 Schematic of three different fiber-optic Raman probe designs. CPC: 
compound parabolic concentrator ((a): adapted from Ref. [220]; (b): adapted from 
Ref. [221]; (c): reprinted from Ref. [222]). ........................................................... 79 
Figure 3.7 Schematic of two fiber-optic Raman probe designs. CF: collection fiber; EF: 
excitation fiber; BPF: band pass filter; LPF: long pass filter ((a): adapted from Ref. 
[99]; (b): reprinted from Ref. [211]). ..................................................................... 80 
Figure 3.8 Schematic of fiber-optic Raman probe with a ball lens (reprinted from Ref. 
[213]). ..................................................................................................................... 81 
Figure 3.9 Schematic of a fiber-optic Raman probe (adapted from Ref. [67]). ........... 82 
Figure 3.10 Schematic of the Raman probe design. CL: collimating Lens; FL: 
Focusing Lens; BPF: Band Pass Filter; LPF: Long Pass Filter; DM: Dichroic 
Mirror; RM: Reflection Mirror; BL: Ball Lens; EP: Epithelium; ST: Stroma. ..... 85 
Figure 3.11 The 785-nm excitation light distributions along the tissue depth and radial 
directions in tissue using the Raman probe designs with different refractive indices 
of the ball lenses (n= 1.46, 1.51, 1.63, 1.76 and 1.83). .......................................... 89 
Figure 3.12 The 785-nm excitation light distributions along the tissue depth using the 
Raman probe designs with different refractive indices of the ball lenses (n=1.46, 
1.51, 1.63, 1.76 and 1.83). ..................................................................................... 90 
Figure 3.13 Distributions of the Raman photons collected from different tissue depths 
using the Raman probe designs with different refractive indices of the ball lens 
(n=1.46, 1.51, 1.63, 1.76 and 1.83). ....................................................................... 91 
Figure 3.14 Depth-resolved Raman photons collected from different tissue depths 
using the Raman probe designs with different refractive indices of the ball lens 
(n=1.46, 1.51, 1.63, 1.76 and 1.83). Note that for comparison purpose, the 
depth-resolved Raman intensity profiles with different refractive indices of the ball 
lens have been vertically shifted to different intensity levels. ............................... 92 
  x
Figure 3.15 Collection efficiency of the Raman probe as a function of the refractive 
index of the ball lens. ............................................................................................. 93 
Figure 3.16 The 785-nm excitation light distributions in tissue using the Raman probe 
designs with different diameters of the ball lens (Φ=1, 2, 3, 5, 8 and 10 mm). ..... 94 
Figure 3.17 The 785-nm excitation light distribution along the tissue depth using the 
Raman probe designs with different diameters of the ball lens (Φ=1, 2, 3, 5, 8 and 
10 mm). .................................................................................................................. 95 
Figure 3.18 Distributions of the origins of the Raman photons collected from tissue 
using the Raman probe designs with different diameters of ball lenses (Φ=1, 2, 3, 
5, 8 and 10 mm). .................................................................................................... 96 
Figure 3.19 Depth distribution of the origins of the Raman photons collected from 
tissue using the Raman probe designs with different diameters of the ball lens 
(Φ=1, 2, 3, 5, 8 and 10 mm). .................................................................................. 96 
Figure 3.20 The simulated performance of the probe design based on various 
combinations of ball lens diameters (i.e., 1, 2, 3, 5, 8 and 10 mm) and refractive 
indices (i.e., 1.46, 1.51, 1.63, 1.76 and 1.83): (a) collection efficiency; (b) 
proportion of the Raman photons from the epithelium to the total collected Raman 
photons from the tissue surface. ............................................................................. 98 
Figure 3.21 (a) Collection efficiency of the Raman probe as a function of probe-tissue 
distances; (b) Percentage of the Raman signal collected from the epithelium layer 
to the overall Raman signal from the entire epithelial tissue. The refractive index 
and the diameter of the ball lens are 1.83, and 3 mm, respectively, in Raman probe 
design. .................................................................................................................... 99 
Figure 3.22 Raman spectra acquired from chicken muscle and fat tissue, as well as 
from the two-layer tissue phantoms with the muscle tissue thickness of 0.3, 1.2, 
2.1, 3 and 3.9 mm, respectively. Spectra: (a) fat tissue; (b)-(f): two-layer tissue 
phantoms with the muscle tissue layer of thickness of 0.3, 1.2, 2.1, 3.0 and 3.9 mm, 
respectively, overlaying on a fat tissue layer (thickness of 5 mm); (g) muscle tissue. 
Note that all tissue Raman spectra are acquired with an integration of 1 s under the 
785-nm excitation power of 1.5 W/cm2. The dotted and solid vertical lines 
indicated in Raman spectra stand for the distinctive Raman peaks originating from 
the muscle and fat chicken tissue, respectively. ................................................... 100 
Figure 3.23 Raman peak intensities at 1004 and 1745 cm-1 as a function of thickness 
ratios of the muscle tissue layer to the fat tissue in a two-layer tissue phantom. 101 
Figure 4.1 (a) Comparison of mean in vivo HW Raman spectra1SD of normal (n=46) 
and precancer (n=46) cervical tissue. (b) Difference spectrum1SD difference 
between precancer (n=46) and normal cervical tissue (n=46). Note that the mean 
in vivo HW Raman spectrum of normal tissue was shifted vertically for better 
visualization (Fig. 4.1(a)); the shaded areas indicate the respective standard 
deviations. ............................................................................................................ 108 
Figure 4.2 The first five principal components (PCs) accounting for about 88% of the 
total variance calculated from in vivo HW Raman spectra of cervical tissue 
(PC1-49.6%, PC2-21.7%, PC3-10.9%, PC4-4.7%, and PC5-1.6%). .................. 109 
Figure 4.3 Scatter plots of the diagnostically significant PCs derived from in vivo HW 
Raman spectra of normal and precancer cervical tissue: (a) PC1 vs PC4; (b) PC1 
vs PC9; (c) PC4 vs PC9. The dotted lines (PC4 = −0.57 PC1 + 0.19; PC9 = 0.96 
PC1 + 0.12; PC9 = 0.62 PC4 − 0.08) as diagnostic algorithms classify precancer 
from normal with sensitivities of 63.0% (29/46), 89.1% (41/46) and 73.9% (34/46); 
specificities of 87.0% (40/46), 84.8% (39/46) and 87.0% (40/46), respectively. 
circle (○): Normal; triangle (▲): Precancer. ........................................................ 110 
  xi
Figure 4.4 Scatter plot of the posterior probability of belonging to the normal and 
precancer cervical tissues using the PCA-LDA technique together with leave-one 
patient-out, cross-validation method. The separate line yields a diagnostic 
sensitivity of 93.5% (43/46) and specificity 97.8% (45/46), for identifying 
precancer from normal cervical tissue. circle (○): Normal; triangle (▲): Precancer.
 .............................................................................................................................. 111 
Figure 4.5 Receiver operating characteristic (ROC) curve of discrimination results for 
in vivo HW Raman spectra of cervical tissue using PCA-LDA algorithms together 
with leave-one patient-out, cross-validation method. The integration area under the 
ROC curve is 0.98, illustrating the efficacy of PCA-LDA algorithms for tissue 
classification. ....................................................................................................... 111 
Figure 5.1 (a) Mean in vivo raw Raman spectra (combined Raman and NIR AF spectra) 
± 1SD; (b) Mean in vivo NIR AF spectra (5th-polynomials) ± 1SD; and (c) Mean in 
vivo Raman spectra (background-subtracted) ± 1SD from normal (n=46) and 
precancer (n=46) cervical tissue, respectively. .................................................... 122 
Figure 5.2 Examples of the diagnostically significant principal components (PCs) 
calculated from (a) raw Raman spectra (PC3, 4.8%; PC6, 1.5%; PC7, 0.4%;), (b) 
NIR autofluorescence spectra (PC3, 3.2%; PC4, 2.5%; PC5, 1.7%;) and (c) Raman 
spectra (PC2, 7.5%; PC3, 4.5%; PC7, 0.3%), respectively. ................................. 125 
Figure 5.3 Correlations between the diagnostically significant PCs scores for normal 
and precancer cervical tissue classification: (a) raw Raman spectra, PC3 vs PC6, 
(b) NIR AF spectra, PC3 vs PC5, (c) Raman spectra, PC3 vs PC7. The separation 
lines (PC6 = 0.38×PC3+0.04; PC5 = 0.36×PC3+0.11; PC7 = −3.21×PC3−0.29) as 
diagnostic algorithms separate precancer from normal cervical tissue with 
sensitivities of 84.8% (39/46), 80.4% (37/46) and 87.0% (40/46); specificities of 
84.8% (39/46), 73.9% (34/46) and 78.3% (36/46) using the three spectral datasets 
of raw Raman spectra (combined NIR AF and Raman spectra), NIR AF and 
Raman, respectively. ............................................................................................ 126 
Figure 5.4 Scatter plots of the posterior probability of belonging to normal and 
precancer categories calculated from the datasets of (a) combined NIR AF and 
Raman, (b) NIR AF, and (c) Raman spectra, respectively, using the 
PCA-LDA-based spectral classification with the leave-one patient-out, 
cross-validation method. The corresponding sensitivity, specificity and accuracy 
are: (a) 93.5% (43/46), 95.7% (44/46), and 94.6% (87/92); (b) 93.5% (43/46), 
87.0% (40/46), and 90.2% (83/92); (c) 91.3% (42/46), 95.7% (44/46), and 93.5% 
(86/92), respectively, using the combined NIR AF and Raman, NIR AF, and 
Raman techniques. ............................................................................................... 127 
Figure 5.5 Receiver operating characteristic (ROC) curves of discrimination results for 
the combined NIR AF and Raman spectra, NIR AF, and Raman spectra, 
respectively. The integration areas under the ROC curves are 0.996, 0.945, and 
0.972, respectively, for the combined NIR AF and Raman, NIR AF, and Raman 
techniques. ........................................................................................................... 128 
Figure 6.1 Schematic of the trimodal spectroscopy system. BPF1: 785-nm band pass 
filter; BPF2: 405-nm band pass filter; LPF1: 800-nm long pass filter; LPF2: 
405-nm long pass filter; ....................................................................................... 137 
Figure 6.2 The mean normalized fluorescence spectra of benign (n=24), LGSILs 
(n=34) and HGSILs (n=22): (a) non-corrected fluorescence, (b) intrinsic 
fluorescence 1, (c) intrinsic fluorescence 2, and (d) intrinsic fluorescence 3. ..... 142 
Figure 6.3 Examples of the first five diagnostically significant principal components 
(PCs) with p-value<0.1: (a) PC1, PC3, PC4, PC5 and PC12 for non-corrected 
  xii
fluorescence; (b) PC1, PC2, PC5, PC11 and PC12 for intrinsic fluorescence 1; (c) 
PC1, PC2, PC5, PC11 and PC12 for intrinsic fluorescence 2; (d) PC1, PC2, PC5, 
PC11 and PC12 for intrinsic fluorescence 3. ....................................................... 143 
Figure 6.4 Scatter plots of two LD function weights for benign (n=24), LGSILs (n=34) 
and HGSILs (n=22) tissues tested with leave-one-out cross-validation: (a) 
non-corrected fluorescence; (b) intrinsic fluorescence 1; (c) intrinsic fluorescence 
2; (d) intrinsic fluorescence 3. Key: (○ in black) benign; (Δ in blue) LGSILs; (☆ in 
red) HGSILs. ........................................................................................................ 144 
Figure 6.5 Two-dimensional ternary plots of the posterior probabilities of each 
spectrum belonging to benign (n=24), LGSILs (n=34) and HGSILs (n=22), 
respectively, using the PCA-LDA-based spectral classification with leave-one-out, 
cross-validation method based on the four different dataset: (a) non-corrected 
fluorescence; (b) intrinsic fluorescence 1; (c) intrinsic fluorescence 2; (d) intrinsic 
fluorescence 3. Each vertex of the triangle represents a 100% confidence that the 
tissue is benign, LGSILs or HGSILs. Key: (○ in black) benign; (Δ in blue) LGSILs; 
(☆ in red) HGSILs. .............................................................................................. 145 
Figure 6.6 Three-dimensional view of the ROC surface calculated from the posterior 
probabilities belonging to benign, LGSILs and HGSILs based on the four different 
datasets: (a) non-corrected fluorescence; (b) intrinsic fluorescence 1; (c) intrinsic 
fluorescence 2; (d) intrinsic fluorescence 3. The corresponding volumes under 
ROC surface are: 0.675, 0.754, 0.772 and 0.74, indicating the rank of the 
diagnostic performance based on different datasets. ........................................... 147 
Figure 6.7 Mean reflectance spectra of benign (n=24), LGSILs (n=34) and HGSILs 
(n=22): (a) non-normalized spectra; (b) normalized spectra. Black: benign; Blue: 
LGSILs; Red: HGSILs. ........................................................................................ 148 
Figure 6.8 Examples of the first four diagnostically significant principal components 
(PCs) with p-value<0.1: (a) PC1, PC4, PC5 and PC6 for non-normalized spectral 
dataset; (b) PC1, PC3 PC4 and PC5 for normalized spectral dataset. ................. 149 
Figure 6.9 Scatter plots of two linear discrimination function weights for benign 
(n=24), LGSILs (n=34) and HGSILs (n=22) tissues tested with leave-one-out 
cross-validation: (a) non-normalized spectral dataset; (b) non-normalized spectral 
dataset; Key: (○ in black) benign; (Δ in blue) LGSILs; (☆ in red) HGSILs. ...... 150 
Figure 6.10 Two-dimensional ternary plots of the posterior probabilities belonging to 
benign, LGSILs and HGSILs, respectively, using the PCA-LDA-based spectral 
classification with leave-one-out, cross-validation method based on the dataset: (a) 
non-normalized spectra; (b) normalized spectra. Each vertex of the triangle 
represents a 100% confidence that the tissue is benign, LGSILs or HGSILs. Key: 
(○ in black) benign; (Δ in blue) LGSILs; (☆ in red) HGSILs. ............................ 150 
Figure 6.11 Color coded prediction results by the PCA-LDA model based on 
non-normalized and normalized spectral datasets. column 1: histology 
classification; column 2: non-normalized reflectance; column 3: normalized 
reflectance. Each grid represents one case. Blue: benign; Green: LGSILs; Brown: 
HGSILs. ............................................................................................................... 152 
Figure 6.12 Three-dimensional view of the ROC surface calculated from the posterior 
probabilities belonging to benign, LGSILs and HGSILs based on the datasets: (a) 
non-normalized reflectance spectra; (b) normalized reflectance spectra. The 
corresponding volumes under ROC surface are: 0.773 and 0.78, indicating the 
rank of the diagnostic performance based on the two different datasets. ............ 153 
Figure 6.13 Color coded prediction results by combining intrinsic fluorescence 2, 
normalized reflectance and Raman. column 1: histology prediction; column 2: 
  xiii
fluorescence prediction; column 3: reflectance prediction; column 4: Raman 
prediction; column 5: product-determined prediction; column 6: max-determined 
prediction; column 7: mean-determined prediction; column 8: majority-determined 
prediction; Blue: benign; Green: LGSILs; Brown: HGSILs; Orange: disagreement 






















































List of Tables 
Table 2.1 Statistics of tissue samples and Raman measurements. ............................... 39 
Table 2.2 The mean scores±1SD for benign, LGSILs and HGSILs tissue groups, 
p-value, percent of total variance of the first six diagnostically significant PCs. .. 51 
Table 2.3 Classification results of Raman-prediction for the three cervical tissue 
groups yielded by the PCA-LDA diagnostic algorithms tested with leave-one-out 
cross-validation method. ........................................................................................ 56 
Table 2.4 Tentative assignments of major Raman vibration bands present in the Raman 
spectra of cervical tissues [5, 51, 108, 189]. .......................................................... 62 
Table 3.1 Specification of BTK 785-nm diode laser. ................................................... 73 
Table 3.2 Optical properties of the two-layer epithelial tissue model for MC 
simulations [191, 229, 240]. .................................................................................. 88 
Table 6.1 Classification results of fluorescence-prediction for the three cervical tissue 
groups yielded by the PCA-LDA diagnostic algorithms tested with leave-one-out 
cross-validation method. ...................................................................................... 146 
Table 6.2 The sensitivity, specificity and accuracy of fluorescence-prediction for the 
three cervical tissue groups yielded by the PCA-LDA diagnostic algorithms tested 
with leave-one-out cross-validation method. ....................................................... 146 
Table 6.3 Reflectance-prediction for the three cervical tissue groups yielded by the 
PCA-LDA diagnostic algorithms tested with leave-one-out cross-validation 
method. ................................................................................................................. 151 
Table 6.4 The sensitivity, specificity and accuracy of reflectance-prediction for the 
three cervical tissue groups yielded by the PCA-LDA diagnostic algorithms tested 











List of Abbreviations 
AF = autofluorescence  
ANOVA = analysis of variance 
ANSI = American National Standards Institute 
BCC = basal cell carcinoma 
BFL = back focal length 
BP = band-pass 
BI-CCD = back-illuminated CCD 
CART = classification and regression tree 
CCAM = congenital cystic adenomatoid malformation 
CCD = charge-coupled device 
CIN = cervical intraepithelial neoplasia 
CIS = carcinoma in situ 
CPC = compound parabolic concentrator 
DNA = deoxyribonucleic acid 
EEMs = excitation-emission matrics 
EFL = effective focal length 
FAD = flavin adenine dinucleotide 
FDA = fisher discriminant analysis 
FI-CCD = front-illuminated CCD 
FT = frourier transform 
FTIR = frourier transform infrared spectroscopy  
FWHM = full width at half maximum 
GI = gastro intestine 
HCA = hierarchical cluster analysis 
HGSILs = high grade squamous intraepithelial lesions 
HP = Helicobacter-pylori 
HPV = human papillomavirus 
HW = high wavenumber 
IM = intestinal metaplasia 
IR = infrared 
KCA = K-means cluster analysis 
LD = linear discriminantion 
LDA = linear discriminant analysis 
LGSILs = low grade squamous intraepithelial lesions 
LP = long-pass 
MC = Monte Carlo 
MDC = multispectral digital colposcopy 
NA = numerical aperture 
NADH = reduced form of nicotinamide adenine dinucleotide 
NIR = near-infrared  
  xvi
os = orifice of the uterus 
pap = papanicolaou 
PC = principal component 
PCA = principal component analysis 
RNA = ribonucleic acid 
ROC = receiver operating characteristic  
SCC = squamous cell carcinoma 
SD = standard deviation 
SILs = squamous intraepithelial lesions 
SMA = SubMiniature version A 
SNR = signal to noise ratio 
SVM = support vector machine 
TCC = translational cell carcinoma 
TE = thermoelectric 
UV = ultraviolet 
VIA = visual inspection after applying acetic acid 
VIS = visible 
VILI = visual inspection after applying Lugol’s iodine 
VUS = volume under the three-way ROC surface 
 
  1
Chapter 1 Introduction 
1.1 Overview 
Cancer is a major cause of human death. As the introduction of various prevention 
programs, the incidence and mortality rates declined in recent decades. However, the 
number of cancer and cancer-induced deaths is still increasing, which may be 
explained by the increased size of worldwide population and the population ageing. In 
particular for cervical cancer, it is the second most frequent cancer among women and 
it is estimated that there are 493,243 new cervical cancer cases in 2010 [1]. Meanwhile, 
there are 273,505 women dying from cervical cancer, which are the third most frequent 
cancer-induced deaths following breast (410,712) and lung (330,786) among women 
[1]. Therefore, great efforts are desired to prevent cervical cancer. 
The prevention of cervical cancer usually comprises three procedures, including 
screening, diagnosis and treatment. The correct screening and diagnosis play a key role 
in the prevention of cervical cancer. At present, papanicolaou (pap) smear screening 
coupled with colposcopic diagnosis is the most common method for the prevention of 
cervical cancer. Pap smear can yield a sensitivity and specificity of around 60% in the 
detection of cervical precancer [2]. Colposcopic examination can improve the 
sensitivity to be above 90%; however, its specificity is even worse (~40%) [3]. 
Moreover, histopathology remains the gold standard for precancer and cancer 
diagnosis, which requires invasive biopsy, lengthens the diagnostic period and 
increases the cost. In this situation, optical spectroscopic technique has recently 
emerged as a promising technique to aid in the prevention of cancer by showing 
advantages of noninvasive, real-time and high-accuracy screening/diagnosis. Till now, 
the common spectroscopy used for screening/diagnosing precancer and cancer in the 
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cervix includes fluorescence, reflectance, infrared and Raman spectroscopy. They 
characterize various tissue pathologies by probing the changes in morphology, 
biochemical composition of tissue associated with tissue maligancy. In particular for 
Raman spectroscopy, it is a vibrational spectroscopic technique and molecular 
fingerprint probe, and has been applied for the detection of cancer and precancer in 
various human organs.  
In this study, we aimed to explore the potential of NIR Raman spectroscopy in both 
fingerprint and high wavenumber (HW) regions for the ex vivo and in vivo detection of 
cervical precancer. To further enhance the acquisition of Raman signal originating 
from the epithelium of cervical tissues, a fiber-optic Raman probe coupled with a ball 
lens was designed and evaluated by using Monte Carlo (MC) simulation method. We 
also investigated the feasibility of combining NIR autofluorescence (AF) and Raman 
to improve the diagnosis of cervical precancer. In addition, we evaluated the 
performance of different optical spectroscopic techniques (i.e., NIR Raman, 
ultraviolet/visible (UV/VIS) autofluorescence and reflectance spectroscopy) in the 
detection of cervical precancer ex vivo; meanwhile, we studied if the diagnosis can be 
improved through combining the three methods as compared to either of them alone.  
In this chapter, firstly, we will introduce the Raman effect and Raman spectroscopy 
instrumentation. Then, we will review the work on Raman spectroscopic diagnosis of 
various human cancers. Subsequently, we will present the background knowledge 
about cervical precancer and cancer. Next, we will review the work on the use of 
Raman spectroscopy and other alternative optical spectroscopic techniques (i.e., 
fluorescence, reflectance and infrared spectroscopy) for the detection of cervical 
precancer and cancer. Finally, we will present the motivations, objectives and 
organization of this thesis.  
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1.2 Raman Spectroscopy 
1.2.1 The Raman Effect 
The Raman effect was discovered by Chandrasekhara Venkata Raman in 1928, who 
was awarded the Nobel Prize in physics in 1930 for his work on discovering Raman 
scattering. The Raman scattering phenomenon was observed as an additional radiation 
to Rayleigh scattering (elastic scattering) and fluorescence emission when C. V. Raman 
was verifying the Rayleigh scattering. When light interacts with a molecule, a majority 
of photons are elastically scattered without frequency changes relative to the incident 
photons. This process is called Rayleigh scattering which is a classical theory of light 
scattering formulated by Lord Rayleigh in 1871. Meanwhile, a small fraction of light 
photons (approximately 1 in 108 incident photons) undergoes energy exchange with the 
molecule and consequently shows a frequency-shift against the incident photons. The 
process is defined as inelastic scattering and is also termed Raman scattering. In theory, 
the light interaction with a molecule leads to a polarization of the molecule and then 
the polarized molecule exhibits an induced dipole moment caused by the external field. 
The induced dipole moment P is proportional to the electric field E and to a property 
of the molecule called the polarizability α as shown in the following equation [4]: 
;P E  0 0cos 2E E v t ; 0 0cos 2P E v t          (1.1)   
where 0E  and 0  are the vibrational amplitude and frequency of the incident light, 
respectively. The polarizability   is dependent upon the position of the nuclei in the 
molecule. For a molecule containing N atoms, there are 3N degrees of freedom 
available to the nuclei. Of there, 3N-6 (3N-5 for a linear molecule) results in the 
vibrations of the molecule. Considering a diatomic molecule with the single normal 
coordinate 1Q , the induced dipole moment is as below [4]: 
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where 0  is the inherent polarizability of the molecule, 01Q  and 1  are the 
vibrational amplitude and frequency of the molecule, respectively. The first term 
represents Rayleigh scattering, and if 1Q is nonzero, Raman scattering occurs. 
The second and third terms represent anti-stokes and stokes Raman scattering, 
respectively, as shown in Fig. 1.1.  
Figure 1.1 Energy transition diagram of vibrational spectroscopy. V is the vibrational quantum 
number. 
For stokes Raman scattering, the scattered photon has a lower energy (longer 
wavelength) than the exciting photon. On the contrary, for anti-stokes Raman 
scattering, the scattered photon is located at shorter wavelength compared to the 
exciting photon. Conventional Raman spectroscopy is based on stokes Raman 
scattering. A Raman spectrum is created by determining the Raman intensity as a 
function of frequency shift (1/λexcitation-1/λRaman), so called Raman shift which is 
quantified in wavenumber (cm-1). Raman spectrum is characterized by a few distinct 
bands attributed to specific group of vibrational bonds in the molecules of the sample. 
Raman spectroscopy has proved to have the potential for diagnosing cancer and 
precancer through measuring Raman spectral changes representing the structural and 
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conformational changes of biomolecules associated with the cancerous transformation. 
In addition, it is noticed in Fig. 1.1 that there exists another vibration spectroscopy (i.e., 
infrared (IR) or near-infrared (NIR) absorption spectroscopy). The extent of energy 
exchange during Raman scattering is identical to the energy absorbed during IR 
absorption. This implies that the frequency shift for certain vibration band of the same 
molecule remains the same for Raman scattering and IR absorption. However, the 
selection rule of Raman scattering differs from that of IR absorption. A molecule 
absorbs IR light only when the dipole moment changes during the molecular vibration. 
Whereas, the Raman effect is caused by an oscillation-induced dipole moment, which 
means that the molecular interaction with light is through the polarizability of the 
molecule. Therefore, not all the molecules are both Raman-active and IR-active, which 
makes Raman spectroscopy and IR spectroscopy complementary to each other.  
1.2.2 Raman Instrumentation 
Raman spectroscopy mainly consists of four parts, including excitation light source, 
spectrograph, detector, and sampling module. In principle, the light is delivered to the 
sample by the sampling module and then interrogates the sample. The Raman scattered 
photons in the sample undergo multi-scattering and absorption, and subsequently are 
collected by the sampling module. Then, the collected Raman photons are fed into the 
spectrograph and collected by the detector. Finally, spectrum is created with the output 
of the detector. 
It is noted that the Raman shift of specific molecular vibration is independent of 
excitation light and Raman scattering is very weak. Therefore, high power 
monochromatic excitation light is required for Raman spectroscopy. As the invention 
and advance of laser technology, laser light from near-ultraviolet to near-infrared 
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regions (e.g., 488-, 515-, 785-, 830-, and 1064-nm) dominates the light source for 
Raman spectroscopy [4]. As for Raman spectrograph, it can be categorized into two 
types, including dispersive and non-dispersive. Dispersive spectrograph separates 
Raman photons spatially and then disperses them onto a multichannel detector using 
grating. In contrast, non-dispersive Raman spectrograph does not require spatial 
separation of Raman photons. At present, Fourier Transform (FT) Raman spectroscopy 
is one of the common non-dispersive Raman spectrograph forms. It is a multiplexing 
technique based on Michelson interferometer which modulates all the different 
wavelengths to produce a complex “interferogram”. The interferogram is detected by a 
single-channel detector and eventually converted to spectrum by Fourier Transform. In 
the early time of Raman spectroscopy, FT Raman spectroscopy is the most prevalent. 
As the invention and advance of charge-coupled device (CCD), dispersive Raman 
spectroscopy based on CCD has become the major form of Raman spectroscopy. 
In addition to light source, spectrograph, and detector, sampling module is also a key 
part of Raman spectroscopy and exerts a big impact on the sensitivity and application 
scope. For example, prior to the introduction of fibers to Raman spectroscopy, it is 
hard to achieve a remote control of Raman spectroscopic measurement. Till now, 
Raman sampling module has the following forms: (1) 90° or 180° scattering mode 
based on normal lens; (2) back-scattering or forward-scattering microscopic mode; (3) 
fiber-optic sampling using various fiber-optic probes. 
1.2.3 Cancer Diagnosis by Raman Spectroscopy 
1.2.3.1 Raman-active Biomolecules 
Raman spectroscopic diagnosis of precancer and cancer is based on the fact that a big 
amount of molecules in biological tissues are Raman-active and meanwhile show 
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significant changes accompanying tissue premalignant and malignant transformation. 
Tissue Raman spectrum is a mixture of Raman signals from various molecules in 
tissue and consequently can represent the changes of those molecules. The spectrum 
variation among different tissue pathologies due to the molecular changes enables 
Raman spectroscopy to differentiate tissues under different histopathological statuses. 
It has been recognized that the major Raman-active biomolecules which are sensitive 
to tissue premalignant and malignant changes are proteins, lipids, nucleic acids and 
carbohydrates [5].  
Proteins take up about 20% of total body weight, provide structural support and are 
also involved in all metabolic processes. Proteins and synthetic polypeptides consist of 
amino acids joined together by peptide bond (-CONH-). Peptide bond gives rise to 
many different types of vibrational modes such as amide A and B bands, amide I, II, III, 
IV, and VII bands. Among these, amide I and III bands correlated with structural 
properties of protein molecules yield very prominent Raman bands at 1645~1657 cm-1 
and 1264~1300 cm-1, respectively, for protein with α-helix structure. The counterpart 
in protein with β-sheet structure is 1650~1680 cm-1 and 1230~1245 cm-1.  
Lipids, covering about 12% of total body weight, serve as structural component and 
energy storage in living organisms. Raman spectroscopy is able to probe biological 
membrane structure and function without perturbing the sample through probing the 
major lipids (fatty acids) and its derivatives (phospholipids). They show a lot of 
vibrational bands in Raman spectra in the region of 100~3000 cm-1, which are 
structurally sensitive and may be assigned to C-C stretching vibration modes and C-H 
stretching vibration modes. 
Nucleic acids are complex and high-molecular-weight biochemical macromolecules 
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composed of nucleotide chains that convey genetic information. The most common 
nucleic acids are deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Nucleic 
acids are found in all living cells and viruses. Raman spectroscopy is extensively used 
to study the conformation of nucleic acids and mechanism of interaction with other 
compounds. Nucleic acids show many structurally sensitive Raman bands which can 
be used to follow the progress of conformational changes or interactions. 
Carbohydrates are the most abundant biological molecules and play an important role 
in living organisms. It stores and transports energy, and also serves as structural 
components. The vibration modes of carbohydrates are very complex and usually 
include OH, C-H, C-C, C-C-O, C-O, C-O-C and C-O-H vibrations. This leads the 
interpretation of Raman spectra to be difficult. For example, C-H stretching vibration 
of carbohydrates gives a complex pattern in the region of 2800~3050 cm-1. The 
complexity arises from the presence of different types of CH-containing groups such 
as -CH3, -CH2, and C-H.  
1.2.3.2 Raman Spectroscopic Diagnosis of Human Cancer and Precancer 
1. Brain: The early Raman study on human brain tumor tissues was conducted by 
Mizuno et al with the use of FT Raman spectroscopy in 1994 [6]. Distinctive Raman 
spectra differences were observed among normal and different types of tumor tissues 
(i.e., glioma grade II and III, acoustic neurinoma and neurocytoma). Raman band at 
960 cm-1 due to hydroxyapatite was suggested as a biomarker indicative of tumor 
pathologies. 
Koljenović and co-workers (2002) investigated the feasibility of Raman spectroscopy 
for grading glioblastoma [7]. They succeeded in delineating cross-sectioned vital and 
necrotic tissues by using Raman-mapping and K-means cluster analysis (KCA). A 
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perfect differentiation between necrotic and vital tissues was made by diagnostic 
model produced by principal component analysis (PCA) and linear discriminant 
analysis (LDA). In their later work, they demonstrated that HW Raman spectra 
(2700~3100 cm-1) can provide essentially equivalent diagnostic information as Raman 
spectra in fingerprint region (400~1900 cm-1) and consequently can be used for tissue 
characterization [8].  
Krafft et al (2005) elucidated the biochemical composition variation among normal 
and different intracranial tumors (i.e., astrocytoma, glioblastoma multiforme and 
meningeoma) by modeling tissue spectrum with reference spectra (i.e., protein, lipid, 
water and cholesterol) [9]. Normal tissue showed higher level of lipid while 
intracranial tumor tissue showed larger content of hemoglobin and lower ratio of lipid 
to protein. Recently (2009), they found an increase in water content and a decrease in 
lipid content in brain tumor as compared to normal brain tissue in a separate study 
[10].  
2. Breast: Redd et al (1993) examined normal and cancerous breast tissues by using 
Raman spectroscopy with the excitation light at 406.7-, 457.9-, and 514.5-nm [11]. The 
results showed that Raman signal of normal tissue was mainly attributed to carotenoids 
(i.e., 1004, 1156, and 1525 cm-1) and lipids (i.e., 1082, 1302, 1444, and 1652 cm-1), 
which diminished obviously in benign and cancerous breast tissues. Frank and 
co-workers (1994) optimized the wavelength of excitation light for Raman 
spectroscopic measurement on human breast tissues [12]. Subsequently, Frank et al 
(1995) used 784-nm light as the excitation source to study Raman spectral differences 
between normal and cancerous breast tissues [13].  
In the later years, Michael Feld’s group did extensive Raman studies on breast cancer. 
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Manoharan et al (1998) and Chowdary et al (2006) demonstrated that NIR Raman 
spectroscopy coupled with multivariate statistical techniques was capable of 
differentiating breast cancer from normal tissue with a fairly good accuracy [14, 15]. 
To further elucidate the biochemical composition changes associated with tissue 
malignant transformation, Shafer-Peltier et al (2002) developed a biochemical and 
morphological model of breast tissue with the component spectra derived from spectra 
of cell cytoplasm, cell nucleus, fat, β-carotene, collagen, calcium hydroxyapatite, 
calcium oxalate dehydrate, cholesterol-like lipid deposits and water [16]. Haka et al 
(2005) extended this study on a larger women population (58 patients) and achieved a 
sensitivity of 94% and specificity of 96% in discriminating cancer tissues from normal, 
fibrocystic and fibroadenoma tissues by performing logistic regression analysis on the 
fitting coefficients [17]. In 2006, Haka et al reported an in vivo study on using Raman 
spectroscopy to delineate the malignancy margin during partial mastectomy and their 
success in real-time Raman spectroscopic diagnosis [18]. Three years later, with the 
use of the same system, they did the first trial on the prospective diagnosis of breast 
cancer using Raman spectroscopy [19]. In the same year (2009), Chowdary et al 
employed nonlinear peak fitting, known as Lavenberg-Marquardt method, to 
deconvolve tissue spectrum into 17 individual Raman bands to elucidate the 
biochemical changes induced by tissue cancerous changes [20].  
Besides cancer detection, calcification also received some research efforts. Haka et al 
(2002) investigated the feasibility of identifying micro-calcification in benign and 
malignant breast lesions using a NIR Raman microscope [21]. A sensitivity of 88% and 
specificity of 87% were achieved in differentiating micro-calcification between benign 
and malignant breast tissues. Matousek et al (2007) demonstrated that transmission 
Raman spectroscopy has the potential to aid conventional screening methods (e.g., 
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mammography and ultrasound) in improving the early diagnosis of breast cancer by 
probing the calcification in breast tissues [22].  
3. Colon and Esophagus: Keller and co-workers (1994) measured Raman spectra 
from a pair of normal and haemorrhagic intestines using FT Raman spectroscopy with 
1064-nm light excitation [23]. Haemorrhage-induced Raman spectral differences were 
observed between these two tissue types. Feld et al (1995) reported another 
preliminary study on Raman spectroscopic examination of normal and cancer colon 
tissues [24]. Obvious spectral difference between normal and adenocarcinoma colonic 
tissues occurred near 1000, 1300 and 1500 cm-1. Shim et al (2000) succeeded in 
acquiring Raman spectrum from gastro intestine (GI) in vivo for the first time using a 
flexible fiber-optic Raman probe through the conventional endoscope [25]. Prominent 
Raman peaks were seen in the vicinities of 1003 (phenyl ring breathing mode), 1260 
(amid III), 1310 (CH2 twisting mode), 1450 (CH2 bending mode), and 1657 cm-1 
(amide I). By using the same Raman system, Molckovsky (2003) demonstrated the 
capacity of Raman spectroscopy for identifying hyperplastic and adenomatous polyps 
both ex vivo and in vivo [26]. Andrade et al (2007) demonstrated the existence of 
intrinsic spectral variation and suggested that this variation should be taken into 
consideration when building spectral database [27]. Widjaja et al (2008) investigated 
the multi-type diagnostic ability of NIR Raman spectroscopy for colon tissues on a 
large dataset [28]. Diagnostic accuracy of 99.9% was yielded by a diagnostic algorithm 
based on PCA and support vector machine (SVM).   
Shim et al (2000) demonstrated the feasibility of measuring Raman spectra from 
esophagus tissues in vivo with the use of fiber-optic probe via conventional endoscope 
[25]. Then, Song et al (2005) proved the in vivo diagnostic potential of NIR Raman 
spectroscopy on a large population of 65 patients, showing an accuracy of about 85% 
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in diagnosing dysplasia [29]. Kendall et al (2003) employed a NIR micro-Raman 
system to test if Raman spectroscopy can identify neoplasia in Barrett’s esophagus [30]. 
Shetty and co-workers (2006) further elucidated the biochemical changes in 
carcinogenesis of esophagus through Raman spectroscopic mapping [31]. The major 
finding was the reduced content of glycogen and elevated content of DNA in abnormal 
area.   
Recently, micro-Raman probe was proposed for acquiring the Raman signal 
originating from the subsurface of esophagus by Hattori et al (2007) [32]. Day and 
co-workers (2009) optimized a confocal Raman probe design for in vivo Raman 
measurement on esophagus via the auxiliary channel of conventional endoscope [33]. 
The probe has been validated ex vivo, showing the ability of acquiring Raman 
spectrum from esophagus with 2 seconds. 
4. Bladder and Prostate: Nie and co-workers (1992) demonstrated for the first time 
that Raman spectroscopy can be used to discriminate bladder cancer from normal 
tissue [34]. Raman spectra of rat bladder tissues measured with NIR FT Raman 
spectroscopy exhibited prominent bands at 1004 (phenylalanine), 1240 and 1268 
(amide III), 1449 (lipid) and 1664 cm-1 (amide I). Jong et al (2002) proved that Raman 
spectroscopy in combination with cluster analysis can characterize bladder wall layers, 
including urothelium, muscle and lamina [35]. Subsequently, they (2003) extended 
their study to investigate the effect of outlet obstruction on the molecular composition 
of bladder muscle tissue by using Raman spectroscopy [36]. They observed collagen 
infiltration and an accumulation of glycogen in obstructed bladder tissues. Crow et al 
conducted a lot of work on applying Raman spectroscopy for the detection of both 
bladder and prostate cancer and elucidating the biochemical changes, such as 
multi-classification among benign, and three grades of prostatic adenocarcinoma 
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tissues [37] and among normal bladder, cystitis and carcinoma in situ 
(CIS)/translational cell carcinoma (TCC) [38]. Later, a fiber-optic Raman system was 
developed for in vivo Raman measurement on bladder and prostatic tissue and has 
been evaluated in vitro [39]. In addition to the study on gross tissues, Crow and 
co-workers (2005) investigated the feasibility of Raman spectroscopy coupled with 
PCA-LDA to characterize various prostatic cancer cell lines [40]. Shortly after their 
study, Taleb et al (2006) employed partial least square discriminant analysis and 
adjacent band ratios to successfully classify Raman spectra of all malignant prostatic 
cells from that of normal cells [41].  
Jong and co-workers (2006) tried to delineate the normal and tumor part of bladder 
tissues with PCA and hierarchical cluster analysis (HCA) [42]. Furthermore, the 
biochemical difference between non-tumor and tumor tissues was elucidated by 
modeling tissue spectra with 18 reference spectra of biochemical representatives. Stone 
et al (2007) used similar chemical fitting method to study the biochemical composition 
variation related to malignant transformation of bladder and prostatic tissues with 8 
reference spectra of actin, collagen I/III, choline, triolein, oleic acid, DNA and 
cholesterol [43]. 
5. Larynx and Nasopharynx: An early study on Raman spectroscopic diagnosis of 
malignant changes in larynx was conducted by Stone and co-workers (2000) [44]. 
Seven normal, four dysplastic and four malignant larynx tissues were examined using 
Raman microscope with 830-nm light and discriminated with an accuracy of more than 
85% by PCA-LDA diagnostic algorithm. Five years later, in another study, Lau et al 
(2005) demonstrated again that Raman spectroscopy can be used for identifying larynx 
tissues [45]. Teh et al (2009) proposed random forest method to develop diagnostic 
algorithm for laryngeal cancer [46]. Random forest method can also provide insight 
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into the biochemical changes associated with tissue malignant transformation. 
As for nasopharynx, two studies were reported in literature. Lau et al (2003) firstly 
reported their preliminary findings on Raman spectroscopic characterization of 
nasopharynx cancer. In recent year, Feng et al (2009) studied the Raman features of 
cancerous and normal nasopharynx tissues by using surface-enhanced Raman 
scattering (SERS) technique [47]. The Raman images created with the Raman bands at 
725, 962 and 1336 cm-1 showed an increased, reduced and increased intensities, 
respectively, in cancerous nasopharyngeal tissues as compared to normal tissues.  
6. Lung: Raman spectroscopy was firstly used to study lung tissue changes other than 
cancer, such as inclusions identification by Buiteyeld et al (1984) [48]. In a later study, 
Schut and co-workers (1997) demonstrated that Raman spectroscopy can probe the 
change of carotenoid content level in lung tissue [49]. The first direct comparison of 
Raman spectra between normal and cancerous lung tissues was performed by 
Kaminaka et al (2001) and showed an increased intensity of Raman peaks at 1448 and 
1666 cm-1 due to collagen in cancer tissue [50].  
Huang et al (2003) examined bronchial tissues (12 normal, 10 squamous cell 
carcinoma (SCC) and 6 adenocarcinoma) from 10 patients using Raman spectroscopy 
[51]. Raman peak intensity ratio of 1445/1655 cm-1 (CH2 scissoring/collagen) was 
found to be an effective diagnostic marker with a sensitivity of 92% and specificity of 
94%. In the same year, they (2003) reported that formalin-fix process had effect on 
tissue Raman spectra and hence suggested the use of fresh tissue for Raman study [52]. 
Following Huang’s ex vivo work, Short et al (2008) successfully designed a flexible 
fiber-optic endoscope Raman probe for in vivo Raman measurement on bronchial 
tissue [53].  
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In addition to Raman spectra classification, Koljenović and co-workers (2004) made 
efforts to gain the understanding of biochemical and morphological composition of 
bronchial tissue using Raman microscopy [54]. Raman map of cross-sectioned 
bronchial tissues was created by implementing PCA and KCA on Raman spectra. The 
Raman map showed a good agreement with the corresponding histology. Krafft et al 
(2008) used similar method to make a pair-wise comparison of Fourier transform 
infrared spectroscopy (FTIR) and Raman imaging between normal and congenital 
cystic adenomatoid malformation (CCAM) lung tissues [55]. It was found that CCAM 
tissues contained an increased lipid and glycogen content and reduced red blood cell 
content as compared to normal tissues. 
The recent studies on Raman spectroscopic diagnosis of lung precancer and cancer 
were performed at cellular levels. Jess and co-workers (2009) measured Raman spectra 
from normal, neoplastic lung cell lines (mild and severe neoplasia) successfully using 
Raman microspectroscopy [56]. Neoplastic cell lines were discriminated from normal 
cell lines with a sensitivity of 91% and specificity of 75%. Moreover, neoplastic cell 
lines were further graded into two stages (i.e., mild and severe) with an accuracy of 
79% and 87%, respectively. Similar study on separating lung cancer cells from normal 
cells with Raman spectroscopy was reported by Oshima et al (2010) [57]. Eighty 
percent of the cell lines were characterized correctly with PCA.  
7. Skin: Basal cell carcinoma (BCC) is the most common form of skin cancer and 
therefore has received most of Raman research efforts. Gniadecka and co-workers 
(1997) carried out Raman measurements on both normal and BCC tissues by using 
NIR FT Raman spectroscopy [58]. Raman spectral features in the regions of 830~900 
cm-1, 900~990 cm-1, and 1220~1300 cm-1 allowed a complete separation between BCC 
and normal tissues, which was confirmed by neural networks analysis. Nijssen et al 
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(2002) obtained a sensitivity of 100% and specificity of 93% in discriminating BCC 
from its surrounding non-cancerous tissues using PCA and logistic regression analysis 
[59]. In their following work, they (2007) demonstrated that NIR Raman spectroscopy 
in HW region (2800~3125 cm-1) was also capable of characterizing BCC [60]. Tissue 
spectral modeling with reference spectra of collagen, oleic acid, palmitic acid and 
albumin revealed a reduced collagen content and increased albumin content in BCC 
tissues as compared to normal tissues. With the similar method, Short et al (2006) 
found that the nucleoli from tumor cells contained less RNA, histone, and actin than 
that from normal cells while more DNA, histone, and actin for the remaining nucleus 
[61]. Ly and co-workers (2008) demonstrated that polarized Raman spectroscopy can 
improve the differentiation between normal and peritumoral dermis as compared to 
conventional non-polarized Raman spectroscopy [62]. In a recent study, Larraona-Puy 
et al (2009) used Raman spectroscopy not only to distinguish BCC from normal tissues 
but also to delineate the tumor margin [63].  
Besides BCC, Raman spectroscopy has also been applied to detect other forms of skin 
cancer, especially melanoma which is the most aggressive skin cancer. At the early 
time, Gniadecka and co-workers (1997, 2004) explored the Raman spectral variation 
among a big variety of skin pathologies and employed neural networks technique to 
distinguish the Raman spectra of different tissue types [64, 65]. Melanoma was 
separated from pigmented nevi, BCC, seborrheic keratoses and normal skin with a 
sensitivity of 85% and specificity of 99%. A perfect prediction of normal, BCC, SCC 
and melanoma by Raman spectroscopy was reported by Lieber et al (2008) [66].  
Meanwhile, several in vivo Raman studies on skin have been reported. Huang et al 
(2001) developed a rapid NIR Raman spectroscopy coupled with a fiber-optic probe 
for in vivo Raman measurement on skin and acquired good-quality cutaneous Raman 
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spectra within 1 second [67]. More recently, Lieber et al (2007) developed a handheld 
in vivo Raman microspectrometer [68]. In a subsequent study, this system was used for 
clinical measurement by the same group [69]. Maximum representation and 
discrimination feature were used to reduce data dimension and sparse multinomial 
logistic regression was used to develop diagnostic algorithm. All abnormal skin tissues 
were predicted correctly and only two normal tissues were misdiagnosed.   
8. Stomach: Teh and co-workers have conducted extensive studies on applying Raman 
spectroscopy for the ex vivo detection of precancer and cancer in stomach from 2008 
till now. Their first report (2008) was made on differentiating dysplasia from normal 
tissue using NIR Raman spectroscopy [70]. PCA-LDA analysis yielded a sensitivity 
and specificity of 95.2% and 90.9%, respectively. In 2009, they extensively 
investigated the potential of empirical method (i.e., intensity ratio) for distinguishing 
stomach dysplasia [71]. The combination of I875/I1450 and I1208/I1655 proved optimal for 
the diagnosis of dysplasia with a sensitivity of 90.5% and specificity of 90.9%. 
They (2008) also attempted to identify stomach cancer using Raman spectroscopy and 
classification and regression tree (CART) technique instead of PCA-LDA [72]. The 
CART algorithm yielded a sensitivity of 90.2% and specificity of 95.7%, and moreover 
found that Raman bands at 875 and 1745 cm-1 were the most significant Raman 
features for cancer discrimination. In their latest work, they (2010) tested the 
possibility of further typing stomach cancer (i.e., intestinal and diffuse 
adenocarcinomas) using Raman spectroscopy [73]. The correct prediction rates are 
88%, 92% and 94% for normal, intestinal type and diffuse type tissues, respectively. In 
addition to precancer and cancer, they (2010) also did a pilot study to characterize 
nonneoplastic stomach lesions (i.e., Helicobacter-pylori (Hp) infection and intestinal 
metaplasia (IM)), which are highly associated with stomach cancer [74]. Good 
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differentiation among normal, IM and Hp-infection tissues was achieved, showing 
accuracies of 91.7%, 80.0%, and 80.0%, respectively. Besides Teh and co-workers, 
several other groups were also involved in applying Raman spectroscopy for stomach 
cancer diagnosis [75-77].  
Recently, Huang et al (2009) reported their success in measuring Raman spectrum 
from stomach in vivo [78]. A fiber-optic endoscopic Raman probe was designed, which 
was flexible and compatible with conventional endoscopy, and consequently allowed 
in vivo Raman measurement on stomach. Moreover, white, autofluorescence and 
narrow band imaging was used to guide the Raman measurement in vivo.  
1.3 Cervical Cancer 
1.3.1 Cervical Cancer Facts and Risk Factors 
1.3.1.1 Cervical Cancer Facts 
Cervical cancer is the 2nd most frequent cancer among women worldwide in 2002 and 
shows an incident rate of 16%. It is ranked 7th, 2nd and 4th in developed countries, 
developing countries and Singapore, respectively [1]. The corresponding incidence rate 
is 13.6%, 16.6% and 15.7%, respectively. More importantly, the incidence rate is still 
growing [1]. Estimated based on the rate in 2002, the incidence rate in 2010 is 17.2%, 
14.1%, 18.3% and 19.4% worldwide, in developed and developing countries, and 
Singapore, respectively. The number of new cervical cases in 2010 is 585,278, 88,702, 
505,592 and 441, respectively, while just 493,243, 83,437, 409,404 and 323 in 2002, 
respectively [1].  
Meanwhile, the mortality rate of cervical cancer is in the 3rd place following breast and 
lung worldwide. In particular for developing countries, it is the highest [1]. In 
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Singapore, it is the 5th highest. In 2002 and 2010, the specific mortality rate of cervical 
cancer is 8.9% and 9.7% in the world, 6.4% and 6.9% in developed countries, 9.5% 
and 10.5% in developing countries, and 9.9% and 13.3% in Singapore, respectively. 
Simultaneously, the number of deaths due to cervical cancer grows from 273,505 to 
327,899 in the world, 39,512 to 43,043 in the developed countries, 233,776 to 291,872 
in developing countries, and 205 to 302 in Singapore [1]. Even given that the incidence 
and mortality rates remain unchanged, the absolute number of new cancer cases and 
cancer-induced deaths still keeps increasing. This may be accounted for by the 
increased population size and population aging [79]. Therefore, prevention and early 
diagnosis of precancer and cancer in the cervix are becoming even more desired, 
especially in developing countries where 80% of the cervical cancers occurs [80]. 
1.3.1.2 Risk Factors 
A variety of factors have been found to separately or jointly lead to cervical cancer, 
such as human papillomavirus (HPV) infection, smoking, oral contraceptive, the 
number of sex partners, the number of full pregnancies, genetic and immunological 
factors. Among the factors above, HPV infection has been recognized as the main 
cause of cervical cancer during the past twenty five years. The eight most common 
HPVs (i.e., HPV-16, -18, -33, -45, -31, -58, -52 and -35 in order of decreasing 
prevalence) account for ~90% of cervical cancer worldwide and HPV-16 and -18 
account for 70% of cervical cancer [81]. Consequently, HPA DNA testing and HPV 
vaccine have emerged as the choice of method for preventing cervical cancer.  
Smoking is another major factor of cervical cancer, leading to a 2-fold increase in the 
risk of cervical cancer [82]. Moreover, the risk also shows a trend of increase with the 
increase in the number of cigarette smoked and years of smoking [82]. Besides, a long 
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term use of oral contraceptive (i.e., >5 years) and the number of full pregnancies 
(i.e., >=7) induce a significant increase up to 4-fold in the risk of cervical cancer of 
HPV-infected patients [83, 84]. Genetic predisposition, the host response and 
immune-suppression are also found to contribute in part to the development of 
precancer and cancer [85, 86]. Diet, education and social class are found not to be 
significantly associated with cervical precancer and cancer [87, 88]. 
1.3.2 Anatomy of Cervix 
The cervix is the lower narrow part of the uterus and protrudes through the upper wall 
of the vagina. It serves to transport the menstrual blood from uterus to vagina and 
direct sperm into uterus during intercourse. The cervix is further divided into 
ectocervix and endocervix. Ectocervix is the portion of the cervix which projects into 
the vagina. It is covered by stratified non-keratinizing squamous epithelium which is 
centered in the external orifice of the uterus (os). The ectocervix is around 3 cm long 
and 2.5 cm wide on average and usually visible under colposcopy [89]. In comparison, 
the endocervix is the part of the cervix connecting external os and uterine cavity. It is 
covered by columnar epithelium. The joint point between ectocervix and endocervix is 
called squamo-columnar junction. The portion of the columnar epithelium that is 
ultimately replaced by squamous epithelium is termed the transformation zone, where 
neoplasia and malignancy arise from [89]. 
The cervix shows a two-layer structure, comprising the superficial epithelium layer 
and the underlying stroma layer. The stroma layer is composed predominantly of 
elastic tissue (i.e., collagen and elastin) forming extracellular matrix. The epithelium is 
separated from the stroma by basement membrane. It differs between ectocervix and 
endocervix. The epithelium of ectocervix shows architecture of multiple cell layers, 
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including superficial layer, intermediate layer, parabasal layer and basal layer from the 
epithelium surface towards the stroma. In contrast, the endocervical canal is covered 
by columnar epithelium, which is composed of a single layer of tall cells. 
1.3.3 Histology of Cervix 
1.3.3.1 Normal Cervix 
The squamous epithelium of normal cervix shows a clear multi-layer structure, 
consisting of basal layer, parabasal layer, intermediate layer, superficial layer [90]. The 
basal layer consists of cells in cylindrical shape with relatively large nuclei. The 
parasal layer is formed by a couple of cell layers with fairly large nuclei and distinct 
intercellular bridges. Mitotic figures are rarely seen in these two layers. The 
intermediate layer on top of parabasal layer is formed by flatten cells with a high level 
of glycogen and frequent vacuolation in cytoplasm. The superficial layer is composed 
of elongated, flattened cells with small pyknotic nucleolus and a large amount of 
cytoplasm. 
1.3.3.2 Cervical Dysplasia 
Cervical dysplasia refers to the cervical intraepithelial changes which show malignant 
potential. It was termed as cervical intraepithelial neoplasia (CIN) by Richard in 1967 
[91], and is the premalignant stage of cervical cancer. Histological features of CIN 
mainly include the absence of cytoplasmic differentiation and orderly stratification, the 
lack of clearly defined boundaries, and large nuclei-cytoplasm ratio in epithelium cells. 
CIN can be graded into three stages (i.e., 1, 2 and 3) according to the spread of 
neoplastic changes in the epithelium. CIN 1 shows neoplastic changes within the lower 
one-third of the epithelium while lower two-thirds and whole epithelium for CIN 2 and 
3, respectively. Besides, CIN 3 also shows undifferentiated, non-stratified, basaloid 
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cells with nuclear crowding and greater nuclear pleomorphism as compared to CIN 1 
and 2. However, CIN does not show any invasion into the underlying stroma, which 
serves as an important criterion for distinguishing CIN from invasive carcinoma.  
Detection of CIN at mild stage followed by effective treatment can reduce incidence 
rate of cervical cancer. However, the diagnostic inconsistency, especially on CIN 1 and 
2 still exists [92]. Therefore, a modified two-tier system (the Bethesda system [93]) 
was proposed, which divided cervical epithelial neoplastic changes into two groups 
including low grade and high grade squamous intraepithelial lesions (LGSILs and 
HGSILs). LGSILs refer to HPV infection and CIN 1, and HGSILs refer to CIN 2 and 3, 
and carcinoma in situ (CIS). However, the discrimination between CIN 1 and 2 is not 
improved under the two-tier system. Consequently, a robust and objective diagnostic 
method is desirable to prevent the aforementioned diagnostic inconsistency among 
pathologists. Optical methods have proven to be a potential candidate.  
1.3.3.3 Cervical Cancer 
Cervical cancer can be usually differentiated from precancer by the invasion of the 
neoplastic changes into the stroma. Cervical cancer mainly has two forms. One is 
squamous carcinoma, constituting 70~78% of cervical cancer. Squamous carcinoma 
shows some of the following characteristics, including relatively large cells, bands, 
discrete islands, infiltrative pattern and/or solid sheets [94]. The other is 
adenocarcinoma, constituting 12~18.6% of cervical cancer [94]. Little or no cytologic 
atypia is observed in adenocarcinoma and the cells are like that of normal counterpart. 
Glandular crypts are often sharply angulated and extend towards a big depth of the 
stroma. In addition, the surrounding stroma shows a loose edematous or desmoplastic 
response.  
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1.3.4 Conventional Screening/Diagnosis and Treatment of Cervical Cancer 
Cervical cancer has a defined premalignant phase for many years. This allows a long 
time for screening or diagnosis of premalignant changes or malignancy at early stage. 
Then, cervical cancer can be prevented and the corresponding mortality rate can be 
reduced significantly. Therefore, various cervical cancer screening methods are 
developed. To date, cervical cytology testing (i.e., pap smear) is widely used as an 
effective screening method for cervical cancer, especially in developed countries. The 
procedures of pap smear include collecting cells from cervix and then examining those 
collected cells under microscopy. However, the use of pap smear in developing 
countries is limited and shows a deteriorated efficacy. Consequently, visual inspection 
techniques, such as visual inspection after applying acetic acid (VIA), visual 
inspection after applying Lugol’s iodine (VILI), are proposed for routine cervical 
cancer screening method as an alternative to pap smear in the developing countries. 
Recently, HPV DNA testing is emerging as another alternative method due to the high 
correlation of HPV with cervical cancer. Moreover, HPV DNA testing can be done on 
site and yield the results immediately. As the advance of HPV DNA testing assay, it is 
growing as a cost-effective, efficient and suitable cervical cancer screening technique, 
especially in developing countries. More recently, HPV vaccine is developed for 
preventing cervical cancer. However, most of the HPV vaccines can only be targeted at 
limited types of HPVs.  
For the diagnosis of cervical precancer and cancer, colposcopic examination and 
colposcopy-directed biopsy remain as the most reliable method. Colposcopy is like a 
telescope which can magnify the cervix for examination. In clinic procedures, 3~5% 
acetic acid will be applied on the cervix for a few minutes prior to checking the 
colposcopic appearance of cervix. Suspicious lesions found under colposcopy will be 
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biopsied for histopathological examination. Histopathology results serve as the gold 
standard for cervical precancer or cancer diagnosis.  
At present, almost all the precancers in the cervix are curable. The treatment strategy 
varies with the severity and size of the lesion. The common treatment methods for 
cervical precancer include loop electrosurgical excision procedure, large loop excision 
of the transformation zone, hysterectomy, laser therapy (vaporizing cervical epithelium 
with laser) and cryotherapy [95, 96].  
The treatment of invasive cancer depends on the stage of invasive cancer. For stage I, 
radical hysterectomy is preferred and minimally invasive surgery recently emerges as 
an alternative for small tumors. For stage II to IV, radiotherapy is usually used. In 
addition, chemotherapy is proposed as an adjunct to radiotherapy to improve 
progression-free survival [95]. 
1.4 Raman Spectroscopic Diagnosis of Cervical Cancer 
Liu and co-workers pioneered Raman measurement on cervical tissues in 1992, 
including malignant and non-malignant (i.e., normal and benign) tissues with NIR FT 
Raman spectroscopy [97]. Their most significant finding was that Raman peak at 1657 
cm-1 (amide I) showed a higher intensity than Raman peak at 1445 cm-1 (C-H bending 
of proteins/lipids) in normal tissue while it showed otherwise in malignant tissue. 
Mahadevan-Jansen et al (1998) demonstrated the capacity of Raman spectroscopy for 
the detection of cervical precancer using both intensity ratio method and multivariate 
statistic technique (i.e., PCA and fisher discriminant analysis (FDA)) [98]. The Raman 
peak intensity and intensity-ratio, including I1070, I1656, I1656/I1330 and I1656/I1454 were 
found to be diagnostically significant for differentiating squamous intraepithelial 
lesions (SILs) from non-SILs as well as HGSILs from LGSILs. In their following 
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work, they proceeded to the in vivo Raman spectroscopic diagnosis of cervical 
dysplasia with the design of a fiber-optic Raman probe [99]. Raman spectra with 
acceptable signal to noise ratio (SNR) can be acquired from cervix in vivo within 90 
seconds. Subsequently, clinical trials were conducted on 13 patients, including normal, 
inflammation, squamous metaplasia, LGSILs and HGSILs [100]. A diagnostic 
algorithm of I1454/I1656 versus I1330/I1454 yielded a good differentiation of HGSILs from 
other tissues.  
Robichaux-Viehoever (2007) employed an improved Raman system for in vivo Raman 
measurement on cervix with integration time reduced to a few seconds [101]. Logistic 
regression analysis was employed to utilize the intensity of the primary peaks (i.e., 
1006, 1055, 1244, 1305, 1324, 1450, 1550 and 1657 cm-1) to develop diagnostic 
algorithm, showing a better performance than colposcopic diagnosis. In a later report, 
Kanter et al (2009) developed a novel statistical method for multi-group classification 
[102]. Maximum representation and discrimination feature were used to extract 
diagnostic information and sparse multinomial logistic regression was used to make 
differentiation. With this method, fairly high correct prediction rate was achieved for 
HGSILs (24/29), LGSILs (18/21), metaplasia (19/29) and normal (208/226). Using the 
same technique, they (2009) investigated the effect of hormonal variation on Raman 
spectra for tissue characterization [103]. The results showed that the accuracy of 
discriminating LGSILs from normal ectocervix could be improved by stratifying the 
tissues according to the menopausal status. 
Besides Anita’s group, several other groups also contributed to applying Raman 
spectroscopy for the detection of cervical precancer and cancer. Jess et al (2007) 
demonstrated that Raman spectra of various cervical cell lines (i.e., normal and 
malignant cell lines, and cell lines expressing HPV16 E7) can be separated well by 
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PCA-based algorithm [104]. They also found that cell fixation resulted in a large 
reduction in peak intensities at 936 and 1090 cm-1 and moreover can increase the 
sensitivity of cell characterization compared to live cell lines. Martinho et al (2008) 
demonstrated that cervicitis may deteriorate the performance of Raman spectroscopy 
for the diagnosis of cervical precancer [105].  
For cervical cancer diagnosis, Krishna and co-workers (2006-2007) explored the 
potential of Raman spectroscopy for cervical cancer detection [106, 107]. The major 
spectral variation associated with tissue malignancy included narrowed amide I and III 
bands, a minor red shift of Raman band at 1450 cm-1, and the vanishing of Raman 
bands at 854, 939, 1269 and 1384 cm-1. Diagnosis with the inclusion of the parameters 
(factor scores, Mahalanobis distance and spectral residual) produced by PCA achieved 
a very high sensitivity and specificity of 99.5% in distinguishing cancer from normal 
tissues. Moreover, they also proved that Raman spectroscopy can be used to evaluate 
the efficacy of radiotherapy [107] 
Lyng et al (2007) elucidated the biochemical changes associated with tissue malignant 
transformation with reference spectra of proteins, nucleic acids, lipids and 
carbohydrates [108]. An absence of glycogen band and an increased intensity of 
nucleic acids and amide I bands were observed in cancer tissue as compared to normal 
tissue. About 99% of normal, dysplasia and cancer tissues can be characterized 
correctly by PCA-LDA diagnostic algorithm. A similar study was reported by 
Kamemoto et al (2010) [109]. They observed that normal squamous cells exhibited a 
more intense Raman scattering than malignant squamous cells. The spectra in the 
region of 775~975 cm-1 exhibited a good correlation with the spectra in the region of 
2800~3100 cm-1.  
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1.5 Other Optical Spectroscopic Techniques for Cervical Cancer 
Diagnosis 
1.5.1 Fluorescence Spectroscopy 
Lohmann and co-workers (1989) measured fluorescence spectra from normal, 
dysplasia, and invasive carcinoma cervical tissues with 365-nm excitation light [110]. 
Tissue fluorescence spectra showed a primary band peaked at 475 nm, which was 
attributed to reduced form of nicotinamide adenine dinucleotide (NADH). The 
intensity of NADH band increased with the progression of tissue from normal to 
severe dysplasia and was very low in tumor tissue. This was confirmed by the 
fluorescence image of cervical tissue cryo-section [111]. The feasibility of using 
fluorescence spectroscopy for discriminating cervical malignancy was explored for the 
first time by Glassman et al (1992, 1994) [112, 113]. The results indicated that the 
excitation band ratio (I335/I380) and emission band ratio (I340/I440) can be a biomarker of 
cervical cancer. Mahadevan et al (1993) recorded fluorescence excitation-emission 
matrices (EEMs) in vitro on 18 biopsied tissues of 10 patients [114]. Fluorescence 
intensity at 380 nm under 330-nm light excitation can distinguish dysplasia with a 
comparable accuracy as compared to colposcopic diagnosis. Koumantakis et al (1997) 
found other fluorescence spectral bands at various wavelengths (i.e., 558-, 583-, 600-, 
630- and 697-nm) under 420-nm excitation as cervical malignancy predictors [115]. 
In the following years, Ramanujam and co-worker conducted an extensive work on 
applying fluorescence spectroscopy for the in vivo detection of cervical dysplasia with 
337-nm excitation light [116-119]. In their first in vivo clinical trial, fluorescence 
spectra were acquired from the cervical tissues of 28 patients, including 66 
colposcopically normal and 49 histologically abnormal (i.e., inflammation, HPV 
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infection, and CIN) using a bifurcate fiber probe [116, 117]. Dysplasia tissue can be 
distinguished with an accuracy of ~90% using overall fluorescence intensity and the 
slope of the spectra in the region of 420~440 nm. Biochemical composition changes 
were elucidated by fitting tissue spectra with reference spectra of pure biochemicals 
[117]. Reduced collagen content occurred in dysplasia while oxyhemoglobin 
attenuation and NADH content were increased. In a later study, they developed 
multivariate statistical algorithm for the diagnosis of cervical dysplasia using PCA and 
logistic discriminant analysis, showing a sensitivity of 88%±1.4 and specificity of 
70%±1 [118]. This multivariate statistic method was further used to evaluate the 
performance of 380- and 460-nm light excited fluorescence in diagnosing cervical 
precancer [119]. Fluorescence spectroscopic diagnosis with 460-nm excitation 
outperformed over that with 380-nm excitation. 
Subsequently, several groups were involved in investigating the various variables 
associated with in vivo clinical trial on fluorescence spectroscopic diagnosis of cervical 
precancer. Utzinger et al (1999) studied whether tissue type, sample size, population 
and SNR affected the fluorescence spectroscopic diagnosis of cervical precancer [120]. 
In the same year, Agrawal et al (1999) investigated the effect of acetic acid, cervical 
mucus and vaginal medication [121]. Chang et al (2002) found that menstrual cycle 
did not result in a significant inter-patient variation and hence menstrual cycle did not 
need to be considered during fluorescence measurement [122]. However, Cox et al 
(2003) observed a reduction in the fluorescence emission in the first several days of 
one cycle and suggested no fluorescence measurement during those days [123]. Gill et 
al (2003) pointed out that menopausal status had a significant effect on the 
fluorescence spectra of cervical tissues, such as a significantly higher stroma 
fluorescence for postmenopausal women [124]. Atkinson et  al (2005) found that 
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overall fluorescence spectral intensity increased with the increase of patient age and 
Follicle Stimulating Hormone [125]. Meanwhile, Brookner et al thought that 
fluorescence spectral difference between the normal areas of cervix of patients with 
and without dysplasia history was statistically significant [126]. Nath et al (2004) and 
Rivoire et al (2004) reported that fiber probe pressure did not cause significant effect 
on the fluorescence intensity and line-shape [127, 128]. Freeberg et al (2007) described 
the device variability of fluorescence and reflectance spectroscopy and the induced 
effect on the spectral measurement [129]. The spectral data analysis should be 
performed on the stratified data as the spectral intensity varied with devices. This is in 
agreement with the findings reported by Pikkula et al (2007) [130]. 
Fluorescence imaging has been widely used to study tissue fluorescence properties 
associated with malignancy. Brookner et al (2000) observed that fluorescence intensity 
decreased in epithelium but increased in stroma of normal cervix with the increase of 
patient age [131]. Subsequently, fluorescence image pattern was correlated with tissue 
premalignancy and malignancy. Ramanujam et al (2001) recorded the fluorescence 
image of cross-sectioned cervical tissues with 365- and 440-nm light excitation [132]. 
The severe dysplasia exhibited the lowest intensity of the epithelium fluorescence, 
intensity ratio of epithelium/stroma and redox ratio. Drezek and co-workers (2001) 
reported an increase in NADH fluorescence and a reduction in collagen fluorescence 
with tissue malignant transformation [133, 134]. Similar studies and findings were also 
reported by other groups [135-138]. Besides NADH and collagen, Chang et al (2006) 
found that flavin adenine dinucleotide (FAD) fluorescence increased and keratin 
fluorescence decreased in the epithelium of dysplasia tissue relative to normal tissue 
through quantitative analysis of tissue fluorescence [139].  
Chang et al (2002) optimized the excitation light wavelength (i.e., 330~340, 350~380 
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and 400~450 nm) for fluorescence spectroscopic diagnosis of cervical precancer [140]. 
In the following year (2003), Benavides et al reported their development of a 
multispectral digital colposcopy (MDC) for in vivo detection of cervical cancer [141]. 
Dysplasia area can be identified with automated diagnostic algorithm. An extensive 
use of MDC was conducted on 46 patients by Milbourne et al (2005) [142]. The MDC 
images can be matched to histopathologic and algorithmic (non-parametric K-nearest 
neighbor classifier) maps, indicating the diagnostic potential of MDC.  
Apart from the literature above, there are some other works reported on fluorescence 
spectroscopic diagnosis of cervical precancer and cancer. Heintzelman et al (2000) 
attempted to explore the fluorescence difference between inflammation and cancer in 
cervix by using EEMs [143]. Nordstrom et al (2001) achieved a differentiation of SILs 
from normal squamous tissues with an accuracy of higher than 85% [144]. Weingandt 
et al (2002) reported that fluorescence intensity under 375- and 440-nm excitation 
decreased with tissue premalignant transformation [145]. Rodero et al (2008) proposed 
a simple intensity-based algorithm to differentiate fluorescence spectra under 488-nm 
light excitation from chronic inflammation, LGSILs and HGSILs [146]. Chidananda et 
al (2006) achieved an accuracy of higher than 95% in differentiating cervical 
malignancy from normal tissue using fluorescence spectroscopy and PCA [147]. The 
ratio of collagen/NADH showed a potential in predicting malignant tissue. 
1.5.2 Reflectance Spectroscopy 
Much less work has been done to use reflectance spectroscopy for cervical precancer 
and cancer detection as compared to fluorescence spectroscopy. Nordstrom et al (2001) 
attempted to characterize cervical precancer and benign changes using diffuse 
reflectance spectroscopy coupled with Mahalanobis distance [144]. Reflectance 
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spectroscopy showed an inferior diagnostic performance to fluorescence spectroscopy. 
Georgakoudi and co-workers (2002) measured in vivo reflectance spectra on cervix 
and extracted the scattering coefficient using a diffuse-model [148]. A sensitivity of 
62% and specificity of 82% in discriminating SILs from non-SILs was produced by 
logistic regression algorithm calculated from the slope and intercept of the reduced 
scattering coefficient function curve. Moreover, the diagnosis was improved by 
combining reflectance with fluorescence and light scattering spectra. Chang et al (2005) 
agreed on the superiority of fluorescence spectroscopy to reflectance; however, they 
did not see any improvement in the diagnosis by combining reflectance and 
fluorescence [149]. Mirabal et al (2002) combined the reflectance spectra of cervix 
measured at four different illumination-collection separations as the input of statistical 
analysis (i.e., PCA) [150]. The differentiation of normal squamous from HGSILs and 
normal columnar from HGSILs was found to be comparable to that based on 
fluorescence spectra. Marín et al (2005) extended Mirabal’s work to further explore the 
reflectance spectral pattern related to precancer on a larger patient population [151]. 
Precancer tissues showed weaker reflectance intensity as compared to normal tissues. 
They also suggested that Soret absorption of hemoglobin and the 
wavelength-dependent slope of spectra should be the most significant diagnostic 
markers.  
To better understand the in vivo reflectance spectra of cervix, Arifler et al (2006) 
proposed MC simulation method to model the in vivo spectra [152]. The effect of 
optical properties (i.e., scattering and absorption coefficients) on the reflectance 
spectra and the depth-selectivity of the probe were revealed. In a later report, Weber et 
al (2008) described an adjoint reflectance and fluorescence model to fit the in vivo 
measured spectra of cervix [153]. Volume fraction of blood, hemoglobin oxygen 
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saturation, concentration of structural protein, the strength and shape of the scattering 
in the stroma represented almost all the diagnostic information in reflectance spectra. 
Chang and co-workers (2009) also used MC method to extract the physiological 
parameters from diffuse reflectance spectra [154]. It was found that total hemoglobin 
concentration was significantly higher in HGSILs than in LGSILs and normal while 
reduced scattering coefficient was reduced in SILs compared to normal tissues. 
1.5.3 Infrared Spectroscopy 
Wong and co-workers (1991) pioneered the use of IR spectroscopy for investigating 
the structural changes of dysplastic and malignant cervical cells and tissues [155, 156]. 
The significant molecular structural changes associated with tissue malignant 
transformation included: (1) reduction in glycogen; (2) extensive hydrogen bonding of 
the phosphodiester groups of nucleic acids; (3) red-shift of IR band at 1082 cm-1; (4) 
reduction in hydrogen bonding of C-OH groups of carbohydrates and proteins; (5) 
increased degree of disorder of methylene chains of membrane lipids; (6) an additional 
band at 970 cm-1; (7) decreased methyl-to-methylene ratio; (8) hydrogen-bond strength 
amide groups decreased in α-helical segments but increased in β-sheet segments. Wood 
et al (1996) employed PCA to discriminate the IR spectra of exfoliated cells from 272 
patients [157]. Eighty-six percent of the IR-predicted normal cells showed normal pap 
smear and seventy-one percent of the IR-predicted malignancies were confirmed by 
biopsies. Similar study was conducted on a larger population of 436 patients by 
Cohenford et al (1997) and achieved a sensitivity of 79% and specificity of 77% in the 
diagnosis of cervical cancer [158]. In the same year, a sensitivity of 98.6% and 
specificity of 98.8% in detecting cervical dysplasia was reported by Fung et al (1997) 
[159]. 
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Subsequently, Chiriboga and co-workers (1997, 1998) conducted a series of studies to 
comprehensively understand the IR spectral features of cervical tissues and exfoliated 
cells [160-162]. In their first study, they collected IR spectra from cervical tissue slices 
using FTIR microscope [160]. CIN tissues showed unique glycogen bands at 1028 and 
1151 cm-1 as compared to normal squamous tissues. Then, to better interpret the 
spectra of exfoliated cells, IR spectra were acquired from various layers of normal 
squamous tissues, including superficial layer, intermediate layer, parabasal layer, basal 
layer and stroma [161]. Lastly, they reported that IR spectra of exfoliated cells can be 
fitted by the spectra of mucus and various layers so that the contribution of different 
layers can be estimated [162].  
Wood and et al (1998) took endeavor to reveal the potential confounding variables 
which may interfere or deteriorate the discrimination of neoplastic or malignant cells 
based on IR band intensity [163]. The results showed that saline, Leukocytes, severe 
infestations of C. albicans, fibroblast, endocervical mucins, sperm contamination and 
thrombocytes may affect IR measurement. Consequently, multivariate statistic 
technique was proposed for developing diagnostic algorithm. Cohenford et al (1998) 
found that normal-appearing cells from patients with dysplasia or malignancy are IR 
spectroscopically differentiable from normal cells of healthy patients [164]. Romeo et 
al (2005) suggested that benign changes and endocervical cells also influence the 
diagnosis of cervical cancer and therefore should be removed prior to PCA-based 
diagnosis [165]. They also mentioned that hormonal status led to a variation in spectral 
features of cervical cells; however, it did not confound the diagnosis of cervical 
dysplasia by PCA [166]. They also attempted to remove the blood component from 
cervical smear [167]. However, the discrimination of dysplasia from normal cells 
became even worse after removing leukocytes, which raised the question on the true 
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origins of spectral difference between normal and malignant cells. 
Apart from the spectral analysis above, mapping and imaging were proposed to 
analyze cervical tissue cryo-section. Chang and colleagues (2003) created the images 
of tissue sections with the ratio of the integrated intensities under IR bands of 
1130~1180 cm-1 and 1180~1260 cm-1, allowing a discrimination of cervical dysplasia 
from normal tissue [168]. In the following year, cluster analysis was used to build the 
image of tissue sections so as to extract IR spectral features of different cell types and 
differentiate among different tissue pathologies. Bambery et al (2004) mapped tissue 
cryo-section with both IR band intensity and clusters generated by unsupervised HCA 
[169]. The results showed that the spectra from the same layer were almost resembled 
into the same cluster. In a separate report, Wood and co-workers (2004) distinguished 
successfully the layer structures of normal, LGSILs and HGSILs tissues with the same 
method and differentiated dysplasia from normal tissue [170]. IR bands at 1470~1740 
cm-1 (amide I and II) showed a good correlation with tissue anatomy and histology. 
Steller et al (2006) suggested that IR spectroscopy coupled with Fuzzy C-means 
clustering for data reduction and HCA for classification have the ability to distinguish 
different tissue types as well as tissue pathologies [171].  
To optimize the performance of IR spectra for screening cervical dysplasia and cancer, 
neural networks was introduced for developing diagnostic algorithms. Mark et al (2004) 
reported their success in grading cervical neoplasia (i.e., CIN 1, 2 and 3) with the use 
of probabilistic neural networks (PNN) with an accuracy rate of ~85% [172]. 
Podshyvalov et al (2005) differentiated cancer from normal tissues with an accuracy 
(>95%) [173].  
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1.6 Thesis Motivations, Objectives and Organization 
1.6.1 Motivations and Objectives 
NIR Raman spectroscopy exhibites advantages for the detection of cervical precancer 
and cancer, such as non-invasive, real-time and higher accuracy, as compared to those 
conventional screening/diagnosis methods (i.e., pap smear and colposcopy). On the 
other hand, it also holds advantages over other optical spectroscopic techniques (i.e., 
UV/VIS fluorescence and reflectance spectroscopy). For instance, it can yield higher 
specificity as it is a molecular fingerprint technique. Moreover, the use of NIR 
excitation light allows a longer penetration depth in tissue and consequently the 
acquisition of Raman signal originating in deeper layer of tissues [51]. In addition, 
NIR light is noncarcinogenetic. However, most of Raman studies in characterizing 
cervical tissues are limited in fingerprint region [98, 100, 102]. Note that the 
fiber-optics materials can produce Raman and fluorescence signal in fingerprint region 
which may interference the tissue Raman signal. Consequently, optical filtering 
modules are used to eliminate the interference from fiber-optics materials and as a 
result complicate the design of Raman probe. Recently, HW Raman spectroscopy has 
been proposed for tissue characterization [8]. HW Raman probe design can be 
simplified with the use of single fiber for both excitation and collection but no optical 
filtering module as fiber-optics materials do not produce Raman scattering in HW 
region [174]. Till now, HW Raman spectroscopy for cervical tissue discrimination has 
not been reported. Meanwhile, most of Raman studies for cancer diagnosis in various 
organs, including cervix, are conducted alone and separated from other optical 
techniques. Note that different optical techniques may provide insights into different 
aspects of tissue premalignant or malignant changes [175, 176]. In particular, for 
cervix, only limited studies were conducted to combine UV/VIS fluorescence and 
  36
reflectance for the diagnosis of cervical dysplasia [148]. Therefore, this thesis work is 
conducted towards two aims. The first one is to explore the potential of HW NIR 
Raman spectroscopy for the detection of cervical precancer in vivo. The second one is 
to investigate the feasibility of combining different optical spectroscopic techniques to 
further improve the diagnosis of cervical precancer as compared to the diagnosis by 
individual spectroscopic method alone. The specific aims are as following:  
(1) To verify the capacity of NIR Raman spectroscopy in fingerprint region (800~1800 
cm-1) for discriminating cervical dysplasia ex vivo; 
(2) To develop a rapid and portable NIR Raman spectroscopy system for in vivo 
Raman measurements on cervix. An in vivo fiber-optic Raman probe design with 
the use of ball lens is proposed to enhance the depth-selective Raman measurement 
on the cervix;  
(3) To explore the feasibility of NIR Raman spectroscopy in HW region (2800~3700 
cm-1) for the in vivo diagnosis of cervical dysplasia with the use of the in vivo 
Raman system developed; 
(4) To combine Raman and NIR autofluorescence background signal to improve the 
detection of cervical dysplasia as compared to the diagnosis by Raman 
spectroscopy alone; 
(5) To optimize the optical diagnosis of cervical dysplasia through combining NIR 
Raman, UV/VIS fluorescence and diffuse reflectance spectroscopy. 
1.6.2 Thesis Organization 
This chapter has provided the background knowledge relevant to this thesis work, the 
objectives and motivations of this thesis work. The remaining thesis is organized as 
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following. Chapter 2 presents an ex vivo study on verifying the ability of Raman 
spectroscopy for differentiating benign, LGSILs and HGSILs of cervix. It describes a 
new Raman spectrum acquisition program integrated with an online-processing 
function developed for Raman spectral acquisition, spectral analysis and multivariate 
statistical analysis. Chapter 3 describes the development of a rapid portable NIR 
Raman spectroscopy for in vivo Raman measurement on cervix. It describes the design 
of a ball lens Raman probe for enhancing in vivo depth-selective Raman measurement 
on cervix in detail. MC simulation method was used to comprehensively evaluate the 
performance of this ball-lens Raman probe configured with a variety of ball lens’ 
diameter and refractive index, and probe-tissue distance. Chapter 4 reviews our work 
on investigating the feasibility of HW Raman spectroscopy for the in vivo diagnosis of 
cervical precancer using the system depicted in Chapter 3. The results demonstrated 
the efficacy of the in-house developed Raman system and the potential of HW Raman 
for discriminating cervical precancer from normal tissues. Chapter 5 depicts our work 
on exploring the possibility of combining Raman and NIR autofluorescence to 
improve the diagnosis of cervical precancer. Chapter 6 reports our attempt to combine 
Raman spectroscopy with UV/VIS fluorescence and diffuse reflectance spectroscopic 
techniques for optimizing the optical diagnosis of cervical precancer. Chapter 7 
summarizes the whole thesis and also gives the future directions. 
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Chapter 2 NIR Raman Spectroscopy for Ex Vivo Detection of 
Cervical Precancer: Multivariate Statistical Analysis and 
Spectral Modeling 
Raman spectroscopy is a unique analytic probe for molecular vibrations and can 
provide molecular fingerprint information of biochemical compositions in tissues. It 
has proven to have the potential for diagnosing precancer and cancer in various human 
organs through probing the biochemical changes associated with tissue cancerous 
transformation. In this chapter, we presented our work on verifying the capabilities of 
Raman spectroscopy in fingerprint region (800~1800 cm-1) for the ex vivo detection of 
cervical dysplasia. A rapid NIR Raman spectroscopy system combined with a bifurcate 
fiber-optic Raman probe was employed for the Raman spectroscopic measurements on 
cervical tissues. A novel data acquisition program was developed using LabVIEW and 
Matlab. In total, 80 spectra were acquired from 30 samples, including 24 spectra from 
9 benign tissues, 34 spectra from 12 LGSILs tissues and 22 spectra from 9 HGSILs 
tissues. Empirical analysis method (i.e., intensity ratio) was used to differentiate 
precancer from benign tissues. PCA and LDA were employed to develop diagnostic 
algorithms. Moreover, tissue spectrum was fitted with reference spectra of pure 
biochemicals using linear least-squares fitting method to elucidate the biochemical 
changes behind Raman spectral variation associated with tissue dysplastic changes. 
The results demonstrated that NIR Raman spectroscopy has the potential to diagnose 
cervical precancer. 
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2.1 Materials and Methods 
2.1.1 Cervical Tissue Samples 
A total of 30 cervical biopsied tissue specimens were obtained from patients who 
underwent colposcopy-guided biopsy or surgical resection for clinically suspicious 
lesions or histologically proven premalignancies. All the patients preoperatively signed 
an informed consent permitting our Raman study on the tissues and this study was also 
approved by the Ethics Committee of the National Healthcare Group of Singapore. 
After biopsy or surgical resection, tissue specimens were immediately stored in 
physiologic saline solution (pH=7.4) and delivered to our laboratory for Raman 
spectroscopic measurement without any pretreatment on the tissue specimens. After 
Raman spectroscopic measurement, tissue specimens were fixed in 10% formalin 
solution and then submitted to the pathology laboratory for histopathological 
examination. The histology results showed that 9 specimens are benign, 12 specimens 
are LGSILs and 9 specimens are HGSILs as shown in table 2.1. Benign tissues 
comprise chronic cervicitis, squamous metaplasia, inflammation and koilocytic atypia. 







of Spectra Chinese Indian Malay others 
Benign 9 0 0 0 29~56 (42.2) 9 24 
LGSILs 7 0 2 1 27~64 (43.5) 12 34 
HGSILs 6 1 1 1 22~48 (37.7) 9 22 
2.1.2 Reference Spectra of Biochemicals 
Five biochemicals were selected to fit Raman spectra of cervix. The five biochemicals 
are: collagen type I, glycogen, DNA, oleic acid and cholesterol (Sigma-Aldrich, St. 
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Louis, MO).  
2.1.3 Raman Instrumentation 
A rapid NIR Raman spectroscopy system was employed for the tissue Raman 
measurement in optical bioimaging laboratory at National University of Singapore. 
Figure 2.1 shows the schematic diagram of the Raman system [78]. The whole system 
mainly consists of a spectrum stabilized 785-nm diode laser (maximum output, 300 
mW; B&W Tek, Newark, DE), a transmissive imaging spectrograph (Holospec f/2.2, 
Kaiser Optical Systems, Ann Arbor, MI), a NIR-optimized, back-illuminated, and 
deep-depletion CCD camera (1340×400 pixels at 20×20 μm/pixel; Spec-10: 
400BR/LN, Princeton Instruments, Trenton, NJ), and a specially developed bifurcated 
fiber-optic Raman probe. The probe is 1.8 mm in outer diameter and 2.5 m in length, 
and comprises 33 ultralow-OH fused-silica fibers (NA=0.22) in which one 200-μm 
central fiber is used for laser light delivery while thirty-two 200-μm surrounding fibers 
are for Raman signal collection. The excitation light is exported out from the diode 
laser by a 200-µm core diameter fiber and then coupled into the central excitation fiber 
of the fiber-optic probe through an in-line filter module integrated with a narrow 
band-pass filter (LL01-785, Semrock, Rochester, NY) for suppressing laser noise, 
fluorescence, and Raman emission from the exporting fiber. Another narrow band-pass 
filter (centered at 785 nm, FWHM = ±2.5 mm) is coated on top of the distal end of the 
excitation fiber to reduce most of the fused-silica noise generated in the excitation 
fiber before the excitation light hits the tissue. The back-scattered Raman photons are 
filtered by an edge long-pass filter (cut off at 800 nm) coated on top of the distal end of 
the collection fibers to block the elastically scattered excitation light prior to being 
collected by the surrounding fibers. Subsequently, the Raman photons are coupled into 
the fiber bundle adapter via an in-line filter module integrated with an edge long-pass 
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filter (LP02-785RU, Semrock, Rochester, NY) for further reduction of the scattered 
laser light while permitting the scattered-tissue Raman photons to pass through toward 
the Raman spectrograph. Eventually, the fiber bundle feeds the Raman photons into the 
Raman spectrograph. The fiber bundle comprises sixty-four 100-μm ultralow-OH 
fibers (NA=0.22; length=1.5 m) and is packed in a round geometry at the long-pass 
in-line filter module. At the entrance slit of the Raman spectrograph, the fiber bundle is 
arranged as a parabolic linear array in an orientation opposite to the image aberration 
of the transmissive spectrograph, which effectively corrects spectrograph image 
aberrations, thereby enables the hardware binning of the entire CCD chip to improve 
the SNR up to 20-fold (400/√400) compared to the complete software binning. The 
spectral resolution of our system is approximately 9 cm-1 (a 100-μm core diameter 
fiber covers 6 pixels with a 1.25×magnification of the spectrograph; each pixel covers 





Figure 2.1 Schematic of the NIR Raman spectroscopy system. BPF: Band Pass Filter; 
LPF: Long Pass Filter.  
2.1.4 Raman Data Acquisition Program Development 
The commercial software for hardware controlling and data acquisition is WinSpec 
(Princeton Instruments, Trenton, NJ). In addition to data acquisition, it is also 
integrated with correction and math functions (i.e., background subtraction and 
smoothing). However, it cannot extract the true tissue Raman spectrum from the raw 
spectrum by eliminating the tissue autofluorescence background. Therefore, we 
developed our own Raman data acquisition program using LabVIEW (National 
Instruments, Austin, TX) and Matlab (The MathWorks, Natick, MA). The most 
significant function provided by our program is to fit the autofluorescence background 
with a polynomial and then subtract it from raw tissue spectrum to yield the true tissue 
Raman spectrum alone in real-time. The program interface is shown in Fig. 2.2. The 
left two spectral windows are a mixture of raw spectrum and fitted autofluorescence 
background (top) and Raman spectrum after autofluorescence background subtraction 
(bottom). The right two spectral windows show the counterpart after smoothing. The 
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complete functions integrated into this program include: (1) set detector temperature; 
(2) set integration time; (3) wavelength-dependent system response function 
calibration; (4) dark subtraction; (5) smoothing; (6) autofluorescence background 
fitting and subtraction; (7) data save. 
 
Figure 2.2 The interface of Raman data acquisition program developed using LabVIEW and 
Matlab. 
2.1.5 Raman Measurement 
All the tissue Raman measurements were done in a light-tight box which can eliminate 
most of the interference from the environmental lights (e.g., computer monitor, light 
indicators). Tissue specimens were mounted onto aluminum foil which does not 
produce Raman signal interference. The laser light irradiance on tissue is 1.56 W/cm2 
which is less than the American National Standards Institute (ANSI) maximum 
permissible skin exposure limit for a 785-nm laser light beam [177]. All the Raman 
spectra were acquired over the range of 781.1~934.1 nm. The spectrum acquisition 
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time was adjusted from 1 to 3 seconds according to the overall intensity and SNR. 
Raman frequencies were calibrated with the spectra of cyclohexane, acetone and 
barium sulfate to an accuracy of ±2cm-1 (the digital data resolution of the CCD 
detector). All spectra were corrected for the wavelength-dependent intensity response 
function of the system using a standard lamp (RS-10, EG&G Gamma Scientific, San 
Diego, CA). 
2.1.6 Data Preprocessing 
The raw spectra acquired from tissue were truncated in the range of 800~1800 cm-1 for 
preprocessing and analysis. The Raw spectra were composed of intense 
autofluorescence, noise and very weak tissue Raman scattering signal. Firstly, the raw 
spectra were preprocessed by a first order Savitzky-Golay filter (window size: 5 pixels) 
to reduce noise [178]. Secondly, a fifth order polynomial was found to optimally fit the 
autofluorescence background signal of all the noise-reduced spectra [51]. The fitted 
polynomial was subtracted from the noise-reduced spectrum to yield the Raman 
spectrum alone. Finally, each background-subtracted tissue Raman spectrum was 
normalized to the integration area under the spectrum to correct the inter- and/or 
intra-patient variation in absolute spectral intensity so as to enable a better comparison 
on the spectral line-shape and relative Raman band intensity. Prior to the statistical 
analysis, empirical analysis method (i.e., intensity ratio of different Raman bands) was 
employed to explore the diagnostic potential of Raman spectroscopy for cervical 
precancer. The histology results serve as the gold standard for us to evaluate the 
sensitivity and specificity of the diagnostic algorithm. 
2.1.7 Multivariate Statistical Analysis 
PCA was firstly performed on the tissue spectral dataset to reduce the data dimension 
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while retaining the most diagnostically significant information for effective tissue 
classification. To eliminate the influence of inter- and/or intra-subject spectral 
variability on PCA, the entire spectra were standardized so that the mean of the spectra 
was zero, and the standard deviation (SD) of all the spectral intensities was one. Mean 
centering ensures that the principal components (PCs) form an orthogonal basis [179, 
180]. The standardized dataset was assembled into data matrices with wavenumber 
columns and individual case rows. Thus, PCA was conducted on the standardized 
spectral data matrices to generate PCs comprising a reduced number of orthogonal 
variables that accounted for most of the total variance in original spectra. Each loading 
vector is related to the original spectrum by a variable called the PC score, which 
represents the weight of that particular component against the basis spectrum. PC 
scores reflected the differences between different classes. One-way analysis of 
variance (ANOVA) was used to identify the most diagnostically significant PCs (p<0.1) 
among benign, LGSILs and HGSILs. These significant PC scores were lastly selected 
as the input of LDA for developing trichotomous classification algorithms. LDA 
determines the discriminant function that maximizes the variances in the data among 
different groups while minimizing the variances among the members within the same 
group. The performance of the diagnostic algorithms rendered by the PCA-LDA 
models for correctly predicting the tissue groups was estimated in an unbiased manner 
using the leave-one spectrum-out, cross-validation method on all model spectra [179, 
181].  
To evaluate the overall trichotomous classification accuracy, a Mossman’s three-way 
Receiver Operating Characteristic (ROC) testing was performed [182]. A ROC surface 
was created by utilizing the posterior probabilities belonging to each of the three tissue 
groups (i.e., benign, LGSILs and HGSILs) produced by PCA-LDA diagnostic model. 
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Each case has three probabilities P1, P2 and P3 (P1+P2+P3=1) belonging to group 1, 2 
and 3, respectively. A threshold value (e.g., T-value 1 = 0:0.1:1) is chosen for judging 
whether a case is from group 1 or not. If P1>T-value 1, then this case is clustered into 
group1; If P1<T-value 1, another threshold (e.g., T-value 2 = −1: 0.2:1) is chosen for 
deciding whether this case is from group 2 or group3. If (P2−P3)>T-value 2, then this 
case is classified into group 2; otherwise, it is classified into group 3. As a result, with 
11×11 different combinations of T-value 1 and 2, 121×3 matrices of correct 
classification rates will be yielded, of which each column is the correct classification 
rate for one group. Then, this matrix can be plotted in three-dimension to create the 
ROC surface. The volume under the three-way ROC surface (VUS) equals the 
probability that the tissue is identified correctly. Thus, VUS represents the overall 
three-group classification accuracy as the area under ROC curve for a two-group 
classification.  
2.1.8 Spectral Modeling 
Linear least-squares fitting with nonnegativity constraints was employed to fit tissue 
spectrum with reference spectra of biochemicals (i.e., collagen, glycogen, DNA, 
cholesterol and oleic acid) [17]. The contribution of each reference spectrum to tissue 
spectrum was calculated by normalizing the fit coefficients such that they sum to one. 
The normalized coefficients represent the percentage of each component’s contribution 
to the target tissue spectrum. LDA was used to evaluate the diagnostic value of the 
normalized fitting coefficients for all the five reference spectra.  
2.2 Results 
2.2.1 Spectral Feature Analysis 
Figure 2.3 shows the averaged Raman spectra yielded by subtracting the 
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autofluorescence background from the raw spectra. It was apparent that the tissue 
Raman spectrum was dominated by a few prominent Raman peaks located in the 
vicinities of 849, 932, 1004, 1039, 1063, 1085, 1125, 1178, 1206, 1254, 1285, 1317, 
1339, 1449, 1580 and 1658 cm-1. However, the tissue Raman spectrum was subject to a 
significant inter- and/or intra- patient intensity variation illustrated by SD as shown in 
the Fig. 2.3. Moreover, it is also challenging in clinical practice to standardize the 
absolute intensities of spectral measurements. Therefore, in this study, we precluded 
tissue diagnosis based on absolute intensities alone; instead, we focused on the 
analysis of the spectral line shape and relative Raman band intensity by normalizing 
the Raman spectrum to the integrated area under the spectrum. 






















Figure 2.3 The averaged Raman spectra±1SD of: (a) benign=24, (b) LGSILs=34, and (c) 
HGSILs=22. Line: averaged spectrum; Grey band: ±1SD. 
Figure 2.4 depicts the average intensity-normalized Raman spectra: (a) benign and 
LGSILs, (c) benign and HGSILs, (e) LGSILs and HGSILs. Significant spectral 
differences were observed among different types of tissues (i.e., benign, LGSILs and 
HGSILs). To better visualize the spectral difference, the difference spectra were 
produced, including LGSILs−benign, HGSILs−benign and HGSILs−LGSILs as shown 
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in Figs. 2.4((b), (d) and (f)), respectively. The spectral intensity was found to increase 
or decrease progressively from benign to LGSILs to HGSILs in the spectral region 
filled with grey color. For instance, Raman peaks at 1004, 1339 and 1449 cm-1 showed 
a continuous increase in intensity with the progression of tissue changes from benign 
to HGSILs while Raman peaks at 849 and 1658 cm-1 showed otherwise. It was noted 
that those prominent Raman peaks can be tentatively assigned to chemical bonds in 
tissues according to the literature report [5, 51]. Hence, those Raman spectral changes 
can represent the biochemical composition and molecular structural changes and 
therefore be related to the tissue precancerous changes. Eventually, they may provide 
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Figure 2.4 The averaged normalized Raman spectra of: (a) benign and LGSILs, (c) benign 
and HGSILs and (e) LGSILs and HGSILs. The corresponding difference spectra are: (b) 
LGSILs−benign, (d) HGSILs−benign, and (f) HGSILs−LGSILs. 
2.2.2 Empirical Analysis  
To verify the potential of Raman spectroscopy for tissue classification, empirical 
method (i.e., intensity ratio of Raman peaks) was firstly employed to develop 
diagnostic functions for characterizing the dysplastic cervical tissues by utilizing those 
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prominent Raman peaks. Figure 2.5 shows several scatter plotting examples of the 
intensity ratios of Raman peaks for the differentiation among benign, LGSILs and 
HGSILs with high accuracies. For example, single ratio of I849/I1004 can achieve a 
sensitivity of 73.5% (25/34) and specificity of 79.2% (19/24) in differentiating LGSILs 
from benign tissues with the diagnostic function of ratio (2.56). For the discrimination 
of HGSILs from benign tissues, the combinations of I932/I1449 vs I1339/I1658 and I932/I1449 
vs I1449/I1658 were found to be optimal, showing a sensitivity of 100.0% and specificity 
of 66.7% (16/24) and 70.8% (17/24), respectively. For the separation of HGSILs from 
LGSILs, the combinations of I932/I1254 vs I932/I1658 and I932/I1449 vs I1004/I1658 achieved 
the best diagnostic performance, showing a sensitivity of 68.2% (15/22) and 63.6% 
(14/22), and specificity of 97.1% (33/34) and 100.0% (34/34), respectively.  





































































Figure 2.5 Scatter plots of the intensity ratio of Raman bands: (a) benign vs LGSILs, 
I849/I1004; (b) benign vs HGSILs, I932/I1449 vs I1339/I1658; (c) benign vs HGSILs, I932/I1449 vs 
I1449/I1658; (d) LGSILs vs HGSILs, I932/I1254 vs I932/I1658; (e) LGSILs vs HGSILs, I932/I1449 vs 
I1004/I1658; Simple straight-line diagnostic function can achieve sensitivities and specificities 
of: (a) 73.5% (25/34) and 79.2% (19/24); (b) 100.0% (22/22) and 66.7% (16/24); (c) 
100.0% (22/22) and 70.8% (17/24); (d) 68.2% (15/22) and 97.1% (33/34); (e) 63.6% (14/22) 
and 100.0% (34/34), respectively. Key: (○ in black) benign; (Δ in blue) LGSILs; (☆ in red) 
HGSILs. 
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2.2.3 PCA-LDA and ROC Analysis  
It was noticed that the diagnostic accuracy achieved by intensity ratio method is 
limited. This may be explained by the use of only limited spectral variables, indicating 
a limited use of the Raman spectral features. Therefore, a comprehensive use of all the 
Raman spectral variables was desired to further improve the diagnostic performance. 
Hence, multivariate statistical techniques (i.e., PCA and LDA) were proposed to 
develop the diagnostic algorithms with the utilization of the spectral features in the 
whole spectral range (800~1800 cm-1). 
Figure 2.6 displays the first six diagnostically significant PC loadings yielded by PCA 
on the tissue Raman spectral data: (a) PC1, (b) PC2, (c) PC4, (d) PC5, (e) PC6 and (f) 
PC11. It was found that all the six PCs appeared to contain many narrow bands and 
some of the PC features can roughly be related to the Raman spectra with peaks and 
troughs positions similar to those of tissue Raman spectra. Table 2.2 lists those six 
PCs’ mean scores±1SD for benign, LGSILs and HGSILs tissue groups, p-value and 
percent of total variance. The total variance covered by PC1, PC2, PC4, PC5, PC6 and 
PC11 is 27.2%, 15.3%, 11.5%, 8.0%, 4.4% and 1.3%, respectively. The first three PCs 
(PC1, PC2 and PC5) can represent more than 50% of the total variance. These results 
indicate the amount of the diagnostic information contained in the Raman spectra for 





























































Figure 2.6 Examples of the first six diagnostically significant PCs with p-value<0.1: 
(a) PC1, (b) PC2, (c) PC4, (d) PC5, (e) PC6 and (f) PC11. 
Table 2.2 The mean scores±1SD for benign, LGSILs and HGSILs tissue groups, p-value, 
percent of total variance of the first six diagnostically significant PCs. 
 
PC 
Mean Score ±SD  
p-value 
Percent of  
Total Variance 
Benign LGSILs HGSILs 
PC1 -0.187±0.908 -0.146±1.150 0.429±0.718 0.05876 27.2 
PC2 0.077±0.759 -0.411±0.936 0.552±1.075 0.00125 15.3 
PC4 -0.223±1.045 -0.119±1.066 0.428±0.712 0.05603 11.5 
PC5 0.566±0.779 -0.530±0.942 0.203±0.916 0.00004 8.0 
PC6 -0.122±0.998 -0.167±0.991 0.391±0.952 0.09574 4.4 
PC11 0.095±0.972 0.253±0.889 -0.495±1.056 0.01859 1.3 
To illustrate the ability of PC scores for tissue characterization, the first six 
diagnostically significant PC scores were scatter-plotted as shown in Figs. 2.7 to 2.9. 
Figure 2.7 describes the scatter plots of PC2, PC4, PC5 and PC11 for the separation 
between benign and LGSILs: (a) PC2 vs PC5, (b) PC2 vs PC11 (c) PC4 vs PC5, (d) 
PC5 vs PC11. It was noticed that LGSILs can be discriminated from benign tissues by 
straight-line diagnostic functions. Almost 75% of the tissues can be characterized 
correctly, indicating that PC2, PC4, PC5 and PC11 contained a wealth of diagnostic 
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information for discriminating LGSILs from benign. Similarly, Fig. 2.8 depicts the 
scatter plots of PC1, PC2, PC4, PC5 and PC11 for distinguishing HGSILs from benign 
tissues: (a) PC1 vs PC11, (b) PC2 vs PC4 (c) PC2 vs PC11, (d) PC4 vs PC5. The 
straight-line can roughly represent the diagnostic function which can distinguish 
around 76% of the tissues, indicating the diagnostic information provided by the PCs. 
Figure 2.9 shows the scatter plots of PC2, PC4, PC5 and PC11, which can separate 
HGSILs from LGSILs with an accuracy of about 80%, demonstrating the diagnostic 
ability of those PCs.  














































Figure 2.7 Scatter plots of the diagnostically significant PC scores for benign and LGSILs 
tissues: (a) PC2 vs PC5, (b) PC2 vs PC11 (c) PC4 vs PC5, (d) PC5 vs PC11. LGSILs can be 
discriminated from benign tissues by straight-line diagnostic functions: (a) PC5 = 
−0.61×PC2+0.2, (b) PC11 = 2.1×PC2+0.41, (c) PC5 = 0.76×PC4+0.95 and (d) PC11 = 
−1.68×PC5+0.29. The corresponding sensitivities and specificities are: (a) 79.4% (27/34) 
and 75.0% (18/24), (b) 76.5% (26/34) and 70.8% (17/24), (c) 85.3% (29/34) and 70.8% 
(17/24), and (d) 79.4 % (27/34) and 75.0 % (18/24), respectively. Key: (○ in black) benign; 
(Δ in blue) LGSILs. 
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Figure 2.8 Scatter plots of the diagnostically significant PC scores for benign and HGSILs 
tissues: (a) PC1 vs PC11, (b) PC2 vs PC4 (c) PC2 vs PC11, (d) PC4 vs PC5. HGSILs can be 
discriminated from benign tissues by straight-line diagnostic functions: (a) PC11 = 
1.39×PC1+0.31, (b) PC4 = −0.19×PC2+0.14, (c) PC11 = 1.11×PC2−0.34 and (d) PC5 = 
1.03×PC4+0.6. The corresponding sensitivities and specificities are: (a) 81.8% (18/22) and 
70.8% (17/24), (b) 72.7% (16/22) and 79.2% (19/24), (c) 86.4% (19/22) and 70.8% (17/24), 
and (d) 81.8% (18/22) and 66.7% (16/24), respectively. Key: (○ in black) benign; (☆ in red) 
HGSILs. 

















































Figure 2.9 Scatter plots of the diagnostically significant PC scores for LGSILs and HGSILs 
tissues: (a) PC2 vs PC5, (b) PC2 vs PC11 (c) PC4 vs PC5, (d) PC4 vs PC11. HGSILs can be 
discriminated from LGSILs by straight-line diagnostic functions: (a) PC5 = −2.5×PC2−0.08, 
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(b) PC11 = 1.09×PC2−0.14, (c) PC5 = −0.78×PC4+0.53 and (d) PC11 = 1.24×PC4−0.21. 
The corresponding sensitivities and specificities are: (a) 86.4% (19/22) and 79.4% (27/34), 
(b) 86.4% (19/22) and 79.4% (27/34), (c) 63.6% (14/22) and % 85.3(29/34), and (d) 86.4% 
(19/22) and 79.4% (27/34), respectively. Key: (Δ in blue) LGSILs; (☆ in red) HGSILs. 
To further improve the diagnosis, LDA was used to incorporate all the significant PCs 
for developing diagnostic algorithms. For the three-group classification, two linear 
discrimination (LD) functions were generated. Figure 2.10 shows the scatter plot of 
two LD weights for the classification of benign, LGSILs and HGSILs. It was seen that 
most of the tissues can be clustered into the three histopathological groups (i.e., benign, 
LGSILs and HGSILs). The posterior probabilities of each tissue site belonging to 
benign, LGSILs and HGSILs were plotted in a ternary plate (Fig. 2.11). It was found 
that all HGSILs had posterior probabilities higher than 80% to be HGSILs except two 
HGSILs with posterior probabilities between 50% and 80%. In comparison, posterior 
probabilities of LGSILs and benign distributed more diversely. Seven benigns 
exhibited posterior probabilities below 75% (i.e., 0~25% (2), 25~50% (2) and 50~75% 
(3)) belonging to benign. Five LGSILs’ posterior probability was located in 0~25% (1), 
25~50% (2) and 50~75% (2) belonging to LGSILs. This distribution also indicates the 
efficacy of the PCA-LDA model for characterizing benign, LGSILs and HGSILs. 
Table 2.3 summarizes the classification results achieved by the PCA-LDA diagnostic 
algorithms with leave-one-out cross-validation methods. Overall, 92.5% of the tissues 
were predicted correctly, among which 83.1% of benign, 94.1% of LGSILs and 
100.0% of HGSILs (sensitivity) were discriminated correctly. Four benigns were 
misclassified, of which two as LGSILs and two as HGSILs. Meanwhile, two LGSILs 
were misclassified as benign and HGSILs, respectively. The corresponding specificity 
and accuracy were 98.2% and 93.8% for benign, 96.6% and 95.0% for LGSILs, 94.8% 
and 96.3% for HGSILs. Figure 2.12 depicts the three-way ROC surface for this 
three-group classification with the ROC-VUS of 0.815.  
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Linear Discrimination Function 1  
Figure 2.10 Scatter plot of two LD function weights for benign, LGSILs and 
HGSILs tissues tested with leave-one-out cross-validation. Key: (○ in black) 
benign; (Δ in blue) LGSILs; (☆ in red) HGSILs. 





































Posterior Probability belonging to Benign (a.u.)  
Figure 2.11 Two-dimensional ternary plot of the posterior probabilities 
belonging to benign, LGSILs and HGSILs, respectively, using the 
PCA-LDA-based spectral classification with leave-one spectrum-out, 
cross-validation method. Each vertex of the triangle represents a 100% 
confidence that the tissue is benign, LGSILs or HGSILs. Key: (○ in black) 




Table 2.3 Classification results of Raman-prediction for the three cervical tissue groups 












Benign 20 2 2 24 
LGSILs 1 32 1 34 
HGSILs 0 0 22 22 
Outcome measure* benign LGSILs HGSILs  
Sensitivity (%) 83.3 94.1 100.0  
Specificity (%) 98.2 96.6 94.8  
Accuracy (%) 93.8 95.0 96.3 92.5 








































Figure 2.12 Three-dimensional view of the ROC surface calculated from the posterior 
probabilities belonging to benign, LGSILs and HGSILs with a VUS of 0.815. 
2.2.4 Biochemical Model of Tissue Spectrum 
To explore the biochemical origins accounting for the Raman spectral features, tissue 
spectrum was fitted with reference spectra of pure biochemicals using linear 
least-squares method with nonnegativity constraints. Figure 2.13 shows the Raman 
spectra of reference biochemicals, including cholesterol, DNA, oleic acid, collagen, 
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and glycogen which are considered as the major Raman scatterers in cervical tissues 
[173, 183-186]. It was obvious that each biochemical showed unique Raman spectral 
pattern composed of several Raman peaks. To estimate the similarity between each 
reference spectrum and tissue spectrum, correlation was calculated for all the 
biochemicals with tissue spectra. The correlation coefficients are yielded by dividing 
the covariance of biochemical spectrum and tissue spectrum by the standard deviations 
of biochemical spectrum and tissue spectrum. The yielded correlation coefficients were 
cholesterol-0.62, oleic acid-0.52, DNA-0.82, collagen-0.88 and glycogen-0.41. The 
correlation coefficients quantified the similarity between reference spectrum and tissue 
spectrum, indicating that collagen was the most alike with tissue spectrum. 









Figure 2.13 Reference Raman spectra of glycogen, collagen, DNA, oleic acid and 
cholesterol. 
Figure 2.14 shows an example of tissue spectrum, fitted spectrum and the 
corresponding residue: (a) benign tissue, (b) dysplasia tissue. It was noticed that tissue 
spectrum was fitted well with the five reference spectra except the spectral regions of 
1000~1200 cm-1. Figure 2.15 shows the mean fitting contribution±1SD of each 
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reference biochemical to benign and dysplasia tissues. It was found that collagen made 
the largest contribution to Raman signal of both benign and dysplasia tissues. 
Moreover, the contribution of each reference biochemical was significantly different 
between benign and dysplasia tissues illustrated by unpaired two-sided Student’s t-test. 
For example, collagen and glycogen exhibited a significantly reduced contribution to 
Raman signal of dysplasia tissue as compared to benign tissue. In contrast, cholesterol, 
DNA and oleic acid showed a significantly higher contribution to Raman signal of 
dysplasia than benign tissue. The above results demonstrate that Raman spectroscopy 
is able to directly assess the biochemical changes associated with premalignant 
transformation in the cervix. To further evaluate the diagnostic value of the fitting 
coefficients, LDA was implemented on the fitting coefficients to develop diagnostic 
algorithm. It yielded a sensitivity, specificity and total accuracy of 69.6%, 75.0% and 
71.3%, respectively.   



























Figure 2.14 Comparison of tissue spectrum and fitted spectrum with reference spectra: (a) 




















Figure 2.15 Mean normalized fitting coefficients with 1±SD for component biochemicals, 
including glycogen, collagen, oleic acid, DNA and cholesterol for benign and dysplasia 
tissues. 
2.3 Discussion 
In this study, we verified the capacity of NIR Raman spectroscopy for characterizing 
pre-dysplasia (benign changes: chronic cervicitis, squamous metaplasia, inflammation 
and koilocytic type atypia) and dysplasia (LGSILs and HGSILs) in the cervix. In the 
clinic diagnosis point of view, the discrimination between benign and dysplasia is not 
the whole colposcopic practice in clinic. The discrimination between LGSILs from 
HGSILs is also clinically desirable. The reason is that LGSILs have a high rate to 
regress to normal without any treatment and however the current colposcopic 
diagnosis is likely to overestimate LGSILs as HGSILs [187]. Meanwhile, 
discrimination between benign and LGSILs is even more challenging because some 
benign changes of cervix may also show some features of LGSILs [188]. For instance, 
inflammation may also exhibit vascular atypia which is the hallmark of high grade 
lesion, and metaplasia may exhibit acetowhite due to the cellular changes [187, 188]. 
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This may increase the false-negative rate for diagnosing dysplasia. Therefore, a 
three-class diagnostic model based on PCA-LDA was developed to discriminate either 
of benign, LGSILs and HGSILs from the remainder.  
Good quality Raman spectra were acquired successfully from benign, LGSILs and 
HGSILs tissues. A high spectral similarity occurred among Raman spectra of benign, 
LGSILs and HGSILs, of which all showed almost the same major Raman vibration 
bands in the vicinities of 849, 932, 1004, 1039, 1063, 1085, 1125, 1178, 1206, 1254, 
1285, 1317, 1339, 1449, 1580 and 1658 cm-1. This implies that the composition of the 
major biochemicals did not alter a lot with the presence of different pathologies. 
Consequently, only subtle spectral differences existed among benign, LGSILs and 
HGSILs, which were manifested clearly in the difference spectra as shown in Fig. 2.4 
((b, (d) and (f)). To elucidate the biochemical basis behind the spectral differences 
above, those major Raman bands were tentatively assigned to vibration bonds of a 
variety of biochemicals in tissues as shown in table 2.4 according to literature [5, 51, 
108, 189]. Consequently, the spectral variations among different types of tissues can be 
explained by the corresponding biochemical changes in tissue accompanying the tissue 
neoplastic changes. For example, Raman peak at 1658 cm-1 (Amide I, C=O stretching 
mode of collagen and elastin) appeared to decrease as tissue progresses from benign to 
LGSILs to HGSILs, which is consistent with the reported findings in literature [98, 
100, 190]. This may be due to a decrease in the relative concentration of collagen and 
elastin. This may also be attributed in part to the epithelium thickening and increased 
cellular density due to the enlarged nucleus-to-cytoplasm ratio associated with tissue 
malignant transformation. This induces a larger attenuation of both excitation light and 
Raman signal from the collagen in stroma since the underlying stroma is well 
recognized to be rich in collagen and elastin [70, 72, 191, 192]. In addition, the Raman 
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signal originating from the stroma of dysplastic cervix also suffers from larger 
hemoglobin absorption due to the neovascularization as compared to normal or benign 
cervix [193]. Meanwhile, another two peaks at 849 (C-C stretching of proline ring and 
ring breathing mode of tyrosine) and 1125 cm-1 (C-C stretching of lipid, C-N stretching 
of protein) followed the same variation trend. The intensity decrease in Raman peak at 
849 cm-1 suggests that the relative concentration of proline and tyrosine drop in 
neoplastic cervical tissues. For the Raman peak at 1125 cm-1, it may result from the 
epithelium thickening. In contrast, some other Raman peaks at 1004, 1339 and 1449 
cm-1 varied in the opposition way. Raman peak at 1004 cm-1 which is associated with 
phenylanaline showed a higher signal in precancer tissue, indicating an increase in the 
essential amino acid phenylanaline relative to the total Raman-active components in 
the precancer tissue due to the fact that cancer cells take up more essential amino acids 
[194]. Raman peak at 1339 cm-1 is mainly attributed to nucleic acid. Hence, its 
intensity elevation may be attributed to the increase in the concentration of nucleic 
acid relative to the total Raman-active scatterers, which gets in an agreement with the 
literature [5] as well as the well-accepted histopathological feature of increased 
nucleus-to-cytoplasm ratio in malignant tissue [195]. For the Raman peak at 1449 cm-1, 
the intensity increase is probably because the lipid content is elevated in neoplastic 






Table 2.4 Tentative assignments of major Raman vibration bands present in the Raman 
spectra of cervical tissues [5, 51, 108, 189]. 
Peak positions (cm-1) Biochemical assignments 
849 C−C stretching of proline ring, Ring breathing mode of  
tyrosine 
932 C−C stretching mode of proline and valine and protein 
backbone (α−helix conformation)/glycogen 
1004 Symmetric ring breathing mode of phenylalanine 
1039 C−H in-plane bending mode of phenylalanine 
1063 C−N stretching mode of protein 
1085 C−C/C−O stretching of phospholipids 
1125 C−C stretching of lipid, C−N stretching of protein 
1178 C−H in-plane bending mode of tyrosine 
1206 C−C6H5 stretching mode of tryptophan and 
phenylalanine 
1254 Amide III (C−N stretching mode of proteins, indicating 
mainly α−helix conformation) 
1285 Amide III 
1317 CH3CH2 twisting mode of collagen/lipids 
1339 CH3CH2 wagging mode of collagen/nucleic acid 
1449 CH2 and CH3 bending mode of collagen, CH2 bending, 
scissoring mode of phospholipids 
1580 C=C bending mode of phenylalanine, pyrimidine ring 
1658 Amide I (C=O stretching mode of collagen and elastin, 
α−helix conformation) 
The diagnostic potential of these prominent Raman bands were explored directly by 
intensity ratio method. For the differentiation between benign and LGSILs, ratio of 
Raman bands I849/I1004 achieved an accuracy of 75%, implying that the changes of 
proline ring and tyrosine (I849) and phenylanaline (I1004) is diagnostically valuable. As 
for separating HGSILs from benign, higher-than-80% accuracy achieved by ratios of 
Raman bands at 932, 1340, 1449 and 1658 cm-1 implies the diagnostic value of the 
changes of proline, DNA, lipid and protein. Among them, proline, lipid and protein 
combined with Amide III can also be used to discriminate HGSILs from LGSILs with 
an accuracy of higher than 85%. These results demonstrate that Raman spectral 
variation among different types of tissues can represent the biochemical composition 
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and molecular structure changes associated with tissue malignant transformation, and 
contain a wealth of information for tissue diagnosis.  
However, the diagnostic accuracy yielded by the intensity ratio method is limited due 
to the fact that only a few individual Raman bands are included for developing 
diagnostic algorithm while missing a lot of biochemical information contained in the 
spectra unused [5]. Therefore, multivariate statistical techniques (e.g., PCA) are 
desired to utilize all the subtle spectral changes to differentiate different types of 
tissues. PCA has been widely used to retrieve the Raman spectral features into the 
size-reduced dataset. Moreover, the PC scores have proven to have the potential for 
distinguishing tissues under different histopathological conditions by simple scatter 
plots of the PC scores. Teh et al achieved a good classification of gastric dysplasia 
from normal gastric tissue by using the scatter plot of a pair of PCs with a accuracy of 
about 90% [70]. This method has also been verified by Huang et al [175, 190]. 
Similarly, in this study, the scatter plots of the first six significant PCs prove again to 
be able to cluster the tissues into different histopathological categories (i.e., benign, 
LGSILs and HGSILs). 
However, scatter plot of PC scores only used two PC scores while missing the 
remaining diagnostic PC scores. Hence, in this study, LDA was further employed to 
utilize all the diagnostic features covered by all the significant PCs. ANOVA was used 
to find out those diagnostically significant PC scores as the input of LDA for 
developing diagnostic functions. The PCA-LDA diagnostic results show that all the 
HGSILs tissues can be differentiated from both benign and LGSILs. Only two of 
LGSILs were misclassified, of which one was classified as benign and the other as 
HGSILs. Four of benign tissue sites were misdiagnosed as LGSILs (2) and HGSILs (2), 
indicating a relatively low specificity.  
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Furthermore, to better understanding the biochemical alterations with tissue neoplastic 
transformation, we also modeled the tissue spectra with reference spectra of pure 
biochemicals, including lipids (i.e., cholesterol and oleic acid), nucleic acid (i.e., 
DNA), protein (i.e., collagen) and carbohydrates (i.e., glycogen). This tissue spectral 
modeling method has been used for uncovering the biochemical composition alteration 
with tissue malignancy behind Raman spectral variations [16, 60, 61, 196]. The results 
show that collagen made the largest contribution to tissue spectrum. This is attributed 
to the fact that collagen takes up a larger proportion of cervix as compared to the rest. 
Meanwhile, it was observed that both collagen and glycogen exhibited a reduced 
contribution to dysplastic tissue spectrum than benign tissue spectrum. The reduced 
contribution from collagen is confirmed by the decreased intensity of Raman peak at 
1658 cm-1 in precancer, which has been explained above. The reduced level of 
glycogen is probably due to the increased cell proliferation [173, 183]. In contrast, 
DNA, cholesterol and oleic acid showed an elevated contribution to dysplastic tissue 
spectrum. DNA is representative of the nucleic acids and one of the major DNA 
Raman peaks located at 1339 cm-1 also exhibited an increased intensity. The increased 
level of DNA is suggestive of an enlarged ratio of nuclei to cytoplasm [184]. The 
elevated level of oleic acid in precancer tissue may contribute to the continuous growth 
stimulus [185]. As for cholesterol, it is an essential element of cell membrane and 
plays a key role in the modulation of membrane fluidity. The increased level of 
cholesterol in dysplastic cervix may be related to the higher minimum surface tension 
of dysplastic cervical tissue [186]. From the discussions above, spectral modeling of 
tissue spectrum with reference spectra of pure biochemicals is an effective tool for 
identifying the origins of biochemical changes with tissue dysplastic transformation. 
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2.4 Conclusion 
In this study, we succeeded in measuring good quality NIR Raman spectra from 
excised human cervical tissues within a few seconds. Significant spectral differences 
were observed among benign, LGSILs and HGSILs tissues. Both empirical analysis 
and tissue characterization with PCA-LDA model demonstrated that NIR Raman 
spectroscopy has the ability to identify benign, LGSILs and HGSILs. Although the 
current dataset size is small, the results still make it promising to apply NIR Raman 
spectroscopy to in vivo clinic diagnosis so as to overcome the limitations of the 
conventional screen methods (i.e., pap smear and colposcopy). In addition, spectral 
modeling of tissue spectrum with reference spectra of pure biochemicals can be used 
to elucidate the origins of biochemical changes behind Raman spectral changes. 
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Chapter 3  In Vivo NIR Raman Spectroscopy Development 
for the Detection of Cervical Precancer 
NIR Raman spectroscopy has been extensively applied to probe the histopathological 
changes in a variety of human organs. In the early times, NIR Raman spectral 
measurement was mostly limited to be ex vivo due to the technical challenges. In 
recent years, the technical advances, especially in diode laser, CCD detector and fiber 
optics, paved the way for in vivo NIR Raman spectroscopic measurement on human 
tissues. However, there still exist some weaknesses, including large size, long 
integration time and interference from the materials of fiber optics. This chapter 
reviews my work on developing a rapid and portable NIR Raman spectroscopy system 
coupled with a ball lens fiber-optic Raman probe for the in vivo Raman measurement 
on epithelial tissues (i.e., cervix). Monte Carlo (MC) simulation was used to evaluate 
the Raman probe design with various configurations (i.e., diameter and refractive 
index of ball lens). Experimental evaluation of a ball lens Raman probe design on a 
two-layer tissue phantom confirms the potential of ball lens Raman probe design for 












At the early time of Raman spectroscopy for biological application, NIR FT Raman 
spectroscopy was accepted as the main form of Raman spectroscopy. NIR FT Raman 
spectroscopy combined with fiber-optic assemblies has proven sensitive enough for 
Raman spectroscopic measurement on biological samples [197]. Subsequently, it was 
employed to study Raman scattering properties of human tissues in situ, such as lens 
[198, 199], artery [200], breast [201] and colon [27]. In principle, FT Raman 
spectroscopy is a multiplex technique, which modulates a series of wavelengths with 
an interferometer. The modulation generates a complex interferogram which is 
subsequently monitored by a single-channel detector. FT Raman spectroscopy shows 
several advantages compared to dispersive Raman spectroscopy. Firstly, it can avoid 
the fluorescence interference from the biological sample since it uses NIR light as 
excitation source while conventional dispersive Raman spectroscopy uses UV/VIS 
light. This is very beneficial especially for biological samples which emit strong 
fluorescence under the excitation of UV/VIS light, masking the weak tissue Raman 
signal. To date, 1064-nm laser light has become the most common excitation light for 
FT Raman spectroscopy. Secondly, it can achieve high spectral resolution stemming 
from the interferometric effect. In contrast, the spectral resolution of dispersive Raman 
spectroscopy is limited by the slit width. If reducing the slit width, the throughput will 
be reduced although the spectral resolution is increased. Lastly, it can acquire the 
spectrum in broad wavelength region than most of the dispersive Raman spectroscopy 
without sacrificing the high spectral resolution.  
However, FT Raman spectroscopy also subjects to some drawbacks, which lead it to 
be used in limited areas. The first one is long integration time. Note that Raman 
cross-section is inversely proportional to the excitation light wavelength. It means that 
  68
Raman signal will become weaker with the excitation light at longer wavelength. 
Moreover, FT Raman spectroscopy scans Raman signal at one by one wavenumber, 
which consequently lengthens the acquisition time. The long integration time impedes 
the application of FT Raman in those areas, which require rapid measurement. 
Secondly, it suffers from water absorption, especially when measuring samples in 
aqueous media. The overtone region of water absorbs not only the excitation light but 
also the Raman scattering due to C-H stretch modes of samples. Besides, the water 
absorption makes reproducible temperature measurement difficult [202]. In addition, 
FT Raman spectroscopy has large body size. All those weaknesses above hinder its 
application on human tissue in vivo.  
With the advance in CCD, diode laser and fiber optics, NIR dispersive Raman 
spectroscopy has undergone a rapid progress in the past two decades, exhibiting a great 
potential for the detection of cancer and precancer in various human organs ex vivo and 
in vivo. In this study, for in vivo Raman measurement on cervix in clinic, we aimed to 
develop a rapid dispersive Raman spectroscopy system with good SNR and compact 
body size. Figure 3.1 shows the schematic of the dispersive Raman spectroscopy. The 
whole system consists of: (1) laser source for Raman scattering excitation; (2) 
spectrometer for collecting Raman signal to create Raman spectrum; (3) Raman probe 
for excitation light delivery and Raman signal collection; and (4) computer for 
controlling spectrometer, Raman spectrum display and save. Hence, the development 
of this Raman spectroscopy system mainly includes the following procedures as 
below: 
(1) Determine the wavelength and select proper laser source; 
(2) Spectrometer selection; 
(3) Raman probe design; 
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In the following sections, the procedures above will be described and discussed in 
detail. 
Figure 3.1 Schematic of the developed dispersive Raman spectroscopy. 
3.2 Excitation Light Source 
To date, almost all the Raman spectroscopy employs laser light as excitation light. 
Thereby, laser light selection is one of the key parts of Raman spectroscopy 
development. The factors which should be considered in laser selection are wavelength, 
output power and cost. At the same time, laser light selection must be done together 
with the design of other parts of Raman spectroscopy. For example, laser light 
wavelength determines the wavelength range of Raman scattering and hence it 
determines the grating central wavelength. Meanwhile, it also requires the detector to 
have high quantum efficiency in the wavelength range of Raman scattering. In the 
current market, there are a big variety of lasers which have been used as excitation 
light source for Raman spectroscopy as below [4]: 
(1) Ar+ and Kr+ lasers are the two main forms of ion lasers. Ion laser can provide high 
power, and a variety of wavelengths from UV to NIR (Ar+: 244, 257, 457, 488 and 
514.5 nm; Kr+: 406, 647 and 752 nm), relatively long lifetime, and hence was widely 
Laser 
Source 








used as excitation light for Raman spectroscopy in the early period of Raman 
spectroscopy. The output wavelength is very stable and accurately known since it is 
dependent on the particular atomic transition. However, the routine use of ion laser 
with Raman spectroscopy is limited by the high cost, complexity and cooling 
requirement. 
(2) Nd:YAG is found to take the place of ion laser for its relatively high efficiency, 
compact size and no need of water-cooling. The Nd:YAG lasers at 532 and 1064 nm 
have been in very common use with Raman spectroscopy. Especially, 1064-nm 
Nd:YAG laser is almost the exclusive light source for FT Raman spectroscopy. 
However, the high cost prohibits its widespread use in Raman spectroscopy. 
(3) He-Ne laser receives great attractiveness as excitation light source of Raman 
spectroscopy for its advantages of accurate wavelength and narrow output spectral 
width. However, the output power is low (~10 mW) and as a result long integration 
time is required for Raman measurement on human tissue showing weak Raman 
scattering. On the other hand, high output power causes He-Ne laser to be too large to 
be used in routine. Meanwhile, the most common laser light by He-Ne is at 632.8 nm, 
under which the fluorescence emission of human tissue is relatively high so that the 
SNR is reduced by the strong fluorescence-determined short noise.  
(4) Ti:Sapphire lasers are advantaged by its robustness, tunability and high output 
power, and hence attractive for NIR Raman spectroscopy, especially for resonance 
Raman. However, it is subject to high cost.  
(5) Diode lasers have been widely used instead of various other lasers above, 
especially for NIR Raman measurement on human tissues. Inasmuch, it shows 
advantages of good stability, small spectral band width, high power, compact size and 
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low cost.  
Selection of excitation light wavelength is mainly dependent on several factors as 
below: 
 (1) Intensity of Raman scattering 
 (2) Fluorescence background  
 (3) Safety to human body 
 (4) Compatibility with other components of Raman system 
Firstly, Raman scattering of biological tissues is inherently very weak. Therefore, great 
effort should be taken to increase the intensity of Raman scattering. In theory, Raman 
scattering intensity is proportional to Raman cross-section, which is inversely 
proportional to the forth power of the excitation light wavelength [4]. As a result, to 
increase the Raman scattering intensity, short wavelength is desired. However, 
shortening the excitation light wavelength (e.g., UV/VIS light) will lead to an increase 
in the tissue autofluorescence emission. The reason is that most of endogenous 
fluorophores are highly fluorescent under UV/VIS light excitation. Moreover, 
fluorescence intensity is usually 6~8 orders higher than Raman intensity. As a result, 
the relatively intense fluorescence signal will obscure the weak Raman signal. To 
reduce fluorescence interference, longer wavelength is preferred. Figure 3.2 shows the 
Raman spectra of human tissues excited by the common lasers used for Raman 
spectroscopy [4]. It was found that Raman spectra under 784- and 830-nm light 
excitation exhibit obvious Raman peaks. This suggests the use of NIR excitation light. 
Besides, considering the safety to human body, the use of short wavelength (e.g., UV 
light) is limited in clinic due to the mutagenic effect. Whereas, NIR light is favored as 
it causes no photochemical effect [175, 203]. Note that the Raman intensity decreases 
as the excitation light wavelength becomes longer and consequently a long spectrum 
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acquisition time is necessitated to obtain Raman spectrum with high SNR. However, 
the advance in NIR diode laser with high power and the multichannel-detector (e.g., 
CCD detector) with high sensitivity in NIR region allows the use of NIR light as the 
excitation source for Raman spectroscopy on biological tissues.  
Figure 3.2 Raman spectra of human biopsied samples under different excitation lights 
(reprinted from Ref. [4]). 
Till now, NIR laser light, especially 785- and 830-nm diode lasers, has been widely 
used as the excitation light source for dispersive Raman spectroscopy. Stone and 
coworkers (2002, 2003) employed 830-nm diode laser as excitation light to explore the 
potential of NIR Raman spectroscopy for the detection of epithelial cancer and 
precancer ex vivo [189, 204]. Anita and coworkers (1998, 2001, 2007, 2009) succeeded 
in using both 785- and 789-nm diode lasers for acquiring Raman spectrum from cervix 
ex vivo and in vivo [98, 100-102]. Our group (2001, 2003~2006, 2008~2010) has also 
demonstrated that 785-nm diode laser light enables an acquisition of good-quality 
Raman spectrum without much intense fluorescence interference from various 
epithelial tissues ex vivo and in vivo, including stomach, colon, lung, skin and cervix 
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[46, 51, 52, 67, 70-73, 78, 175, 205-207]. Therefore, 785-nm diode laser (B&W TEK, 
Newark, DE) is chosen as the excitation source for its small full width at half 
maximum (FWHM), good stability and high output power. The spectral width of the 
excitation line has a large impact on the spectral resolution of tissue Raman spectrum 
as Raman scattering is not dependent on wavelength but Raman shift which is the 
frequency shift relative to excitation light. For the same reason, the wavelength 
stability of excitation light is also very important as it causes a shift of Raman 
vibration bands due to the same biochemical bonds and consequently results in spectral 
variation with the lapse of time. The specification of this diode laser is shown in Table 
3.1. 
Table 3.1 Specification of BTK 785-nm diode laser. 
Peak Wavelength 785±0.3 nm 
FWHM Typical<0.2 nm; Max<0.3 nm 
Power Output >100 mW 
Optical Power Stability <3%, p-p over 8 hours 
Noise <0.5% rms 
Output Fiber Multi-model fiber (100 µm, NA=0.22) 
Connector SMA 905 
Expected Lifetime >10,000 hours 
Input Power 240V-AC 
Control TTL modulation 0-100 kHz 
Cooling Internal thermoelectric cooled 
Warm-up Time <15 minutes 
Physical Dimension 265×155×100 mm 
Weight 2 kg 
Ambient Temperature 10-35 ºC 





Spectrometer is actually the core component of Raman spectroscopy system, which is 
an integration of spectrograph and detector. In particular, dispersive Raman 
spectroscopy mainly comprises a dispersive spectrograph and multi-channel detector. 
At present, dispersive spectrograph can be configured based on two different schemas, 
including Czerny-Turner structure and holographic transmission grating-based 
configurations as shown in Fig. 3.3. Czerny-Turner spectrograph (Fig. 3.3(a)) is the 
conventional form of dispersive spectrograph. In principle, the light is fed into the 
spectrograph via an entrance slit and subsequently is collimated by a curved 
collimating mirror. The collimated light is shed onto the diffraction grating and then 
reflected off at wavelength-dependent angle. Subsequently, the dispersed light is 
focused onto the detector. The light at different wavelengths is imaged on different 
columns of the array detector. Finally, the spectrum is created through binning the 
signal along each column. The spectral resolution is determined by the entrance slit 
width, groove density of the grating, column number and pixel size of the array 
detector. The other form of dispersive spectrograph is based on holographic 
transmission grating (Fig 3.3(b)). The light is focused onto the entrance slit and then 
collimated by lens. The collimated light is then dispersed by a transmission 
holographic grating. Subsequently, the dispersed light is focused onto the detector, and 
light at various wavelengths is imaged on the different columns of the detector. The 
spectrum is yielded through vertically binning the collected signal along each column. 
The major difference between Czerny-Turner and holographic transmission grating is 
the working mode which is off-axis and on-axis, respectively. On-axis working mode 
with optical axis normal to the lenses before and after grating allows an excellent 
optical aberration correction as well as good image quality. To date, low f number (i.e., 
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f/1.8) can be achieved with this holographic grating design, allowing large throughput 
[208]. In contrast, dispersive spectrograph in off-axis mode is subject to astigmatism 
and other aberration, including spherical aberration and coma. To eliminate the 
aberration, small aperture is usually used in Czerny-Turner, which consequently limits 
the throughput of the spectrograph. In this study, Czerny-Turner spectrograph defeats 
holographic transmission spectrograph by virtue of its compact size, portability and 
low cost. The relatively low throughput can be compensated by the high sensitivity of 
detector, especially the advent of high performance CCD.   
Figure 3.3 System schematic of dispersive spectrographs: (a) Czerny-Turner configuration; 
(b) Holographic transmission grating-based configuration. 
In 1980s, CCDs emerged as a promising multichannel detector to facilitate the 
development of Raman spectroscopy, especially dispersive Raman spectroscopy. The 
first CCD was invented by George Smith and Willard Boyle in 1969 [209]. The 
fundamental concept is to store charge in potential wells created on the surface of a 
semiconductor and move the charge (representing information) over the surface by 
moving the potential minimum. CCD is sort of electronic memory that can be charged 
by light. It can hold a charge corresponding to variable shades of light, which makes 
them useful as imaging devices for cameras, scanners, and fax machines. Currently, the 


























spectroscopy are Front-illuminated CCD (FI-CCD) and Back-illuminated CCD 
(BI-CCD, also called Back-thinned CCD) as shown in Fig. 3.4. FI-CCD means that 
photons are shed on the side of CCD containing the circuit mask, so called front side, 
while the other side is called back side. However, its quantum efficiency is limited (i.e., 
40% for visible light) due to the big absorption of light by the gate oxide film, 
polysilicon electrodes, and surface protective film deposited on CCD front side. To 
improve the quantum efficiency, especially for the detection of low light, BI-CCD was 
developed, in which photons are shed on the back side of CCD and the generated 
electrons go through the CCD and are immobilized and stored in the potential well on 
the front side. Compared to FI-CCD, no film is needed on top of the back side of CCD 
so that the light loss in those films can be avoided. Consequently, BI-CCD has much 
higher quantum efficiency. As shown in Fig. 3.5, BI-CCD’s quantum efficiency is 
almost 2.5 times higher in NIR region than FT-CCD’s. However, BI-CCD suffers from 
etaloning effect due to the multi-reflections of the light between the front and back 
surfaces. This leads to constructive and destructive interference fringes which 
artificially modulate spectrum. This etaloning effect can be reduced or minimized by 
various ways: (1) NIR-optimized anti-reflection coating to reduce the light reflected 
back into CCD; (2) Increase the thickness of silicon; (3) The use of low f/# 
spectrometer; (4) Full-frame binning of CCD to create spectrum. 





Figure 3.5 Spectral response function of front-illuminated CCD and 
Back-thinned CCD (back-illuminated) (reprinted from Ref. [210]). 
From the discussions above, a dispersive Czerny-Turner spectrograph coupled with a 
NIR-enhanced BI-CCD was selected. This selected spectrometer model is QE65000 
(Ocean Optics, Dunedin, FL) equipped with an NIR-enhanced charge-coupled device 
(CCD) detector (S7031-1006, 1024 × 58 with pixel sizes of 24.6 μm, QE > 90%, 
Hamamatsu). The CCD is cooled by thermoelectric (TE) cooling system to reduce the 
dark current. The reason is that CCD dark current, as one of the major noise sources 
for CCD based dispersive Raman spectroscopy, decreases as CCD working 
temperature decreases. Hence, CCD cooling can reduce the noise level and eventually 
improve the low detection limit of system and the SNR of Raman system. TE cooling 
can cool CCD efficiently down to be at -20 ºC by a heat sink and natural convection.  
3.4 Raman Probe Design 
3.4.1 History of Fiber-Optic Raman Probe 
Raman probe is to deliver the light to sample and collect the Raman photons from 
sample. The probe determines the sampling location and volume of tissue. The 
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collection efficiency of Raman probe has a huge impact on the sensitivity of Raman 
spectroscopy system and SNR. It is also recognized as the dominant factor for in vivo 
Raman measurement on human body as remote control, compact size and flexibility 
are required for in vivo measurements on most of the human organs. Therefore, great 
efforts have been taken to develop and improve Raman probe.  
In the past three decades, with the advance in fiber optics, fiber-optic Raman probe 
became prevailing and enabled in vivo Raman measurement on various human organs 
[67, 78, 99, 174, 211-216]. In the early 1980s, McCreery et al reported the first design 
of fiber-optic probe for remote Raman spectrum acquisition [217, 218]. However, the 
application of this probe on biological tissues is limited due to the interference from 
the fiber material. During the propagation of the excitation light in the excitation and 
collection fibers, the fiber materials will be induced to produce interfering spectral 
signal [219]. For example, fused-silica produces Raman signal which interferes with 
true tissue Raman signal; impurities and dopants emit intense fluorescence which adds 
short noise to the collected spectral signal; fiber jacket materials may make additional 
interference. Therefore, a variety of filtering designs were proposed to eliminate the 
interference from fiber materials. Myrick et al (1990) designed a fiber-optic probe 
coupled with a pair of band pass and long pass filters as shown in Fig. 3.6(a) [220]. 
Band pass filter serves to block the laser noise and optical signal from fiber material 
while transmitting excitation light; long pass filter is transparent to tissue signal while 
eliminating elastically scattered excitation laser light. However, the excitation and 
collection fibers are obliquely oriented, leading to non-compactness. Tanaka et al 
(1996) proposed a probe design to enhance the detection of tissue Raman signal by 
adding a compound parabolic concentrator (CPC) at the distal end of the probe (Fig. 
3.6(b)). It achieved a 7-fold increase in collection efficiency compared to the probe 
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without CPC [221]. Owen et al (1995) reported a similar probe design with 
holographic grating and notch filters as shown in Fig. 3.6(c) [222]. The excitation light 
is collimated and then diffracted into the bottom light path by a transmission grating. 
Subsequently, excitation light is selected from the diffracted light by a spatial filter and 
notch filter, and then focused onto tissue by an objective. The backscattered tissue 
signal is collected by the same objective and filtered by another notch filter and 
eventually coupled into collection fiber by another objective. 
Figure 3.6 Schematic of three different fiber-optic Raman probe designs. CPC: compound 
parabolic concentrator ((a): adapted from Ref. [220]; (b): adapted from Ref. [221]; (c): reprinted 
from Ref. [222]). 
Mahadevan-Jansen et al (1998) firstly designed a compact fiber-optic Raman probe 
which enables in vivo Raman measurement on human cervix as shown in Fig. 3.7(a) 
[99]. The excitation light from excitation fiber is focused by a 3-mm quartz lens and 
the focused light is directed onto the tissue surface by a golden mirror with oblique 












collection fiber by a pair of lens. A band pass filter and a long pass filter are inserted 
into the light delivery path and collection path, respectively. Raman spectra with clear 
Raman peaks can be acquired from cervix in vivo within 90 seconds. In the following 
year, Shim et al (1999) evaluated a bifurcate fiber-optic probe design with a central 
fiber for excitation light delivery and six surrounding fibers for tissue Raman signal 
collection as shown Fig. 3.7(b) [211]. Moreover, the collection fibers are beveled to 
increase the overlap of collection cone with excitation cone so as to improve the probe 
collection efficiency. This probe design also shows a good compatibility with 
endoscope for its compact size and flexibility and has proven to have the potential for 
acquiring Raman spectra in vivo from gastrointestinal tissues within 30 seconds [25]. 
Recently, it has been used for in vivo Raman measurement on cervix and only a short 
integration time of 5 seconds are required [101]. 
Figure 3.7 Schematic of two fiber-optic Raman probe designs. CF: collection fiber; EF: 
excitation fiber; BPF: band pass filter; LPF: long pass filter ((a): adapted from Ref. [99]; 
(b): reprinted from Ref. [211]). 
Motz et al (2004) introduced ball lens into fiber-optic Raman probe design (Fig. 3.8) to 









lens to a n-to-1 round bifurcate probe. A long pass filter tube and a short pass filter are 
incorporated between excitation/collection fibers and ball lens. With the use of this 
probe, high-quality Raman spectrum can be acquired within 1 second. Santos et al 
(2005) proposed a single fiber probe for measuring HW Raman spectrum since silica 
does not produce Raman and fluorescence interference with tissue Raman in HW 
region [174]. More recently, Matsuura et al (2007) developed a single fiber probe using 
hollow fiber with a ball lens installed at the distal end [216]. This single fiber probe 
allows tissue Raman measurement in both fingerprint and HW regions.  
 
Figure 3.8 Schematic of fiber-optic Raman probe with a ball lens (reprinted from Ref. [213]).  
In our early work, we developed a fiber-optic probe (Fig. 3.9) for in vivo rapid Raman 
measurement on skin [67]. A n-to-1 round fiber bundle adapter was specially designed 
and arrayed in parabolic line to correct the image aberration of spectrograph. This 
special design allows complete CCD vertical binning, leading to a 3.3- to 16-fold 
improvement in SNR. With this fiber-optic probe, good quality Raman spectrum can 
be acquired within 0.5 second. This probe has also proven its capability for ex vivo 
Raman measurement on human organs, including lung [51], larynx [45], nasopharynx 
[223], colon [28], stomach [70, 72]. In our recent work, we successfully developed an 
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endoscopic bifurcate fiber-optic Raman probe (32-to-1 round, outer diameter: 1.8 mm) 
which can be used to acquire Raman spectrum from stomach in vivo with 1 second or 
even shorter time through the biopsy channel of conventional endoscope under the 
guide of wide-field endoscopic imaging modalities.   
Figure 3.9 Schematic of a fiber-optic Raman probe (adapted from Ref. [67]). 
3.4.2 Raman Probe Design 
This thesis study is aimed at exploring the potential of NIR Raman spectroscopy for 
the in vivo diagnosis of cervical precancer. Note that cervix comprises two layers, 
including the superficial epithelium and the underlying stroma layer. Precancerous 
change usually arises in the basal layer and spreads towards the epithelium surface. 
The changes of tissue morphology or biochemical constituents associated with disease 
transformation may be depth-dependent [133]. For instance, the dysplasia-related 
changes (precancer) may be associated with the thickening of epithelial tissue (e.g., 
cervix), which results in an attenuation of the excitation light to penetrate into deeper 
areas of tissue and also the attenuation of Raman emission from deeper tissue regions 
(e.g., stroma) [190, 192]. On the other hand, the changes of other optical properties 
(e.g., absorption coefficient, scattering coefficient, anisotropic factor, refractive index) 
of tissue are also correlated with tissue physiologic/pathologic status, significantly 
affecting the overall Raman signal collection from biomedical tissue [224]. However, 
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the overall Raman signals acquired from the tissue surface are usually a mixture of 
Raman signal originating from different tissue depths, which consequently results in 
difficulties in analyzing Raman spectroscopic information emitted from tissue for 
tissue diagnosis and characterization [78, 211]. Hence, to better understand the origins 
of Raman signals collected from tissue surface for further improving the diagnosis of 
epithelial precancer (i.e., CIN), it is highly desirable to develop a depth-resolved 
Raman spectroscopic technique for facilitating the depth-selective Raman 
measurement of cervical epithelial tissues. 
A number of fiber-optic probe designs have been reported for depth-resolved optical 
spectroscopic measurements, but most work are centered on fluorescence and 
reflectance spectroscopy for tissue diagnosis [191, 225-229]. The depth-resolved fiber 
probe designs can mainly be classified into two types: (1) single-fiber probe in which 
the same fiber is used for both light excitation and reflectance/fluorescence/Raman 
collection, and (2) multiple-fiber probe in which separate fibers are used for light 
delivery and reflectance/fluorescence/Raman collection [190, 224-227]. Although the 
single-fiber probe with a smaller aperture (i.e., core diameter) shows a high sensitivity 
of detecting spectral signal particularly emitted from the superficial layer of epithelial 
tissue, its collection efficiency is much reduced when the fiber diameter decreases. 
With multiple-fiber probe designs, varying the excitation-collection fiber separations 
or the oblique angles between the excitation-collection fibers permit the 
depth-discrimination of fluorescence/Raman signals from tissue [226, 227]. Although 
the multi-fibers probe design has shown a better depth-selectivity for spectroscopic 
acquisitions, the bulky probe design is unsuited for endoscope-based biomedical 
applications. In this work, we proposed a fiber-optic Raman probe design coupled with 
a ball lens for improving the collection efficiency of depth-resolved Raman 
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measurements, particularly for probing subsurface regions of epithelial tissue (e.g. 
cervix). The use of a single ball lens as both illumination and collection optics of 
spectroscopic probes allows a complete overlap of illumination and collection cone 
and has proven to be efficient for epithelial tissue measurement [213]. Moreover, the 
use of a ball-lens probe also shows some advantages, such as compactness and short 
working distance (probe-tissue contact configuration), which are in favor of in vivo 
tissue measurement. 
Figure 3.10 depicts the schematic of ball lens Raman probe design. The Raman probe 
comprises two optical arms (one for laser light delivery; one for scattered tissue 
Raman collection) integrated with optical filtering modules. The 785-nm excitation 
light is coupled into the excitation arm of the Raman probe through a 200-m fiber 
(NA=0.22), and delivered into the filtering module incorporated with a NIR lens for 
excitation light collimation and a narrow band-pass (BP) filter (centered at 785 nm, 
FWHM= 2.5 nm) for removing fiber fluorescence and laser noise, and then focused 
onto the tissue through a NIR-coated sapphire ball lens (5 mm in diameter, refractive 
index n=1.76) mounted on the tip of the Raman probe. The backscattered tissue Raman 
photons are efficiently collected by the same ball lens and subsequently reflected back 
into the collection arm through a dichroic mirror and a reflection mirror. The 
backscattered light is further filtered by using an edge long-pass (LP) filter (cut off at 
800 nm) to block the Rayleigh scattered laser light while allowing the Raman scattered 
light to pass into the spectrometer through a specially designed round to line fiber 
bundle adapter (28×50 µm, NA=0.22) for maximizing tissue Raman signals detection 
through vertical binning of the entire CCD [67]. All the optics of the Raman probe is 
sealed into the stainless steel sleeve (outer diameter of 8 mm) with 
polytetrafluoroethylene gasket for in vivo cervical tissue measurements. Each spectrum 
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was acquired within 1 s with light irradiance of 1.6 W/cm2, which is less than the 
ANSI maximum permissible skin exposure limit for a 785-nm laser light [177]. The 
estimated temperature rise is about 0.3 ℃ after 1 minute of 785 nm laser irradiation 
with an incident power of 15 mW on a spot diameter of 0.2 mm during Raman 
measurement, which is far below the level to generate cytotoxicity in tissues and cells 
[230]. 
Figure 3.10 Schematic of the Raman probe design. CL: collimating Lens; FL: Focusing 
Lens; BPF: Band Pass Filter; LPF: Long Pass Filter; DM: Dichroic Mirror; RM: Reflection 
Mirror; BL: Ball Lens; EP: Epithelium; ST: Stroma. 
3.4.3 Evaluation of Raman Probe Design by Monte Carlo Simulation 
Monte Carlo (MC) simulations have been widely used to mimic light propagation in 
turbid media (e.g., biological tissue) [191, 229, 231], and also simulate the 
fluorescence generation and propagation in biological tissue [191, 229, 231-233]. With 
the development of MC simulation model to evaluate the fiber probe design coupled 
with a ball lens for depth-resolved fluorescence measurement on layered epithelial 
tissue [191, 229], we further modified the MC model to study Raman light generation 
and propagation in epithelial tissue as well as Raman signal collection with the use of 
ball lens fiber-optic Raman probe. The modified MC codes include the following 
modules: (1) excitation light propagation in ball lens and tissue; (2) Raman photons 
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generation and propagation in tissue; (3) Raman photons collection by the ball lens and 
propagation in the ball lens; (4) Raman photons collection by the focusing lens and 
subsequently by the collection fibers of the Raman probe.  
In MC simulations, one hundred million excitation light photons are launched into the 
tissue through the ball lens. The photons are initialized as a uniform light beam with a 
beam diameter the same as the ball lens’ diameter. When the excitation light photons 
are incident into the ball lens or the Raman photons pass through the ball lens, the 
direction of the refracted light is calculated using Snell’s law. The photon weight is 
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where αi and αt are the incident angle and the refracted angle, respectively. In this 
simulation, Raman generation is estimated with the probability (p) of the excitation 
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              (3.2)   
where a  is the Raman scattering coefficient for generating Raman photons, s  is 
the scattering coefficient, RY (<<1) is the Raman quantum yield. To determine the 
Raman photon generation at a particular scattering position, a random number between 
0 and 1 is generated; if the probability yielded in Eq. (3.2) is larger than the random 
number, then Raman photon is produced; otherwise, no Raman photon is generated. In 
our MC programs, we presume that the radiation angle of Raman photons emitted from 
the Raman scatterers is isotropic [224, 236] and the emitted Raman photons will not be 
reabsorbed by the Raman scatterers for generating secondary emission of Raman 
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photons due to their extremely low intensity levels. The deflection angle (β) of each 
scattering in the medium is described by Henyey-Greenstein phase function as the 
following equation [231, 237]: 
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      (3.3)    
where g is anisotropy factor and ξ is a random number between 0 and 1. The azimuthal 
angle ψ can be determined by 2πξ.  
After escaping from tissue surface, Raman photons are collected by the ball lens within 
the collection cone angle [238]: 
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          (3.4)    
where θ is half-angle of the collection cone of the ball lens; nb and nt are the refractive 
indices of the ball lens and tissue, respectively. Tissue Raman photons which pass 
through the ball lens will be coupled into the collection fibers by a focusing lens (focal 
length, f=12 mm) of the Raman probe. Tissue Raman photons after ball lens are 




            (3.5)    
where L, L’ and f are object distance, image distance, and focal length, respectively. 
The image position of Raman photons determines the light trace after focusing lens, 
which further determines the incident angle and position on the collection fiber surface 
plane. All those photons that reach the collection fibers within the collection cone 
angle of the collection fibers (NA=0.22) will be considered as the collected Raman 
photons by the Raman probe. The 2-D distributions of excitation light and the origins 
of the Raman photons collected from tissue will be given by MC simulations to 
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evaluate the performance of the fiber-optic Raman probe design for depth-resolved 
tissue Raman measurements. In addition, the collection efficiency of the Raman probe 
defined as the ratio of the collected tissue Raman photon numbers to the incident 
excitation light photon numbers is also estimated by using MC simulations. 
A two-layer tissue model which mimics the epithelial tissues is used for MC 
simulations of the excitation light and Raman photons propagation in tissue. Table 3.3 
gives the optical properties (Raman scattering coefficient, a ; scattering coefficient, 
s ; anisotropy factor, g; tissue refractive index, nt; and tissue thickness, d) of the 
modeled tissue [240]. The wavelengths of excitation light and Raman scattered photon 
light are selected at 785 and 820 nm, respectively, for MC simulations [51, 67].  






  (cm-1) s  (cm-1) g nt d (mm) 
Epithelium 785 
(excitation) 
0.9 25 0.9 1.4 0.3 
Stroma 0.45 165 0.9 1.4 3 
Epithelium 820 
(Raman) 
0.8 24 0.9 1.4 0.3 
Stroma 0.3 150 0.9 1.4 3 
3.4.3.1 Effect of the Refractive Index of the Ball Lens on Tissue Raman 
Measurements 
Figure 3.11 shows the MC simulation results of the 785-nm excitation light 
distribution in epithelial tissue for the fiber-optic Raman probe designs with different 
refractive indices of the ball lens and a fixed diameter of 3 mm. Note that the indices 
selected for simulation correspond to different optical materials (1.46-UV fused silica; 
1.51-Boro-crown glass; 1.63-Dense flint glass; 1.76-Sapphire; 1.83-Lanthanum flint 
glass). Overall, the excitation light exhibited higher intensity over the whole tissue 
when increasing the refractive index of the ball lens. A 1.1- to 1.5- fold increase in 
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excitation intensity distribution in tissue was found for the use of ball lens at refractive 
indices of 1.51, 1.63, 1.76 and 1.83 as compared to the refractive index of 1.46. The 
corresponding excitation light distribution in the epithelium was approximately 1.1- to 
2.7- fold stronger. This suggests that Raman probe with a larger refractive index of the 
ball lens achieve higher efficiency in focusing the excitation light photons into the 




































































































Figure 3.11 The 785-nm excitation light distributions along the tissue depth and radial directions 
in tissue using the Raman probe designs with different refractive indices of the ball lenses (n= 
1.46, 1.51, 1.63, 1.76 and 1.83). 
Figure 3.12 shows the 785-nm excitation light distributions along the tissue depth 
which are the sum of the excitation light distribution (Fig. 3.11) over the radial 
dimension at each tissue depth. Each depth profile was normalized to the integrated 
area under the profile for better comparison among different refractive indices of the 
ball lens in Raman probe. The excitation light underwent a shorter penetration into 
tissue when increasing the refractive index of the ball lens. For instance, an intensity 
maximum of the excitation light in epithelium layer was observed around the focal 
plane of the ball lens when using the refractive index of 1.76 or 1.83 of the ball lens 
(Fig. 3.12). This suggests that increasing the refractive index of the ball lens of the 
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Raman probe design make the excitation light to be more tightly focused in the 
shallower regions of tissue (i.e., the epithelium). The findings above can be explained 
by the enhanced focusing ability of the ball lens attributed to the increase of refractive 
index. The ball lens focal length can be estimated using the following equations [238]: 
 ;2 4 1bb
n DDBFL EFL EFL
n
           (3.6) 
where BFL is back focal length, representing the distance from the ball lens front tip to 
the focal point; EFL is effective focal length, representing the distance from the ball 
lens center to the focal point; D and nb is the diameter and the refractive index of the 
ball lens, respectively. According to Eq. (3.6), if keeping diameter D constant, EFL and 
BFL are inversely proportional to refractive index nb. That is why the ball lens with a 
larger refractive index leads to a shorter light penetration depth in tissue.  
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Figure 3.12 The 785-nm excitation light distributions along the tissue depth using 
the Raman probe designs with different refractive indices of the ball lenses (n=1.46, 
1.51, 1.63, 1.76 and 1.83). 
Figure 3.13 shows the calculated results of the origins of the Raman photons generated 
from different tissue locations of epithelial tissue. Similar to the excitation light 
distribution in tissue (Fig. 3.11), the Raman photons generated from different tissue 
depths were also dependent on the use of the refractive index of the ball lens in Raman 
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probe designs. With the increase of the refractive index of the ball lens, Raman 
photons radiation tended to be more strongly coming from the shallower regions of the 
epithelium layer (e.g., ~5 orders of magnitude stronger in Raman intensity using the 
ball lens’s refractive index of 1.83 as compared to that using the ball lens’s refractive 
index of 1.46) (Fig. 3.13). This is due to the fact that excitation light is more tightly 
focused in the shallower layer of the epithelium, and the ball lens with a larger 
refractive index has larger collection cone angle (Eq. (3.4)), leading to the significant 
improvements of Raman signal collections from the epithelium in tissue. The findings 
above imply that increasing the refractive index of the ball lens in Raman probe design 
can effectively improve the collection efficiency of tissue Raman photons from the 
































































































Figure 3.13 Distributions of the Raman photons collected from different tissue depths using the 
Raman probe designs with different refractive indices of the ball lens (n=1.46, 1.51, 1.63, 1.76 
and 1.83). 
Figure 3.14 shows the depth distribution of the origins of Raman photons collected 
from tissue for the use of different refractive indices of the ball lens in Raman probe 
designs. The depth distribution was created by integrating the 2-D distribution (Fig. 
3.13) over the radial dimension at each tissue depth and was then normalized to the 
integrated area under the profile. It can be used to represent the relative contribution of 
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Raman photons from different tissue depths to the overall collected Raman photons. 
The relatively weak Raman photons were generated throughout different tissue depths 
when using the ball lens with refractive indices of less than 1.63 (Fig. 3.14); but 
stronger Raman photons generation tended to be arising from the epithelium layer in 
tissue when using the ball lens with larger refractive indices (e.g., n=1.76, 1.83). For 
instance, a maximum Raman radiation appeared in the shallower region (~80 m) of 
the epithelium layer in tissue for the use of ball lens with refractive index of 1.83 (Fig. 
3.14). This indicates that the Raman probe design with the use of high refractive index 
ball lens is in favor of detecting Raman signal emitted from subsurface layer of the 
epithelial tissue. 


























Figure 3.14 Depth-resolved Raman photons collected from different tissue depths using 
the Raman probe designs with different refractive indices of the ball lens (n=1.46, 1.51, 
1.63, 1.76 and 1.83). Note that for comparison purpose, the depth-resolved Raman 
intensity profiles with different refractive indices of the ball lens have been vertically 
shifted to different intensity levels. 
We also evaluated the collection efficiency of the Raman probe versus the refractive 
index of the ball lens (Fig. 3.15). The collection efficiency of the Raman probe 
increased monotonously when increasing the refractive index of 1.46 up to 1.83. All 
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the MC simulation results above confirm that Raman probe design with the use of a 
larger refractive index of the ball lens has the advantage of preferentially detecting the 
Raman signal from subsurface regions of the epithelium in tissue with high collection 
efficiency. 



















Refractive index of ball lens  
Figure 3.15 Collection efficiency of the Raman probe as a function of the refractive 
index of the ball lens.  
3.4.3.2 Effect of the Ball Lens Diameter on Tissue Raman Measurements 
Figure 3.16 shows the MC simulation results of the 785-nm excitation light 
distribution in epithelial tissue for the fiber-optic Raman probe designs with different 
diameters of the ball lens (refractive index of 1.83). With the use of smaller diameters 
of the ball lens in Raman probe design, the incident light was found to be more tightly 
focused into shallower regions of epithelial tissue with stronger incident light 
distribution as compared to the use of large diameters of the ball lens. This can be 
explained by the shortening of the ball lens focal length (Eq. (3.6)) [238] when using 




























































































































Figure 3.16 The 785-nm excitation light distributions in tissue using the Raman probe designs with 
different diameters of the ball lens (Φ=1, 2, 3, 5, 8 and 10 mm). 
Figure 3.17 presents the depth distribution of the 785-nm excitation light in tissue 
calculated by integrating the 2-D intensity distribution (Fig. 3.16) over the radial 
dimension at each tissue depth. The excitation light from the Raman probe appeared to 
have a shorter penetration depth in tissue when using a smaller diameter of the ball 
lens. For instance, an incident light intensity maximum occurred at the subsurface 
region (~40 μm) of the epithelial tissue when the Raman probe used the ball lens with 
a diameter of 1 mm. Whereas the incident light tended to penetrate into deeper regions 
of the epithelial tissue when using the ball lens with larger diameters (e.g., 10 mm) 
(Fig. 3.17). Again, this implies that the Raman probe design with the use of smaller 
diameters of the ball lens can be more efficiently focusing the excitation light into the 
shallower regions of the epithelium layer in tissue.  
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Figure 3.17 The 785-nm excitation light distribution along the tissue depth using the 
Raman probe designs with different diameters of the ball lens (Φ=1, 2, 3, 5, 8 and 
10 mm).  
Figure 3.18 depicts the 2-D distributions of the origins of the Raman photons collected 
from tissue using the Raman probes with different diameters of the ball lens. Similar to 
the corresponding excitation light distribution in tissue (Fig. 3.16), the tissue Raman 
photons collected with the use of a small diameter of the ball lens in Raman probe 
design appeared to be mostly originating from the shallower areas of the epithelium 
layer in tissue as compared to the Raman probe design with larger diameters of the ball 
lens. This can be more clearly displayed in the depth distribution of the origins of the 
Raman photons collected from tissue using the Raman probe designs with different 
diameters of the ball lens (Fig. 3.19). The relative contribution of the Raman photons 
from the epithelium became more dominant when reducing the ball lens’ diameter in 
Raman probe design. For example, the Raman probe design with the use of 1-mm ball 
lens enabled a detection of ~95% of Raman signal arising from the epithelium, while 
only about 50% of Raman signal originating from the epithelium can be detected if 
using the 10 mm ball lens. Hence, the Raman probe design with a smaller diameter of 
ball lens can efficiently improve the detection of the Raman signal originating from the 
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Figure 3.18 Distributions of the origins of the Raman photons collected from tissue using the 
Raman probe designs with different diameters of ball lenses (Φ=1, 2, 3, 5, 8 and 10 mm).  






























Figure 3.19 Depth distribution of the origins of the Raman photons collected from tissue 
using the Raman probe designs with different diameters of the ball lens (Φ=1, 2, 3, 5, 8 
and 10 mm). 
MC simulations were also carried out to exhaustedly search for all the possible 
combinations of the diameters and the refractive indices of the optimized Raman probe 
designs for improving depth-resolved Raman measurements. Figure 3.20 describes the 
depth-resolved measurement performance of the probe design as a function of the 
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combination of the ball lens’ diameter and refractive index. The results show that the 
ball lens with a refractive index of 1.83 and diameter of 3 mm achieved the highest 
collection efficiency (Fig. 3.20(a)). With the use of this probe design, Raman photons 
originating in the epithelium of tissue covered 90% of the overall Raman photons 
collected from the surface of epithelial tissue as shown in Fig. 3.20(b), indicating a 
good depth-selectivity to the epithelium. Although the depth-selectivity can be further 
improved by reducing the diameter of the ball lens down to 2 mm, the collection 
efficiency will drop by about 30%. This implies that the Raman probe design with the 
use of a ball lens with the diameter of 3 mm and the refractive index of 1.83 is optimal 
for selectively detecting the Raman signal from the epithelial tissue. The above results 
indicate that Raman probe designs with a proper selection of the refractive index and 
diameter of the ball lens can improve both the collection efficiency and the ability to 
preferentially acquire the Raman photons emitted from the epithelium layer of 
epithelial tissue. In our clinic Raman system, Raman probe is configured with a 
sapphire ball lens at refractive index of 1.76 and diameter of 5 mm other than the 
optimal configuration suggested by the simulation results above. This is due to the fact 
that sapphire produces low interference signal and therefore is chosen as the ball lens 
material. The refractive index of sapphire is about 1.76 at 785 nm. Meanwhile, the 
reason we chose diameter of 5 mm is to increase the probe’s sensitivity to the stroma 































































Figure 3.20 The simulated performance of the probe design based on various combinations of ball 
lens diameters (i.e., 1, 2, 3, 5, 8 and 10 mm) and refractive indices (i.e., 1.46, 1.51, 1.63, 1.76 and 
1.83): (a) collection efficiency; (b) proportion of the Raman photons from the epithelium to the 
total collected Raman photons from the tissue surface.  
3.4.3.3 Effect of the Probe-tissue Distance on Tissue Raman Measurements 
In practical tissue measurements, the probe-to-tissue distance may play a significant 
role in depth-resolved tissue spectroscopic measurement [191, 225, 226, 229]. We also 
comprehensively studied the relationship of the collection efficiency of the ball lens 
Raman probe designs versus probe-tissue distances. Fig. 3.21(a) shows an example of 
the collection efficiency versus probe-tissue distances using the Raman probe with the 
ball lens’ diameter of 3 mm and refractive index of 1.83. The maximum collection 
efficiency of the Raman probe occurred at the probe-to-tissue distance of ~300 µm. We 
also studied the effect of the probe-tissue distance on the ratio of the Raman signal 
collected from the epithelium layer to the overall Raman signal from the entire 
epithelial tissue in depth-resolved Raman measurements (Fig. 3.21(b)). It was found 
that when the probe-to-tissue distances were in the range of 275 to 660 µm, Raman 
photons arising from the tissue epithelium layer accounted for over 90% of the total 
Raman photons of the entire epithelial tissue. The above results suggest that the 
collection efficiency and the depth-selectivity of the Raman probe design can be 
optimized by setting a proper gap between the probe and the tissue.  
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Probe-to-tissue distance (m)  
Figure 3.21 (a) Collection efficiency of the Raman probe as a function of probe-tissue distances; 
(b) Percentage of the Raman signal collected from the epithelium layer to the overall Raman 
signal from the entire epithelial tissue. The refractive index and the diameter of the ball lens are 
1.83, and 3 mm, respectively, in Raman probe design. 
3.4.4 Experimental Evaluation of Raman Probe Design 
We also carried out tissue Raman measurements on a two-layer tissue phantom to 
evaluate the performance of a ball lens Raman probe design using a sapphire ball lens. 
The two-layer tissue phantom was constructed by overlaying different thicknesses of 
chicken muscle tissue on a chicken fat tissue: the thickness of fat tissue layer was fixed 
to be 5 mm, while the thickness of the muscle tissue layer varied from 0.3 to 3.9 mm. 
Figure 3.22 shows Raman spectra acquired from chicken muscle and fat tissue, as well 
as from the two-layer tissue phantoms with the muscle tissue thickness of 0.3, 1.2, 2.1, 
3 and 3.9 mm, respectively. It was observed that chicken muscle and fat tissue showed 
distinctively different Raman spectral features. For instance, the Raman spectrum of 
muscle tissue showed distinct Raman peaks at 936 (C-C stretching of proteins), 1004 
(C-C stretching of phenylalanine), 1209 (C-C6H5 stretching of tryptophan and 
phenylalanine), and 1339 cm-1 (CH3CH2 wagging of collagen). In contrast, the Raman 
spectrum of fat tissue exhibited four different unique peaks at 972 (Calcium-phosphate 
stretching of cholesterols/lipids), 1080 (C-C/C-O stretching of phospholipids), 1301 
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(CH2 twisting and wagging modes of lipids, triglycerides (fatty acids)) and 1745 cm-1 
(C=O stretching of ester (phospholipids)) [51, 190]. With the thickness of muscle 
tissue layer increasing from 0 to 3.9 mm in the two-layer tissue phantom, the Raman 
intensity at 1004 cm-1 for muscle tissue increased by 2.1- to 5.6-folds, whereas the 
Raman signal at 1745 cm-1 for fat tissue underwent a 28- to 1.6-fold reduction in 
intensity (Fig. 3.23). This implies that the Raman signal contribution of the surface 
muscle layer to the overall Raman signal increases as the muscle tissue thickness 
increases while the signal contribution of the deeper fat tissue layer reduces 
concomitantly. The results above indicate the potential of the ball lens Raman probe 
design for effective depth-selective Raman measurements in layered tissue. 

























Figure 3.22 Raman spectra acquired from chicken muscle and fat tissue, as well as from the 
two-layer tissue phantoms with the muscle tissue thickness of 0.3, 1.2, 2.1, 3 and 3.9 mm, 
respectively. Spectra: (a) fat tissue; (b)-(f): two-layer tissue phantoms with the muscle tissue 
layer of thickness of 0.3, 1.2, 2.1, 3.0 and 3.9 mm, respectively, overlaying on a fat tissue 
layer (thickness of 5 mm); (g) muscle tissue. Note that all tissue Raman spectra are acquired 
with an integration of 1 s under the 785-nm excitation power of 1.5 W/cm2. The dotted and 
solid vertical lines indicated in Raman spectra stand for the distinctive Raman peaks 
originating from the muscle and fat chicken tissue, respectively. 
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Figure 3.23 Raman peak intensities at 1004 and 1745 cm-1 as a function of thickness 
ratios of the muscle tissue layer to the fat tissue in a two-layer tissue phantom. 
3.5 Data Acquisition Program 
OOIBase32 (Ocean Optics, Dunedin, FL) is the official software for controlling Ocean 
Optics spectrometer and data acquisition. Besides, it also incorporates online 
dark-subtraction function as well as several basic spectral data process functions (e.g., 
smoothing by boxcar function, average consecutive spectra).  
3.6 Conclusion 
In summary, we successfully developed a rapid and portable Raman spectroscopy for 
in vivo Raman spectroscopic measurements on cervical tissues. A fiber-optic Raman 
probe was specially designed with the use of a ball lens for improving depth-resolved 
Raman measurements of epithelial tissue. We comprehensively evaluated the effects of 
optical configurations of the ball lens Raman probe design on depth-resolved Raman 
measurements using Monte Carlo simulations. The MC calculation results show that 
depth discriminations of Raman signals are achievable by changing either the 
refractive index or diameter of the ball lens, or the ball lens-tissue distances. The 
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Raman probe design by increasing the refractive index or reducing the diameter of the 
ball lens is in favor of probing Raman signals particularly arising from the shallower 
regions of the epithelium layer of tissue. Experimental evaluation of a ball lens probe 
design confirms its ability for efficient depth-resolved measurement on layered tissues. 
The efficacy of this Raman spectroscopy system for in vivo Raman measurement on 
cervical tissues will be discussed in chapter 4 and 5. 
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Chapter 4  High Wavenumber Raman Spectroscopy for In 
Vivo Detection of Cervical Dysplasia 
The chapter is to present our work on applying NIR Raman spectroscopy in the high 
wavenumber (HW) region (2800~3700 cm-1) for in vivo detection of cervical dysplasia. 
A rapid-acquisition NIR Raman spectroscopy system associated with a fiber-optic 
Raman probe was used for in vivo spectroscopic measurements at 785-nm light 
excitation. A total of 92 in vivo HW Raman spectra (46 normal, 46 dysplasia) were 
acquired from 46 patients with pap smear abnormalities in the cervix. Significant 
difference in Raman intensities of prominent Raman bands peaking at 2850 and 2885 
cm-1 (CH2 stretching of lipids), 2940 cm-1 (CH3 stretching of proteins), and the broad 
Raman band of water peaking at 3400 cm-1 in the 3100~3700 cm-1 range were 
observed in normal and dysplasia cervical tissues. The diagnostic algorithms based on 
PCA and LDA together with the leave-one patient-out, cross-validation method on in 
vivo HW Raman spectra yielded a diagnostic sensitivity of 93.5% and specificity of 
97.8% for dysplasia tissue identification. This study demonstrates for the first time that 
HW Raman spectroscopy has the potential for the noninvasive, rapid, in vivo diagnosis 









NIR Raman spectroscopy has been applied for optical diagnosis of cervical dysplasia 
and Raman spectral differences between normal and dysplasia cervical tissues have 
been observed [98, 100], demonstrating the diagnostic ability of NIR Raman 
spectroscopy. To date, most of cervical NIR Raman studies are centered on the 
fingerprint region (i.e., 800~1800 cm-1) owing to the great wealth of biochemical 
information contained in this spectral region for tissue characterization [51, 78, 100, 
189]. However, the strong autofluorescence background and silica Raman signal 
arising from fiber optic Raman probe also fall into the fingerprint region which 
severely interfere the detection of inherently weak tissue Raman signal [98, 175]. This 
makes the light filtering modules in Raman probe design to be complicated and bulky, 
and unsuitable for in vivo biomedical applications. To tackle this problem, Puppels and 
co-coworkers [8, 174] proposed to use Raman spectroscopy in the so-called high 
wavenumber (HW) region (i.e., 2400~3800 cm-1) for tissue diagnosis and 
characterization. The main advantages of using HW Raman spectroscopy are the 
significant reduction of fluorescence/Raman background from optical fibers [8], more 
intense tissue Raman signals generated compared to the fingerprint region [241], as 
well as the possibility of an unfiltered, simplified single fiber Raman probe design for 
facilitating in vivo Raman clinical procedures [242]. For instance, HW Raman studies 
[60] showed that basal cell carcinoma could be distinguished with a 100% prediction 
accuracy, suggesting that diagnostic information extracted from the HW Raman 
spectral region could compete with those extracted from the fingerprint region. To date, 
the clinical potential of HW Raman spectroscopy for identification of cervical 
dysplasia (i.e., precancer) has yet been reported in literature. Therefore, in this study, 
we aimed to evaluate the feasibility of utilizing HW Raman spectroscopy for in vivo 
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diagnosis of cervical precancer. Multivariate statistical techniques, including PCA and 
LDA, were employed to develop diagnostic algorithms for differentiation between 
normal and precancer cervical tissue. Receiver operating characteristic (ROC) testing 
was also conducted to further evaluate the performance of PCA-LDA algorithms on in 
vivo HW Raman spectroscopy for cervical precancer diagnosis.  
4.2 Materials and Methods 
4.2.1 Raman Instrumentation 
The Raman spectroscopy used in this study has been described in detail in Chapter 3.  
4.2.2 Patients  
A total of 46 women (mean age of 42.6 years old) who underwent colposcopic 
examinations for abnormal pap smears were recruited through colposcopy clinics at 
the National University Hospital (NUH) of Singapore. All patients preoperatively 
signed an informed consent permitting the in vivo spectroscopic measurements on the 
cervix. This study was approved by the Ethics Committee of the National Healthcare 
Group of Singapore. Prior to Raman spectroscopic measurements, a complete routine 
colposcopic examination was performed on the patients by experienced colposcopists. 
A 5% acetic acid was applied to the cervix for a couple of minutes to allow the 
inspection of acetic acid whitening changes of epithelium which was then graded 
according to the degree of acetic acid-whiteness, the shape and margin of lesion area 
and the vascular pattern. Evaluation of Raman spectra acquired before and after the 
application of acetic acid indicates that acetic acid does not lead to any significant 
change on the tissue Raman spectra. In vivo HW Raman spectra were acquired from 
the suspicious lesion sites and the surrounding normal sites for each patient through 
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gently placing the ball-lens Raman probe on the cervix. The measured abnormal sites 
were biopsied and then submitted to pathology laboratories of NUH for 
histopathologic examination to confirm the colposcopic diagnosis. The measured 
normal sites are normal mature squamous epithelium without showing acetowhite. A 
total of 92 in vivo HW Raman spectra were acquired from 46 patients with cervical 
abnormalities, in which 46 were from normal sites, while 46 from cervical dysplasia 
lesions, including 10 CIN 1, 9 CIN 2 and 27 CIN 3.  
4.2.3 Data Preprocessing 
The raw HW Raman spectra (2800~3700 cm-1) measured from in vivo cervical tissue 
represented a composition of Raman signal, autofluorescence background and noise. 
Thus, the raw spectra were preprocessed by a first-order Savitzky-Golay filter 
(window width of 3 pixels, which corresponded to the system spectral resolution) to 
reduce noise [178]. A first-order polynomial was found to be optimal for fitting the 
autofluorescence background in the noise-reduced spectrum, and this polynomial was 
then subtracted from the raw spectrum to yield the tissue HW Raman spectrum alone. 
Each of background-subtracted HW Raman spectra was also normalized to the 
integrated area under the curve from 2800 to 3700 cm-1, enabling a better comparison 
of the spectral shapes and relative band intensities among the different cervical tissues.  
4.2.4 Multivariate Statistical Analysis 
PCA-LDA was employed for developing diagnostic algorithms and has been described 
in detail in the section Multivariate Statistical Analysis in Chapter 2.  
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4.3 Results 
4.3.1 Spectral Feature Analysis  
Figure 4.1(a) shows the comparison of mean in vivo HW Raman spectra ± 1 standard 
deviation (SD) of normal (n=46) and dysplasia (n=46) cervical tissues. Prominent 
Raman bands, such as 2850 and 2885 cm-1 (CH2 stretching vibrations of lipids), 2940 
cm-1 (CH3 stretching vibrations of proteins), and the broad Raman band of water (OH 
stretching vibration band peaking at 3400 cm-1 in the 3100~3700 cm-1) [8, 174, 241], 
were clearly observed in both normal and dysplasia cervical tissues. Overall, precancer 
cervical tissue showed significantly lower intensities for the Raman bands in the 
2800~3000 cm-1 region (paired two-sided Student’s t-test, p<0.001, n=46), while being 
higher for OH bands in the 3100~3700 cm-1 (paired two-sided Student’s t-test, p<0.001, 
n=46) compared to normal tissue as shown in the difference spectrum in Fig. 4.1(b). 
Nevertheless, there were significant variations and overlapping in intensities of in vivo 
HW Raman spectra of normal and precancer tissue among inter-subjects (Fig. 4.1). 
Thus, tissue diagnosis simply based on spectral intensities alone was precluded. In 
addition, it is also difficult to standardize the absolute intensities of spectral 
measurements in clinical settings. Therefore, in this study we focused on analyzing 
spectral feature differences following a standardization/normalization data 






















  Normal (n=46)













Raman Shift (cm-1)  
Figure 4.1 (a) Comparison of mean in vivo HW Raman spectra1SD of normal (n=46) 
and precancer (n=46) cervical tissue. (b) Difference spectrum1SD difference between 
precancer (n=46) and normal cervical tissue (n=46). Note that the mean in vivo HW 
Raman spectrum of normal tissue was shifted vertically for better visualization (Fig. 
4.1(a)); the shaded areas indicate the respective standard deviations.  
4.3.2 PCA-LDA and ROC Analysis  
We employed the multivariate statistical methods (e.g., PCA, LDA) together with 
paired two-sided Student’s t-test by incorporating the entire HW Raman spectra to 
determine the diagnostically significant Raman features for tissue diagnosis and 
classification. Figure 4.2 shows the first five PCs calculated from PCA on all HW 
Raman spectra. The first PC accounted for the largest variance (e.g. 49.6% of the total 
variance), whereas the successive PCs described the spectral features that contributed 
progressively smaller variances. Some PC features, such as peaks, troughs, spectral 
shapes, were similar to those of tissue HW Raman spectra (Fig. 4.1). The paired 
two-sided Student’s t-test on the obtained PCs showed that there were three 
diagnostically significant PCs (i.e., PC1, PC4, and PC9) (p<0.05) for discriminating 
dysplasia tissue from normal tissue.  
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Figure 4.2 The first five principal components (PCs) accounting for about 88% of the 
total variance calculated from in vivo HW Raman spectra of cervical tissue 
(PC1-49.6%, PC2-21.7%, PC3-10.9%, PC4-4.7%, and PC5-1.6%). 
Figure 4.3 shows the correlations between the diagnostically significant PC scores for 
normal and dysplastic cervical tissue, illustrating the utility of significant PCs for 
classification of Raman spectra between normal and precancer cervical tissues. Normal 
and dysplasia tissues can be largely clustered into two separate groups based on 
different combinations of significant PCs: (a) PC1 vs PC4, (b) PC1 vs PC9, and (c) 
PC4 vs PC9. The corresponding separation lines (i.e., diagnostic algorithms) classify 
dysplasia from normal tissue with the sensitivity of 63.0% (29/46), 89.1% (41/46) and 
73.9% (34/46); specificity of 87.0% (40/46), 84.8% (39/46) and 87.0% (40/46), 
respectively. These results show that selection of different combinations of significant 
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Figure 4.3 Scatter plots of the diagnostically significant PCs derived from in vivo HW Raman 
spectra of normal and precancer cervical tissue: (a) PC1 vs PC4; (b) PC1 vs PC9; (c) PC4 vs PC9. 
The dotted lines (PC4 = −0.57 PC1 + 0.19; PC9 = 0.96 PC1 + 0.12; PC9 = 0.62 PC4 − 0.08) as 
diagnostic algorithms classify precancer from normal with sensitivities of 63.0% (29/46), 89.1% 
(41/46) and 73.9% (34/46); specificities of 87.0% (40/46), 84.8% (39/46) and 87.0% (40/46), 
respectively. circle (○): Normal; triangle (▲): Precancer. 
To further improve tissue diagnosis, all the three diagnostically significant PCs were 
loaded into the LDA model for generating effective diagnostic algorithms for tissue 
classification. Figure 4.4 shows the posterior probability of classification results based 
on PCA-LDA technique together with leave-one patient-out, cross-validation method. 
The PCA-LDA diagnostic algorithms yielded the diagnostic sensitivity of 93.5% 
(43/46) and specificity 97.8% (45/46) for distinguishing dysplasia from normal 
cervical tissue. To evaluate the performance of the PCA-LDA-based diagnostic 
algorithms derived from all the significant PCs of tissue HW Raman dataset, the 
receiver operating characteristic (ROC) curve (Fig. 4.5) was generated from the scatter 
plot in Fig. 4.4 at different threshold levels to determine the correct or incorrect 
classification of cervical tissues. The integration area under the ROC curve is 0.98, 
demonstrating the efficacy of PCA-LDA diagnostic algorithms developed that utilize 
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the entire spectral features of HW Raman spectroscopy for in vivo diagnosis of cervical 
precancer.  

























Figure 4.4 Scatter plot of the posterior probability of belonging to the normal and 
precancer cervical tissues using the PCA-LDA technique together with leave-one 
patient-out, cross-validation method. The separate line yields a diagnostic sensitivity 
of 93.5% (43/46) and specificity 97.8% (45/46), for identifying precancer from 
normal cervical tissue. circle (○): Normal; triangle (▲): Precancer.  
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Figure 4.5 Receiver operating characteristic (ROC) curve of discrimination results 
for in vivo HW Raman spectra of cervical tissue using PCA-LDA algorithms 
together with leave-one patient-out, cross-validation method. The integration area 
under the ROC curve is 0.98, illustrating the efficacy of PCA-LDA algorithms for 
tissue classification.  
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4.4 Discussion 
Raman spectroscopy has proven to be capable of probing biochemical structures and 
compositions in tissues associated with tissue malignant transformation. Likewise, 
Fourier transform infrared spectroscopy (FTIR), as the other vibrational spectroscopy 
technique, can also been used for tissue differentiation. Particularly for human cervix, 
FTIR spectroscopy and imaging technique has been successfully applied to the 
identification of the malignant cervical cells and tissues [155, 157, 170]. In principle, 
Raman and FTIR spectroscopy are complementary to each other due to the different 
selection rules for molecular vibrational modes [4], and have been recently 
demonstrated as complementary techniques for tissue identification [243]. However, 
FTIR is limited to in vitro spectroscopic measurement on human tissue. In contrast, 
Raman spectroscopy has shown the potential to be a clinically useful tool for precancer 
and cancer diagnosis in humans; however, due to the weak signal, an efficient and 
quick detection of tissue Raman signals is important for in vivo Raman clinical 
applications. In this work, we developed a rapid and portable NIR Raman spectroscopy 
system coupled with a ball-lens fiber-optic Raman probe [191, 229] to provide a high 
degree of collection efficiency for real-time in vivo cervical tissue measurements. 
Compared to the conventional fiber-optic Raman probes with a relatively small 
collection angle (of ~13 degrees; NA=0.22) [25], our Raman probe coupled with an 
NIR-coated sapphire ball lens (diameter of 5 mm; refractive index of 1.77) offers a 
large collection angle (of up to 55 degrees) to maximize the collection of back 
scattered Raman photons from tissue. In addition, the unique round-to-line fiber 
bundle adapter connected to the Raman probe optimizes the coupling of Raman 
photons collected into the spectrometer for further improving tissue Raman 
acquisitions [67]. As a result, good quality (SNR of up to 30 at 1 s integration times) 
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HW Raman spectra in the range of 2800~3700 cm-1 can be acquired from cervical 
tissue in vivo using the rapid Raman spectroscopy system developed.  
We applied this rapid HW Raman spectroscopy for the first time for the in vivo 
diagnosis and detection of cervical precancer during clinical colposcopic examination. 
The overall intensity of Raman signals of cervical dysplasia in the region (2800~3050 
cm-1) involving proteins (e.g., 2940 cm-1) and lipids (e.g., 2850 and 2885 cm-1) were 
significantly lower than those in normal cervical tissue. Our MC simulations based on 
the two-layer (i.e., epithelium, stroma) tissue model according to the cervical tissue 
optical properties [192, 240] show that the 785-nm laser light from our ball-lens 
Raman probe can penetrate into the tissue depth of 690 m in normal cervical tissue, 
while 630 m in dysplastic tissue, thereby interrogating with cervical tissue volumes 
comprising both epithelium and stroma tissue in the cervix. Due to the changes of 
tissue optical properties (e.g., thickening of epithelium) and morphologies (e.g., higher 
cellular density resulting from the increased nucleus to cytoplasm ratios) associated 
with dysplastic transformation [72, 191], these effects significantly attenuate the 
excitation light penetration and also obscure the tissue Raman photons emitted from 
the underlying stroma in precancer tissue as compared to normal cervical tissue. 
Further MC simulations indicate that the overall Raman signals in the 2800~3050 cm-1 
emitted from normal tissue are 1.15-fold stronger than dysplastic cervical tissue, which 
is in good agreement with the observation in our HW Raman cervical tissue 
measurements (Fig. 4.1). We have also studied the differences of the two respective 
tissue layers (i.e., epithelium, and stroma) in contributions to the HW Raman signals 
between normal and dysplastic cervical tissues. The MC results show that the stroma 
tissue (i.e., collagen) in dysplasia cervical tissue contribute only about 10% to the 
overall HW Raman signal in the 2800~3050 cm-1 as compared to the 50% of 
  114
contributions from normal stroma tissue. This also explains the significant reduction of 
collagen Raman signal (at 2940 cm-1) observed in dysplasia tissue (Fig. 4.1). Similar 
results in the finding of much reduced collagen signals associated with cervical 
dysplastic changes have also been reported using fluorescence spectroscopy and 
Raman spectroscopy in the fingerprint region [100, 102, 134, 138]. On the other hand, 
we have also observed that the water vibrational signal in the 3100~3700 cm-1 is 
significant higher in dysplastic cervical tissue (Fig. 4.1), indicating the increase of 
water contents in percentage relative to all the Raman-active components in dysplastic 
cervical tissue. The increase of water concentrations associated with tumor alterations 
in other organs have also been reported using NIR spectroscopy techniques [244-246]. 
This phenomenon is probably due to the increase of certain types of aquaporins (AQPs) 
at dysplastic cervical cells which could increase the plasma membrane osmotic water 
permeability of up to 10-fold, thereby facilitating the influx of water molecules into the 
intracellular space in dysplasia tissue [247, 248]. Therefore, the distinctive spectral 
differences observed in the in vivo HW Raman spectra of normal and dysplastic 
cervical tissue in this study suggest the diagnostic potential of HW Raman 
spectroscopy for noninvasively distinguishing dysplastic tissue from normal cervical 
tissue. 
To develop the diagnostic algorithms, empirical method, intensity ratio of specific 
bands [51], was employed prior to PCA-LDA analysis. The Raman band ratio of 2850 
to 2940 cm-1, ascribed to lipid/protein, was significantly higher in precancer compared 
to normal tissue. The result is in an agreement with Raman bands ratio finding in 
fingerprint region, higher ratio of 1445/1657 cm-1 (lipid/protein) in precancer [5]. 
Besides the reason of less contribution of collagen as discussed above, the higher ratio 
may also be attributed to the increased content of lipid relative to the total Raman 
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scatterers in tissue. This ratio of lipid/protein achieved a sensitivity of 78.3%, 
specificity of 89.1% and accuracy of 83.7% in differentiating dysplasia from normal 
tissues, confirming the lipid/protein ratio as a biomarker for cervical dysplasia. 
However, the ratio method only utilized a limited number of band intensities while 
neglecting most of Raman spectral features [70]. Moreover, biological tissue is very 
complex, it is thereby likely that there are many biochemical species influencing 
diseases concurrently [70, 244]. Therefore, in this work, the multivariate statistical 
analysis (e.g., PCA and LDA) was implemented by utilizing the entire HW Raman 
spectrum (2800~3700 cm-1) to determine the diagnostically significant spectral 
features for dysplastic cervical tissue diagnosis and classification.  
With the limited HW Raman spectral datasets we acquired to date, PCA-LDA together 
with leave-one patient-out, cross-validation technique was applied to the HW Raman 
spectra for dysplastic tissue identification in an unbiased manner. The cross-validated 
diagnostic sensitivity of 93.5%, specificity 97.8% and accuracy of 95.7% achieved for 
distinguishing dysplasia from normal cervical tissue confirm the diagnostic potential of 
HW NIR Raman spectroscopy for cervical precancer diagnosis. To further verify if the 
utilization of the entire HW spectral region (i.e., 2800~3700 cm-1) is robust for 
providing good tissue classification accuracy, we have also evaluated the diagnostic 
abilities based on the two Raman sub-regions, i.e., 2800~3050 cm-1 (containing 
proteins and lipids biomolecular constituents), and 3100~3700 cm-1 (representing water 
molecule) for cervical precancer diagnosis. PCA-LDA analysis yielded a diagnostic 
sensitivity of 89.1%, specificity of 89.1% and accuracy of 89.1% in the spectral region 
of 2800~3050 cm-1; and sensitivity of 84.8%, specificity of 89.1% and accuracy of 
87% in the region of 3100~3700 cm-1, respectively, for cervix dysplasia identification. 
The highest diagnostic accuracy (~96%) achieved by employing the entire HW 
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spectral region from 2800~3700 cm-1 compared to the truncated HW Raman 
sub-regions (i.e., 2800~3050 cm-1 and 3100~3700 cm-1) further reinforces that the 
unique combination of different Raman biomolecular signals ranging from water, 
lipids to proteins (i.e., 2800~3700 cm-1) can provide good differentiation between 
normal and dysplastic cervical tissue. The overall diagnostic accuracy rate of 96% 
achieved in the 2800~3700 cm-1 in this study is, in fact, comparable with those 
achieved via Raman spectroscopy in the fingerprint spectral region (accuracy of 
90-100% in 800~1800 cm-1) for in vivo detection of cervical dysplasia [100, 102]. 
Hence, HW Raman spectroscopy (2800~3700 cm-1) together with PCA-LDA can be 
used to yield high diagnostic accuracy for in vivo detection of cervical precancer. 
However, this PCA-LDA model may be skewed to the detection of CIN 2 and 3 
because CIN 2 and 3 subjects are dominant in the total dysplasia subjects. Hence, this 
model needs to be further validated on the dataset including comparable amount of 
CIN 1 subjects. 
In addition, in the clinic diagnosis point of view, the discrimination between normal 
and dysplasia is not the whole colposcopic practice in clinic. The discrimination 
between LGSILs from HGSILs is also clinically desirable. The reason is that LGSILs 
have a high rate to regress to normal without any treatment [187] and however the 
current colposcopic diagnosis is likely to overestimate the LGSILs to be HGSILs. 
Meanwhile, discrimination between normal and LGSILs is even more challenging 
because some benign changes of cervix may also show some features of LGSILs [188]. 
For instance, HPV infection or inflammation may also exhibit vascular atypia which is 
the hallmark of higher grade lesion, and metaplasia may exhibit acetowhite due to the 
cellular changes [187, 188]. Therefore, we have also evaluated the performance of HW 
Raman spectroscopy in discriminating LGSILs from HGSILs, and LGSILs from 
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normal. For the former, 80.0% (8/10) of LGSILs and 97.2% (35/36) of HGSILs were 
distinguished correctly. For the latter, 80.0% (8/10) of LGSILs and 97.8% (45/46) of 
normal were distinguished correctly. These results show that HW Raman spectroscopy 
has the potential to differentiate LGSILs from both normal and HGSILs so as to 
eliminate the overassessment of colposcopic findings and protect LGSILs patients 
from unnecessary treatment. In addition, the results also encourage the use of HW 
Raman spectroscopy to resolve other challenges during colposcopic diagnosis, such as 
the low sensitivity to CIN 3, choice of biopsy site and inter-colposcopist variability 
[187, 188].  
4.5 Conclusion 
In conclusion, in vivo HW Raman spectra in the range of 2800~3700 cm-1 from normal 
and precancer cervical tissue can be acquired in 1 second using the rapid Raman 
system integrated with a ball lens fiber-optic Raman probe. Distinctive Raman spectral 
differences are observed for the first time between normal and dysplastic cervical 
tissue in vivo in the spectral range of 2800-3700 cm-1 which contains water, lipids and 
collagen signals. Good differentiation between normal and dysplastic cervical tissue 
can be achieved using HW Raman spectroscopy and PCA-LDA techniques. Due to the 
small data size, in vivo HW Raman measurements on a larger series of patients are 
currently in progress at NUH to further validate the clinical merits of HW Raman 
spectroscopy for the early diagnosis and detection of cervical precancer and cancer in 
vivo during clinical colposcopic examinations. In addition, clinical variables, such as 
subjects’ age, race, menopausal status, chronic disease history, deserve to be taken into 
consideration to optimize the diagnostic model. 
  118
Chapter 5  In Vivo Diagnosis of Cervical Precancer Using 
NIR-excited Autofluorescence and Raman Spectroscopy 
In this chapter, we investigated the feasibility of combining NIR autofluorescence (AF) 
and Raman spectroscopy for improving in vivo diagnosis and detection of cervical 
precancer. NIR Raman spectroscopy system coupled with a ball lens fiber-optic Raman 
probe was employed for in vivo Raman measurements on the cervix. A total of 92 in 
vivo Raman spectra (46 normal and 46 dysplasia) were acquired from the cervix of 46 
patients under the guidance of colposcopy. Multivariate statistical techniques including 
principal components analysis (PCA) and linear discriminant analysis (LDA) were 
employed to develop diagnostic algorithms for differentiating precancer from normal 
tissue based on their spectral features. Classification results obtained from the 
leave-one patient-out, cross-validation of the PCA-LDA model based on the three 
spectral datasets (i.e., Raman, NIR AF, and the combined NIR AF and Raman) yielded 
diagnostic sensitivities of 91.3%, 93.5%, 93.5%, specificities of 95.7%, 87.0%, 95.7%, 
and accuracies of 93.5%, 90.2%, 94.6%, respectively, for precancer identification. 
Receiver operating characteristic (ROC) curves confirm that the most effective 
diagnostic algorithm can be derived from the combined NIR AF and Raman technique. 
This work demonstrates that the integrated NIR autofluorescence and Raman 
spectroscopy has a potential to provide an effective and accurate diagnostic scheme for 




5.1 Introduction  
Optical spectroscopic techniques, such as fluorescence spectroscopy, diffuse 
reflectance, infrared spectroscopy and Raman spectroscopy, have been 
comprehensively investigated for ex vivo and in vivo diagnosis of malignancies in 
various organs including the cervix [25, 46, 51, 72, 78, 98, 102, 138, 175, 189, 205, 
249-251]. Light-induced autofluorescence (AF) spectroscopy has shown great promise 
in differentiating precancer from normal tissues presumably due to the fact that 
neoplastic transformation leads to the changes in  tissue morphologic structures, 
optical properties (e.g., absorption and scattering coefficients), and the content and 
distribution of endogenous fluorophores in tissue [134, 138, 249, 250]. Raman 
spectroscopy is a molecular vibrational spectroscopic technique that is capable of 
probing biochemical and biomolecular changes of tissue associated with neoplastic 
transformation [51, 98, 189]. With the use of near-infrared (NIR) light as the excitation 
light source, NIR Raman spectroscopy holds significant advantages over other 
vibrational spectroscopy techniques (e.g., IR spectroscopy) in that water exhibits very 
low absorption at the working wavelength range, and tissues exhibit far less AF than 
that using visible light excitation, leading to an increased ratio of Raman signal to AF 
background [12]. Raman spectroscopy has revealed significant differences between 
normal and malignant tissues in various organs ex vivo and in vivo [25, 51, 78, 98, 100, 
189], indicating the ability of Raman technique for cancer diagnosis. However, most 
studies have evaluated tissue Raman spectroscopy in isolation without considering the 
concomitant intense AF background from tissue. We recently found that NIR AF 
background still contained useful diagnostic information and retained the diagnostic 
ability, and hence combining Raman spectroscopy with NIR AF can enhance the 
diagnostic accuracy in skin tumor models [175]. In this study, we further extended the 
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NIR-excited tissue AF and Raman spectroscopy into a clinical setting to evaluate its 
utility for in vivo diagnosis of cervical precancer. A rapid-acquisition NIR Raman 
system coupled with a ball lens Raman probe developed in house [190] was used to 
acquire in vivo NIR Raman spectra associated with AF background from cervical 
tissue during clinical colposcopic examination. Multivariate statistical techniques, such 
as principal components analysis (PCA) and linear discriminant analysis (LDA), were 
employed to compare the diagnostic performance of Raman, NIR AF, and the 
combined Raman and NIR AF spectroscopy for classification of cervical precancer in 
vivo.  
5.2 Materials and Methods  
5.2.1 NIR Autofluorescence and Raman Instrumentation 
The NIR AF and Raman instrumentation used in this study has been described in detail 
in Chapter 3.  
5.2.2 Patients 
The patient information has been given in the section Patients in Chapter 4. 
5.2.3 Data Preprocessing 
Under the 785-nm laser excitation, the raw Raman spectra acquired in vivo from cervix 
in the 800~1800 cm-1 range comprised prominent tissue NIR AF background, weak 
tissue Raman scattering signals, and noise. Hence, the raw Raman spectra were 
smoothed by a first-order, 5-pixel Savitzky Golay filter for noise reduction [178]. The 
broad NIR AF background was fit by a 5th order modified polynomial [28, 51]. This 
polynomial was then subtracted from the raw Raman spectrum to yield the tissue 
Raman spectrum alone. Hence, three datasets including the raw Raman spectra 
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(combined Raman and NIR AF), NIR AF spectra (i.e., polynomials), and Raman 
spectra (i.e., background-subtracted raw Raman spectra) were generated, and utilized 
for multivariate statistical analysis. 
5.2.4 Multivariate Statistical Analysis 
PCA-LDA was employed for developing diagnostic algorithms and has been described 
in detail in the section Multivariate Statistical Analysis in Chapter 2.  
5.3 Results  
5.3.1 Spectral Feature Analysis 
Figure 5.1 shows the mean in vivo spectra  1 standard deviation (SD) of (a) raw 
Raman spectra (i.e., combined NIR AF and Raman), (b) NIR AF spectra, and (c) 
Raman spectra acquired from normal (n=46) and precancer (n=46) tissues in the cervix. 
It was observed that both raw Raman spectra (Fig. 5.1(a)) and background NIR AF 
(Fig. 5.1(b)) exhibited significantly higher intensity in precancer tissue as compared to 
normal tissue (paired 2-sided Student’s t-test, p<0.00l). On the contrary, Raman spectra 
showed a reduction in the overall intensity in dysplasia tissue as compared to normal 
tissue. However, due to the large inter- and/or intra-subjects variation and overlapping 
in spectral intensities illustrated by SD of all in vivo tissue spectra acquired (Fig. 5.1), 
tissue diagnosis simply based on the spectral intensity alone was precluded. It is also 
challenging in clinical settings to standardize the absolute intensities of spectral 
measurements. Therefore, in this study, we focused on analyzing the spectral variation 
in line-shape and relative intensity of NIR AF and Raman spectra associated with 
tissue neoplastic changes through normalizing each spectrum to the integrated area 
under the spectrum.  
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Figure 5.1 (a) Mean in vivo raw Raman spectra (combined Raman and NIR AF 
spectra) ± 1SD; (b) Mean in vivo NIR AF spectra (5th-polynomials) ± 1SD; and 
(c) Mean in vivo Raman spectra (background-subtracted) ± 1SD from normal 
(n=46) and precancer (n=46) cervical tissue, respectively.  
It was observed that raw Raman was a superimposition of weak Raman signal on 
relatively intense autofluorescence signal. Raman spectra of both normal and precancer 
tissues showed primary Raman bands in the vicinities of 850, 943, 1087, 1269, 1337, 
1450, 1659 and 1765 cm-1 as shown in Fig. 5.1(c). The primary Raman peaks above 
can be tentatively assigned to different biochemical bonds as following: 850 to C-C 
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stretching of collagen, 943 to C-C stretching of protein, 1087 to phosphate ion 
stretching and C-N stretching of protein, 1269 to C-N stretching and N-H bending of 
amide III, 1337 to CH2CH3 wagging of proteins and nucleic acids, 1450 to CH2 
bending of proteins and lipids, 1659 to C=O stretching of Amide I and 1765 cm-1 to 
C=O stretching of phospholipids according to literature [51, 73, 102, 175, 189]. 
Therefore, Raman spectral variations in line shape and intensity associated with tissue 
premalignant transformation can be correlated to the changes in biochemical 
composition, accounting for the diagnostic potential of NIR Raman spectroscopy for 
cervical precancer. Although no distinctive shift in Raman peak position occurred 
between normal and precancer tissues, significant relative peak intensity variation can 
be observed in the intensity-normalized Raman spectra (data not shown).  
On the other hand, NIR AF showed apparent spectral line-shape variation between 
normal and precancer. For example, NIR AF intensity declined from 800 to 1800 cm-1 
more gently in dysplasia tissue than in normal tissue. More spectral variations were 
elucidated by the NIR AF spectra ratio of normal to precancer (data not shown), which 
declined steeply from 800 to 850 cm-1, then gently from 850 to 1350 cm-1, and 
eventually kept increasing until 1800 cm-1. The spectral features above were 
subsequently utilized by PCA-LDA for developing diagnostic algorithms for 
differentiating dysplasia from normal tissues.  
5.3.2 PCA-LDA and ROC Analysis  
Figure 5.2 shows the first three diagnostically significant PC loadings yielded by PCA 
on the three datasets of: (a) raw Raman spectra, (b) NIR AF spectra and (c) Raman 
spectra. PC loadings revealed the correlation of each PC with original spectral data. 
For instance, PC 2 calculated from Raman spectra were negatively correlated with 
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Raman peak at 1087 cm-1 and positively correlated with Raman peaks at 1269 and 
1450 cm-1 with loading value of 0.83, 0.78 and 0.6, respectively. This implies that PC 2 
contains the spectral features of these three peaks. Moreover, PC loadings showed 
different patterns between NIR AF and Raman spectra. In particular, PC loadings of 
Raman spectra were characterized by narrow peaks and troughs while PC loadings 
generated from NIR AF spectra were comprised by a few broad bands. Meanwhile, 
some of the PC loading features above can also be observed in the PC loadings of raw 
Raman spectra. For example, PC 3 of raw Raman spectra showed an overall line-shape 
similar to that of NIR AF and similar peaks and troughs (i.e., trough at 1069 and peak 
at 1308 cm-1) as that of Raman spectra. This suggests that PCA on raw Raman spectra 
can extract the diagnostic information originating from both NIR AF and Raman 
spectra. The total variance covered by the PCs above was 6.7%, 7.4%, and 12.3% for 
the combined NIR AF and Raman, NIR AF and Raman spectra, respectively, indicating 
the amount of the diagnostic information contained in the respective spectral datasets 


















































Figure 5.2 Examples of the diagnostically significant principal components (PCs) 
calculated from (a) raw Raman spectra (PC3, 4.8%; PC6, 1.5%; PC7, 0.4%;), (b) 
NIR autofluorescence spectra (PC3, 3.2%; PC4, 2.5%; PC5, 1.7%;) and (c) 
Raman spectra (PC2, 7.5%; PC3, 4.5%; PC7, 0.3%), respectively.   
To illustrate the use of PC scores for the diagnostic classifications of the three 
spectroscopic techniques, Fig. 5.3 shows examples of scatter plots of the diagnostically 
significant PC scores for normal and precancer tissues: (a) raw Raman spectra (PC3 vs 
PC6), (b) NIR AF spectra (PC3 vs PC5), (c) Raman spectra (PC3 vs PC7). Simple 
straight lines can classify precancer from normal tissues with sensitivities of 84.8%, 
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80.4% and 87.0%;  specificities of 84.8%, 73.9% and 78.3% for the combined NIR 
AF and Raman, NIR AF and Raman spectra, respectively. This indicates the diagnostic 
potential of the significant PC scores yielded by the three spectral datasets. 
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Figure 5.3 Correlations between the diagnostically significant PCs scores for normal and 
precancer cervical tissue classification: (a) raw Raman spectra, PC3 vs PC6, (b) NIR AF 
spectra, PC3 vs PC5, (c) Raman spectra, PC3 vs PC7. The separation lines (PC6 = 
0.38×PC3+0.04; PC5 = 0.36×PC3+0.11; PC7 = −3.21×PC3−0.29) as diagnostic algorithms 
separate precancer from normal cervical tissue with sensitivities of 84.8% (39/46), 80.4% 
(37/46) and 87.0% (40/46); specificities of 84.8% (39/46), 73.9% (34/46) and 78.3% (36/46) 
using the three spectral datasets of raw Raman spectra (combined NIR AF and Raman spectra), 
NIR AF and Raman, respectively. 
To incorporate all significant spectral features, LDA was employed to develop tissue 
diagnostic algorithms by utilizing all the statistically significant PC scores. Then, the 
classification accuracies achieved by the PCA-LDA diagnostic algorithms were 
considered as the criterion for evaluating the performances of different spectral 
datasets in tissue diagnosis. Figure 5.4 shows the posterior probabilities of each 
spectrum belonging to normal and precancer tissue groups as calculated for (a) 
combined NIR AF and Raman spectra, (b) NIR AF spectra, and (c) Raman spectra, 
respectively. The diagnostic sensitivities of 93.5% (43/46), 93.5% (43/46) and 91.3% 
  127
(42/46); specificities of 95.7% (44/46), 87.0% (40/46), and 95.7% (44/46); and 
accuracies of 94.6% (87/92), 90.2% (83/92) and 93.5% (86/92), respectively, can be 
achieved by using the combined NIR AF and Raman, NIR AF, and Raman techniques. 
It was found that the combined NIR AF and Raman achieved the highest sensitivity as 
NIR AF, and the highest specificity as Raman and consequently the optimal overall 
accuracy. 
























Figure 5.4 Scatter plots of the posterior probability of belonging to normal and precancer 
categories calculated from the datasets of (a) combined NIR AF and Raman, (b) NIR AF, and 
(c) Raman spectra, respectively, using the PCA-LDA-based spectral classification with the 
leave-one patient-out, cross-validation method. The corresponding sensitivity, specificity and 
accuracy are: (a) 93.5% (43/46), 95.7% (44/46), and 94.6% (87/92); (b) 93.5% (43/46), 87.0% 
(40/46), and 90.2% (83/92); (c) 91.3% (42/46), 95.7% (44/46), and 93.5% (86/92), 
respectively, using the combined NIR AF and Raman, NIR AF, and Raman techniques. 
To further evaluate the performance of the PCA-LDA-based diagnostic algorithms on 
the three spectral datasets (i.e., combined NIR AF and Raman, NIR AF, and Raman), 
ROC curves were generated from the posterior probability distributions of different 
types of tissue (Fig. 5.4) as shown in Fig. 5.5. The areas under the ROC curves are 
0.996, 0.945 and 0.972 for the combined NIR AF and Raman, NIR AF, and Raman 
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techniques, respectively. This further confirms the improvement in the diagnosis 
achieved by the combined NIR AF and Raman which contains both NIR AF and 
Raman spectral signatures as compared to either of NIR AF and Raman spectra alone. 

















Figure 5.5 Receiver operating characteristic (ROC) curves of discrimination results for 
the combined NIR AF and Raman spectra, NIR AF, and Raman spectra, respectively. 
The integration areas under the ROC curves are 0.996, 0.945, and 0.972, respectively, for 
the combined NIR AF and Raman, NIR AF, and Raman techniques.  
5.4 Discussion   
Considerable research efforts have been made to develop advanced optical modalities 
for the noninvasive in vivo detection of cervical precancer during colposcopic 
examination. Optical spectroscopic techniques, such as fluorescence under the 
ultraviolet (UV) light or short-wavelength visible (VIS) light excitation, diffuse 
reflectance, light scattering and NIR Raman spectroscopy, have prevailed to date for 
cervical precancer and cancer diagnosis [102, 144, 148]. Among the different 
spectroscopic techniques, fluorescence, diffuse reflectance and light scattering are 
supposed to be complementary in detecting tissue neoplastic changes; therefore, they 
are combined for further improving the diagnosis of cervical precancer as compared to 
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the diagnosis by either of the three techniques alone [148]. Subsequently, Huang et al 
suggested that NIR AF and Raman also provide complementary information for cancer 
diagnosis in an in vitro study on mice skin model [175]. In this study, we attempted for 
the first time to combine NIR AF and Raman to improve and facilitate the in vivo 
diagnosis of cervical precancer. The diagnostic results produced by PCA-LDA 
diagnostic model calculated from the combined NIR AF and Raman, NIR AF and 
Raman demonstrate that although fairly good classification accuracy can be achieved 
by either of NIR AF and Raman alone, the diagnostic accuracy can be further 
improved by combining NIR AF with Raman.  
To date, limited work has been conducted to explore NIR AF technique for tissue 
discrimination, probably due to the fact that most of the recognized fluorophores in 
tissue are not highly fluorescent under NIR excitation as NIR light is located in the tail 
part of the fluorophores’ excitation spectrum [252]. Consequently, NIR AF spectrum is 
quite disparate from typical tissue fluorescence spectrum at the excitation of UV/VIS 
light. This also holds true for our study, showing that tissue NIR AF spectrum 
exhibited broad band almost like straight line instead of a composite of narrow spectral 
bands. Our study also showed that tissue NIR AF was more intense in precancer tissue 
as compared to normal tissue. This may be attributed to the elevated porphyrins in 
precancer tissue. The reason is probably that porphyrins exhibits an intense emission 
with significant absorption of NIR light [252]. Moreover, endogenous porphyrins is 
elevated in malignant or neoplastic tissues, due to its affinity with cancer cells [253] 
and hypervascularization which is more common in malignant tissues [254]. On the 
other hand, Raman spectra of cervix in our study showed similar prominent Raman 
peaks as reported in literature [102]. Except Raman band at 1337 cm-1, all the 
prominent Raman bands showed a decreased intensity in precancer tissue than in 
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normal tissue as reported in our previous study [175]. The intensity increase of Raman 
band at 1337 cm-1 may result from the increased nuclear content in precancerous tissue 
[51]. Besides the absolute intensity change, distinctive difference in relative band 
intensity was also found between normal and precancer tissue (data not shown). For 
instance, Raman bands at 1087 and 1659 cm-1 due to collagen exhibited lower intensity 
in precancer tissue than in normal tissue while Raman bands at 1450 and 1765 cm-1 
due to phospholipids showed otherwise [51, 98]. The relative peak intensity change 
can be related to biochemical changes (i.e., reduced collagen content and increased 
phospholipids content) associated with tissue neoplastic transformation [72, 98, 254], 
forming the base of NIR Raman spectroscopic diagnosis of cervical precancer. The 
diagnostic accuracy yielded by PCA-LDA model (i.e., 90.2% for NIR AF and 93.5% 
for Raman) further confirms the diagnostic ability of both NIR AF and Raman for 
cervical dysplasia.  
However, in most of the past and current NIR Raman studies for tissue diagnosis, the 
NIR AF background is usually discarded as non-diagnostic information. Our results 
show that Raman spectrum was superior to NIR AF background in terms of specificity 
(95.7% for Raman vs 87.0% for NIR AF). This may be explained by the fact that 
Raman spectrum shows a bigger amount of fingerprint spectral features representing 
molecular structure and composition of tissues [51, 255]. However, the diagnostic 
sensitivity (91.3%) by Raman technique was lower than that of NIR AF (93.5%). The 
relatively higher sensitivity of NIR AF to tissue dysplastic changes may be owed to the 
intense fluorescence emission from tissue, particularly compared to weak Raman 
scattering. Hence, one diagnostic technique with a sensitivity and specificity as high as 
that of fluorescence and Raman, respectively, is desirable for improving in vivo 
diagnosis of cervical dysplasia. The diagnostic results based on PCA-LDA model show 
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that the combined NIR AF and Raman achieved the highest sensitivity as NIR AF 
alone and the highest specificity as Raman alone, respectively. This indicates that 
combining NIR AF and Raman is an efficient choice of method to utilize the 
diagnostic features of both NIR AF and Raman for developing diagnostic algorithm so 
as to further improve or optimize the tissue diagnosis. The combination-induced 
improvement may be further explained as the following. It is known that tissue is 
composite of various fluorophores (e.g. keratin, collagen, lipids, etc.), of which each 
has a different autofluorescence spectral pattern under the excitation of specific 
wavelength. Meanwhile, most of the biomolecules (e.g. proteins, lipids, DNA, etc.) in 
tissue are Raman-active, showing fingerprint Raman spectral features. Consequently, 
the raw Raman spectral data (composite Raman and AF signatures) allows the 
examination of the endogenous fluorophores and morphological structures in tissue 
(autofluorescence) and the biomolecular structure and composition of tissue (Raman). 
Thereby, it can provide more diagnostic information for tissue diagnosis and 
characterization, resulting in an improvement in tissue diagnosis. Despite the small 
case number, the performances of the diagnostic algorithms derived from the combined 
NIR AF and Raman, NIR AF, and Raman spectra by using PCA-LDA with 
leave-one-out cross validation have formed a foundation and shown the potential for 
the in vivo diagnosis of cervical precancer. 
In addition, to better understand the spectroscopic diagnosis, we also evaluated the 
interaction of the NIR excitation light with cervical tissue by using Monte Carlo (MC) 
method. The propagation of 785-nm light in cervical tissue and the light interaction 
with cervical tissue were simulated based on a two-layer (i.e., epithelium and stroma) 
cervical tissue optical model [229]. The results show that more than 90% of collected 
NIR AF and Raman photons originated in the epithelium. This suggests that our 
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Raman probe coupled with a ball lens has a good depth-selectivity to the epithelium of 
cervical tissue and as a result can enhance the detection of NIR AF and Raman from 
the epithelium. Note that precancer changes are usually confined in the epithelium. 
Hence, the use of our ball lens Raman probe may improve the sensitivity for detecting 
cervical dysplasia by NIR AF and Raman. 
5.5 Conclusion 
In this study, we demonstrated that combining NIR AF and Raman can improve the 
diagnosis of cervical precancer as compared to either of NIR AF and Raman 
techniques alone. This implies that NIR AF and Raman are not necessarily competing 
approaches but could be complementary by providing informations about different 
aspects of cervical tissue under investigation. In addition to spectroscopy combination, 
these two techniques may be more expected to be combined in another form of NIR 
AF image-guided Raman spectroscopy in some clinic procedures. For example, in 
surgical resection of malignant tissue, it is desirable to delineate the tumor margin 
accurately. In this case, NIR fluorescence imaging can serve to rough the malignant 
tissue quickly and subsequently Raman spectroscopy can further confirm the tumor 
margin. Therefore, it can be concluded that Raman spectroscopy combined with NIR 
AF spectroscopy or imaging shows promise as an effective and clinically useful 
diagnostic schema for the detection of precancer and cancer as well as an aid for the 
cancer therapy. Further investigation on a larger series of patients in which the 
diagnostic algorithms are tested prospectively on new cases is ongoing to confirm 
these results. Meanwhile, the development of an in vivo NIR autofluorescence imaging 
system is also in progress for future imaging-guided Raman spectroscopic diagnosis.  
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Chapter 6 Combining NIR Raman, UV/VIS Autofluorescence 
and Diffuse Reflectance Spectroscopy for Improving Cervical 
Precancer Detection 
Optical spectroscopic techniques, such as near-infrared (NIR) Raman, 
ultraviolet/visible (UV/VIS) autofluorescence and reflectance spectroscopies, have 
shown a great potential for the detection of precancer and cancer in the cervix. 
However, these techniques are mostly employed separately and very little work has 
been done to combine these three different techniques for optimizing the diagnosis of 
pre-neoplastic (i.e., benign) and neoplastic changes (i.e., LGSILs and HGSILs) in 
cervical tissues. Therefore, in this study, we aimed at combining these three optical 
spectroscopic modalities to further improve the discrimination of cervical dysplasia. 
Eighty Raman (785-nm excitation), fluorescence (405-nm excitation) and reflectance 
spectra were acquired from the same batch of cervical biopsied tissues, including 24 
spectra from 9 benign, 34 spectra from 12 LGSILs and 22 spectra from 9 HGSILs 
tissues. Trinary classification results yielded by principal components analysis (PCA) 
and linear discriminant analysis (LDA) together with the leave-one-out, 
cross-validation method showed that Raman spectroscopy can predict benign, LGSILs 
and HGSILs cervical tissues correctly with accuracies of 83.3%, 94.1% and 100%, 
respectively, and the corresponding total accuracy is 92.5% which is higher than than 
that of fluorescence (81.3%) and reflectance (87.5%). Furthermore, the prediction was 
improved through combining NIR Raman with UV/VIS fluorescence and reflectance, 
showing accuracies of benign-100%, LGSILS-97.1% and HGSILs-100%, 
overall-98.8%. This demonstrated that NIR Raman, UV/VIS fluorescence and 
reflectance can provide complementary diagnostic information and hence be integrated 
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together for optimizing the optical spectroscopic diagnosis of cervical dysplasia as 
compared to the individual use of either of Raman, fluorescence and reflectance.  
6.1 Introduction 
Optical spectroscopic techniques, such as Raman, fluorescence and reflectance 
spectroscopy, have emerged as promising methods for ex vivo and in vivo diagnosis of 
malignancies in various organs [51, 78, 98, 100, 119, 131, 134, 138, 150, 151, 175, 189, 
190, 250, 251, 256]. In particular for cervix, Anita and coworkers succeeded in 
measuring Raman spectra in fingerprint region (1000~1800 cm-1) with 785-nm 
excitation light from cervix ex vivo and in vivo and achieved a fairly good 
differentiation among normal, and dysplastic tissues [98, 100-102]. Recently, we 
demonstrated the feasibility of using Raman spectra in HW region for discriminating 
cervical dysplasia in vivo with sensitivity of 93.5% and specificity of 97.8% [190]. 
Meanwhile, Rebecca and coworkers have done an extensive work on applying 
fluorescence spectroscopy for the detection of cervical precancer, such as optimizing 
excitation light wavelength as well as diagnostic algorithms [119, 127, 131, 134, 257]. 
Reflectance spectroscopy has also been developed for the in vivo diagnosis of cervical 
precancer [150, 151]. All the literature work above demonstrated that Raman, 
fluorescence and reflectance spectroscopies have the potential for the detection of 
cervical precancer with advantages, such as higher accuracy, noninvasive, fast and 
subjective as compared to conventional method (i.e., pap smear and colposcopy). 
Although these three different techniques can do similar diagnostic work, the 
biomarkers which are utilized by them for diagnosis are different. Specifically, Raman 
spectroscopy is a vibrational spectroscopic technique and can provide molecular 
fingerprint information about biological tissues. Therefore, it is capable of probing the 
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changes in tissue biochemical composition associated with malignant transformation 
[51, 98, 189]. The major biomarkers sensible for Raman spectroscopy include proteins, 
lipids, nucleic acids and carbohydrates [51, 98, 189]. In comparison, fluorescence 
spectroscopy is based on the transition of electronic state of atoms and molecules. It 
can mainly detect the changes in a limited number of fluorophores (i.e., tryptophan, 
flavin adenine dinucleotide (FAD), reduced form of Nicotinamide adenine dinucleotide 
(NADH), collagen and porphyrins) in tissues [258]. Reflectance spectrum is a measure 
of tissue scattering and absorption properties, which are associated with the 
morphology and architecture of tissues. From the introduction above, it can be 
concluded that Raman, fluorescence and reflectance make diagnosis through providing 
insights into different aspects of tissues. The diagnostic information (i.e., biochemical 
composition and morphology) characteristic of biological tissues could be 
complementary and thus used in combination for optimizing the optical spectroscopic 
diagnosis of pre-cancer and cancer. However, to date, most of optical spectroscopic 
diagnosis work was performed with an individual use of either of these three different 
techniques rather than in combination [259]. Therefore, in this study, we aimed to 
combine near-infrared (NIR) Raman, ultraviolet/visible (UV/VIS) fluorescence and 
reflectance spectroscopy together for the first time to improve the early diagnosis of 
cervical dysplasia. In addition, intrinsic fluorescence was retrieved for diagnostic 
algorithm development as measured fluorescence is inevitably distorted by tissue 
rescattering and reabsorption [260]. Multivariate statistical techniques, including 
principle component analysis (PCA) and linear discriminant analysis (LDA), were 
employed to develop diagnostic algorithms. The combination was implemented based 
on the strategies which produce the diagnostic decision with the use of the diagnostic 
results yielded by either of Raman, fluorescence and reflectance alone. 
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6.2 Materials and Methods 
6.2.1 Spectroscopy Instrumentation 
Figure 6.1 depicts the trimodal spectroscopic measurement setup. It comprises Raman, 
fluorescence and reflectance spectroscopy. Raman spectroscopy system has been 
described in the section Raman Instrumentation in Chapter 2. It mainly consists of a 
spectrum stabilized 785-nm diode laser (B&W TEK, Newark, DE), a transmissive 
imaging spectrograph, a NIR-optimized, back-illuminated, and deep-depletion 
charge-coupled device (CCD) detector (Holospec f/2.2, Kaiser Optical Systems, Trento, 
NJ), and a specially developed bifurcated fiber-optic Raman probe.  
Fluorescence spectroscopy mainly comprises a spectrometer (QE65000, Ocean Optics, 
Dunedin, FL), a 405-nm diode laser (LDCU12/7318, 50 mW, Power Technology, AR, 
USA) as the excitation light source and a bifurcate fiber-optic probe 
(QR400-7-VIS-NIR, working wavelength region: 400~2500 nm, Ocean Optics, 
Dunedin, FL). The probe is constructed with a single 400-µm fiber for excitation and 
six surrounding 400-µm fibers for collection. The excitation laser light is filtered by 
405-nm band pass filter (LD01-405/10-25, bandwidth=10 nm, Semrock, NY, USA) 
and then coupled into the central fiber of the probe via a SMA (SubMiniature version 
A) connector. The emitted fluorescence photons are collected by the surrounding 
collection fibers and then filtered by 405-nm long pass filter (BLP01-405R-25, cut off 
at 418 nm, Semrock, NY, USA) to block the back-scattered excitation light prior to 
being fed into spectrometer.  
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Diffuse reflectance spectroscopy is built by removing the band pass and long pass 
filters from fluorescence spectroscopy setup and replacing the laser with a tungsten 
halogen light source (LS-1, Ocean Optics, Dunedin, FL). The illumination light is 
directly coupled into the central fiber of the probe via a SMA connector. The 
back-scattered light photons are collected by the surrounding six collection fibers. The 
collected photons are eventually fed into the spectrometer to create the reflectance 
spectrum. 
Figure 6.1 Schematic of the trimodal spectroscopy system. BPF1: 785-nm band pass filter; 
BPF2: 405-nm band pass filter; LPF1: 800-nm long pass filter; LPF2: 405-nm long pass filter;  
6.2.2 Cervical Tissue Samples 
Tissue samples measured has been described in the section Cervical Tissue Samples 
in Chapter 2.  
6.2.3 Spectroscopic Measurement 
All the tissue spectroscopic measurements were done in a light-tight box which can 
































monitor, light indicators). The tissue samples were mounted onto aluminum foil for the 
measurement. Raman, fluorescence and reflectance spectra were acquired from the 
same tissue sample in tandem. The acquisition times were 1 to 3 seconds for Raman 
and fluorescence measurement and 0.1 to 0.2 seconds for reflectance measurement 
depending on the signal to noise ratio. All Raman and fluorescence spectra were 
corrected for the wavelength-dependent intensity response function of the system using 
a standard lamp (RS-10, EG&G Gamma Scientific, San Diego, CA). Diffuse 
reflectance measurement includes the acquisition of reference spectrum from Diffuse 
Reflectance Standard (WS-1, Ocean Optics, Dunedin, FL), dark spectrum with the 
light off and tissue spectrum. The reflectance spectrum is created by the calculation 
based on the following equation: 
   DRDSREL          (6.1)    
where S is the light intensity from sample, D is the dark spectrum, and R is the 
reference spectrum.  
6.2.4 Data Preprocessing 
1) Raman: Raman spectral data preprocessing has been described in the section Data 
Preprocessing in Chapter 2. 
2) Fluorescence/Reflectance: Fluorescence spectra in the region of 430~700 nm and 
reflectance spectra in the region of 400~700 nm were truncated for analysis. The 
spectrum was noise-reduced and normalized in the same way as Raman spectrum. 
3) Retrieve intrinsic fluorescence: A simple model was used to retrieve the intrinsic 
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tissue fluorescence signal from the measured fluorescence signal by correcting the 
effect of tissue reabsorption and rescattering. This model is to divide the measured 
fluorescence spectrum by the reflectance spectrum acquired from the same tissue to a 




FLFL           (6.2)   
where FLi is the retrieved intrinsic fluorescence, FLm is the measured fluorescence, 
and REL is the corresponding diffuse reflectance spectrum. The power k is the ratio 
between the path lengths of fluorescence and diffuse reflectance light which is the 
function of light wavelength due to the wavelength-dependent scattering properties of 
tissues. In this model, it is assumed to be independent of light wavelength to simplify 
the model. The power k is optimized by minimizing the hemoglobin-absorption effect 
on the fluorescence spectrum. It is noted that fluorescence and diffuse reflectance 
spectra appear to have two dips which are centered at the similar wavelength positions 
(i.e., 542 and 576 nm) for fluorescence and diffuse reflectance. With the assumption 
that the dip area represents the extent of the hemoglobin absorption, the power k is 
optimized by minimizing the dip area. The dip area is approximated by the triangle 
covering the dip. Two triangles are determined by two sets of three points (520, 542, 
560 nm) and (560, 576, 590 nm) for the two dips at 542 and 576 nm, respectively. 
Three different powers are generated by minimizing 542 nm dip area, 576 nm dip area 
and the sum of the areas of dips at both 542 and 576 nm. The corresponding 
fluorescence is denoted as intrinsic fluorescence 1, 2 and 3, respectively.  
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6.2.5 Multivariate Statistical Analysis 
The multivariate statistical methods have been described in the section Multivariate 
Statistical Analysis in Chapter 2. 
6.2.6 Strategies of Combining Raman, Fluorescence and Reflectance  
Four different strategies were employed to combine Raman, fluorescence and 
reflectance spectroscopy to explore the possibility of further improving the diagnosis 
compared to the diagnosis by either of Raman, fluorescence and reflectance alone. The 
first one is to make the final diagnosis with the majority of the predictions by different 
techniques, so called majority-determined prediction. The other three combination 
strategies were implemented by utilizing the posterior probabilities of each case 
belonging to benign, LGSILs and HGSILs, which were produced by these three 
techniques. These three strategies are to determine the combined posterior probability 
of each case belonging to benign, LGSILs and HGSILs with the product, maximum 
and mean of its posterior probabilities generated by Raman, fluorescence and 
reflectance diagnosis, which are also called product-determined, max-determined and 
mean-determined predictions, respectively. The final diagnosis was determined by the 
highest combined posterior probability of belonging to benign, LGSILs and HGSILs. 
Note that one of fluorescence datasets (i.e., measured and intrinsic fluorescence) with 
the highest accuracy, one of reflectance datasets (i.e., non-normalized and normalized 
reflectance) with higher accuracy and Raman are selected for the combination.  
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6.3 Results  
6.3.1 NIR Raman 
The results of NIR Raman have been presented in the section Results in Chapter 2. 
6.3.2 UV/VIS Fluorescence  
Figure 6.2 depicts the mean normalized fluorescence spectra of benign, LGSILs and 
HGSILs: (a) non-corrected fluorescence, (b) intrinsic fluorescence 1, (c) intrinsic 
fluorescence 2 and (d) intrinsic fluorescence 3. Non-corrected fluorescence spectra 
showed two obvious absorption dips, which however almost disappeared in intrinsic 
fluorescence 1, 2 and 3. Apart from this, non-corrected fluorescence spectra and 
intrinsic fluorescence spectra looked very alike. Obvious intensity difference among 
benign, LGSILs and HGSILs was observed, especially in the region of 475~530 nm, 
while relatively small difference in the regions of 430~475 nm and 600~700 nm. 
Moreover, the three different power k optimization criteria exhibited similar correction 
extent illustrated by almost the same spectral shape. The corresponding k values are 











































Figure 6.2 The mean normalized fluorescence spectra of benign (n=24), LGSILs (n=34) and 
HGSILs (n=22): (a) non-corrected fluorescence, (b) intrinsic fluorescence 1, (c) intrinsic 
fluorescence 2, and (d) intrinsic fluorescence 3. 
To test whether correcting the effect of tissue absorption and scattering can improve 
the tissue diagnosis and also find out the optimal correction criterion, PCA-LDA was 
employed to develop the diagnostic algorithms to evaluate the efficacy of the various 
correction methods. Figure 6.3 shows the correlation of the first five diagnostically 
significant (p<0.1) PCs with the wavelength variables: (a) PC1, PC3, PC4, PC5 and 
PC12 for non-corrected fluorescence, accounting for 69.5%, 5.68%, 1.05%, 0.8% and 
0.01% of the total variance, respectively; (b) PC1, PC2, PC5, PC11 and PC12 for 
intrinsic fluorescence 1, accounting for 71.3%, 14.1%, 1.05%, 0.02% and 0.01% of the 
total variance, respectively; (c) PC1, PC2, PC5, PC11 and PC12 for intrinsic 
fluorescence 2, accounting for 69.1%, 14.1%, 1.04%, 0.02% and 0.01% of the total 
variance, respectively; (d) PC1, PC2, PC5, PC11 and PC12 for intrinsic fluorescence 3, 
accounting for 70.7%, 14.1%, 1.04%, 0.02% and 0.01% of the total variance, 
respectively. It was observed that PC1 covers most (~70%) of the total variance for the 
four different fluorescence datasets. It also showed a big similarity in the shape and 
coefficient value among different datasets. However, there still existed a slight 
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difference on PC1 between non-corrected fluorescence and intrinsic fluorescence, 
which was that a small peak at the vicinity of 576 nm appeared in PC1 of 
non-corrected fluorescence while disappearing in PC1 of intrinsic fluorescence. This 
peak may be correlated to the blood absorption dip at 576 nm and consequently the 














































































Figure 6.3 Examples of the first five diagnostically significant principal components (PCs) 
with p-value<0.1: (a) PC1, PC3, PC4, PC5 and PC12 for non-corrected fluorescence; (b) PC1, 
PC2, PC5, PC11 and PC12 for intrinsic fluorescence 1; (c) PC1, PC2, PC5, PC11 and PC12 
for intrinsic fluorescence 2; (d) PC1, PC2, PC5, PC11 and PC12 for intrinsic fluorescence 3. 
To develop diagnostic algorithms, LDA was performed with all the significant PCs as 
input. Two LD functions were produced for the three-group classification. Figure 6.4 
shows scatter plots of two LD function weights for the four different spectral datasets. 
It was observed that the data points belonging to the same group mostly assembled 
together, indicating the efficacy of PCA-LDA for characterizing benign, LGSILs and 
HGSILs. In addition, a better separation of HGSILs cluster from the clusters of benign 
and LGSILs occurred compared to the separation between benign and LGSILs. Figure 
6.5 shows the posterior probabilities of each case belonging to benign, LGSILs and 
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HGSILs produced by the PCA-LDA diagnostic models. The distribution of the 
HGSILs was better separated from the distribution of benign and LGSILs, especially 
for the intrinsic fluorescence datasets. 

































Linear Discriminant Function 1




















































Linear Discriminant Function 1  
Figure 6.4 Scatter plots of two LD function weights for benign (n=24), LGSILs (n=34) and 
HGSILs (n=22) tissues tested with leave-one-out cross-validation: (a) non-corrected 
fluorescence; (b) intrinsic fluorescence 1; (c) intrinsic fluorescence 2; (d) intrinsic 
fluorescence 3. Key: (○ in black) benign; (Δ in blue) LGSILs; (☆ in red) HGSILs. 
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belonging to Benign (a.u.)  
Figure 6.5 Two-dimensional ternary plots of the posterior probabilities of each spectrum belonging 
to benign (n=24), LGSILs (n=34) and HGSILs (n=22), respectively, using the PCA-LDA-based 
spectral classification with leave-one-out, cross-validation method based on the four different 
dataset: (a) non-corrected fluorescence; (b) intrinsic fluorescence 1; (c) intrinsic fluorescence 2; (d) 
intrinsic fluorescence 3. Each vertex of the triangle represents a 100% confidence that the tissue is 
benign, LGSILs or HGSILs. Key: (○ in black) benign; (Δ in blue) LGSILs; (☆ in red) HGSILs. 
The predications are summarized in table 6.1. The sensitivities, specificities and 
accuracies calculated from the statistics data in table 6.1 are described in table 6.2. An 
increase was found in the diagnostic sensitivity and total accuracy of benign and 
HGSILs by intrinsic fluorescence compared to non-corrected fluorescence. In contrast, 
intrinsic fluorescence did not show any significant improvement in the identification of 
LGSILs. The overall accuracy for benign, LGSILs and HGSILs was 77.5% (62/80) for 
non-corrected fluorescence spectra while an increased rate of 81.3% (65/80) is 
achieved for intrinsic fluorescence 1, 2 and 3. 
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Table 6.1 Classification results of fluorescence-prediction for the three cervical tissue groups 














Benign 17 6 1 24 
LGSILs 2 29 3 34 
HGSILs 3 3 16 22 
Intrinsic 
fluorescence 1 
Benign 20 3 1 24 
LGSILs 6 28 0 34 
HGSILs 1 4 17 22 
Intrinsic 
fluorescence 2 
Benign 18 5 1 24 
LGSILs 5 29 0 34 
HGSILs 0 4 18 22 
Intrinsic 
fluorescence 3 
Benign 20 3 1 24 
LGSILs 5 28 1 34 
HGSILs 1 4 17 22 
Table 6.2 The sensitivity, specificity and accuracy of fluorescence-prediction for the three 










Sensitivity 70.8% (17/24) 85.3% (29/34) 72.7% (16/22) 
Specificity 91.1% (51/56) 80.4% (37/46) 93.1% (54/58) 
Accuracy 85.5% (68/80) 82.5% (66/80) 87.5% (70/80)) 
Intrinsic 
fluorescence 1 
Sensitivity 83.3% (20/24) 82.4% (28/34) 77.2% (17/22) 
Specificity 87.5% (49/56) 84.8% (39/46) 98.3% (57/58) 
Accuracy 86.3% (69/80) 83.8% (67/80) 92.5% (74/80) 
Intrinsic 
fluorescence 2 
Sensitivity 75.0% (18/24) 85.3% (29/34) 81.8% (18/22) 
Specificity 91.1% (51/56) 80.4% (37/46) 98.3% (57/58) 
Accuracy 86.3% (69/80) 82.5% (66/80) 93.8% (75/80) 
Intrinsic 
fluorescence 3 
Sensitivity 83.3% (20/24) 82.4% (28/34) 77.3% (17/22) 
Specificity 89.3% (50/56) 84.8% (39/46) 96.6% (56/58) 
Accuracy 87.5% (70/80) 83.8% (67/80) 91.3% (73/80) 
 
Due to the fact that three intrinsic fluorescence datasets showed the same overall 
accuracy, it was hard to judge which correction can provide the optimal diagnostic 
performance. Also, it is desirable to further confirm the improvement in the diagnosis 
by correcting the tissue absorption and scattering effect. Therefore, three-way ROC 
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analysis was performed on the posterior probabilities calculated from all the four 
datasets. Figure 6.6 depicts the three-way ROC surfaces for the four different spectral 
datasets. The ROC surfaces for intrinsic fluorescence spectra (Fig. 6.6(b) to (d)) 
exhibited an obvious increase in the region of TPR of HGSILs (0~1.0) and TPR of 
benign (0.75~1). The volume under the ROC surface (VUS) was calculated, which was 
0.675, 0.754, 772 and 0.74 for non-corrected fluorescence, intrinsic fluorescence 1, 2 
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Figure 6.6 Three-dimensional view of the ROC surface calculated from the posterior probabilities 
belonging to benign, LGSILs and HGSILs based on the four different datasets: (a) non-corrected 
fluorescence; (b) intrinsic fluorescence 1; (c) intrinsic fluorescence 2; (d) intrinsic fluorescence 3. 
The corresponding volumes under ROC surface are: 0.675, 0.754, 0.772 and 0.74, indicating the 
rank of the diagnostic performance based on different datasets. 
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6.3.3 Diffuse Reflectance  
Figure 6.7 shows the mean non-normalized (Fig. 6.7(a)) and normalized (Fig. 6.7(b)) 
spectra of benign, LGSILs and HGSILs. Overall, benign tissues appeared to exhibit the 
highest reflectance, HGSILs showed the weakest reflectance and LGISLs showed the 
reflectance in between. The reflectance difference between benign and dysplasia 
(LGSILs and HGSILs) was larger than that between LGSILs and HGSILs, especially 
in the blood absorption dip area in the central part of the reflectance spectrum. To 
avoid the misdiagnosis caused by the inter- and/or intra-patient variation, all the 
spectra were normalized to the integrated area under the spectrum as shown in Fig. 
6.7(b). It was observed that the spectra were altered continuously in the overall slope 
from benign to LGSILs to HGSILs. For instance, the reflectance spectrum of HGSILs 
seemed the steepest while the gentlest slope for benign and LGSILs in between. These 
spectral differences among different types of tissues indicate the potential of 
reflectance spectroscopy for the characterization of benign, LGSILs and HGSILs 
cervical tissues. 




































Figure 6.7 Mean reflectance spectra of benign (n=24), LGSILs (n=34) and HGSILs (n=22): (a) 
non-normalized spectra; (b) normalized spectra. Black: benign; Blue: LGSILs; Red: HGSILs. 
To utilize those spectral differences for tissue diagnosis, PCA was firstly used to 
reduce the data dimension from 80×383 to 80×79. Then, one-way analysis of variance 
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(ANOVA) was performed on the PC scores to find out those diagnostically significant 
PCs with p-value<0.1. Figure 6.8 shows the correlation of the first four significant PCs 
with the wavelength variable: (a) PC1, PC4, PC5, PC6 for non-normalized spectral 
dataset, accounting for 74.3%, 1.33%, 0.33% and 0.05% of the total variance, 
respectively; (b) PC1, PC3, PC4 and PC5 for normalized spectral dataset, accounting 
for 78.2%, 8.98%, 0.76% and 0.18% of the total variance, respectively. Obviously, 
PC1 covered the majority of the total variance for both non-normalized and normalized 
spectral datasets, and however showed a distinctive difference in the correlation with 
wavelength variables for the two datasets. This may be due to the intensity feature 
which was gotten rid of by normalization. Also, the correlation curves appeared to 
contain some features, of which a rough counterpart could be found in the reflectance 
spectrum, such as two absorption dips in the region of 520~600 nm. This indicates that 
the spectral features remain in the PCs after dimension reduction.  





















































Figure 6.8 Examples of the first four diagnostically significant principal components (PCs) with 
p-value<0.1: (a) PC1, PC4, PC5 and PC6 for non-normalized spectral dataset; (b) PC1, PC3 PC4 
and PC5 for normalized spectral dataset.  
To develop diagnostic algorithms, LDA was carried out with the significant PC scores 
as input. Two linear discriminant (LD) functions were generated for tri-group 
classification. Figure 6.9 depicts the scatter plots of the LD functions for (a) 
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non-normalized spectra and (b) normalized spectra. It was noticed that the spectra from 
the same type of tissue was mostly assembled into the same cluster for non-normalized 
spectra and clustering was improved for normalized spectra. Figure 6.10 presents the 
posterior probabilities of each spectrum belonging to benign, LGSILs and HGSILs.  

















































Linear Discrimination Function 1  
Figure 6.9 Scatter plots of two linear discrimination function weights for benign (n=24), 
LGSILs (n=34) and HGSILs (n=22) tissues tested with leave-one-out cross-validation: (a) 
non-normalized spectral dataset; (b) non-normalized spectral dataset; Key: (○ in black) benign; 
(Δ in blue) LGSILs; (☆ in red) HGSILs. 




































Posterior Probability belonging to Benign (a.u.)
(a)


































 Posterior Probability belonging to Benign (a.u.)  
Figure 6.10 Two-dimensional ternary plots of the posterior probabilities belonging to benign, 
LGSILs and HGSILs, respectively, using the PCA-LDA-based spectral classification with 
leave-one-out, cross-validation method based on the dataset: (a) non-normalized spectra; (b) 
normalized spectra. Each vertex of the triangle represents a 100% confidence that the tissue is 
benign, LGSILs or HGSILs. Key: (○ in black) benign; (Δ in blue) LGSILs; (☆ in red) HGSILs. 
The classification results yielded by PCA-LDA model are summarized in table 6.3 and 
the corresponding sensitivities and specificities are tabulated in table 6.4. Twenty-one 
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benigns, thirty-one LGSILs and seventeen HGSILs were predicted correctly by 
non-normalized spectra. Normalized spectra yielded the same correct predication rate 
for benign and HGSILs and improved the prediction of LGSILs by one case. Although 
both non-normalized- and normalized-based LDA models showed the same accuracy 
in predicting benign and HGSILs, the misclassification was different. For example, 
three benigns were misclassified, including two as LGSILs and one as HGSILs for 
non-normalized spectra. In contrast, three benigns were all misclassified as LGSILs for 
normalized spectra. Hence, Fig. 6.11 elucidates the prediction variation between these 
two datasets. The LDA models based on non-normalized and normalized spectra got 
into an agreement in the prediction of 82.5% of the tissue spectra.  
Table 6.3 Reflectance-prediction for the three cervical tissue groups yielded by the PCA-LDA 













Benign 21 2 1 24 
LGSILs 2 31 1 34 
HGSILs 2 3 17 22 
Normalized 
Benign 21 3 0 24 
LGSILs 2 32 0 34 
HGSILs 4 1 17 22 
Table 6.4 The sensitivity, specificity and accuracy of reflectance-prediction for the three 
cervical tissue groups yielded by the PCA-LDA diagnostic algorithms tested with 










Sensitivity 87.5% (21/24) 91.2% (31/34) 77.3% (17/22) 
Specificity 92.9% (52/56) 89.1% (41/46) 96.6% (56/58) 
Accuracy 91.3% (73/80) 90.0% (72/80) 91.3% (73/80)) 
Normalized 
Sensitivity 87.5% (21/24) 94.1% (32/34) 77.3% (17/22) 
Specificity 89.3% (50/56) 91.3% (42/46) 100.0% (58/58) 





Figure 6.11 Color coded prediction results by the PCA-LDA model based on 
non-normalized and normalized spectral datasets. column 1: histology classification; 
column 2: non-normalized reflectance; column 3: normalized reflectance. Each grid 
represents one case. Blue: benign; Green: LGSILs; Brown: HGSILs. 
To further confirm the improvement in the diagnosis achieved by using the normalized 
spectral data, three-way receiver operating characteristic (ROC) testing was performed. 
Figure 6.12 shows the three-way ROC surface. The volumes under the ROC surface 
were 0.773 and 0.78 for non-normalized and normalized spectra data, respectively, 
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Figure 6.12 Three-dimensional view of the ROC surface calculated from the posterior probabilities 
belonging to benign, LGSILs and HGSILs based on the datasets: (a) non-normalized reflectance 
spectra; (b) normalized reflectance spectra. The corresponding volumes under ROC surface are: 
0.773 and 0.78, indicating the rank of the diagnostic performance based on the two different 
datasets.  
6.3.4 Compare and Combine NIR Raman, Fluorescence and Reflectance 
The results above indicated that intrinsic fluorescence 2 is the best of the four different 
fluorescence spectra datasets with VUS of 0.772, and normalized reflectance is better 
than non-normalized reflectance with VUS of 0.78. A comparison of the VUS of 
Raman, intrinsic fluorescence 2 and normalized reflectance produced a rank of the 
diagnostic performance of these three different techniques, which is in an order of 
Raman, reflectance and fluorescence from best to worst. 
To investigate the complementarity among Raman, fluorescence and reflectance, 
normalized reflectance and intrinsic fluorescence 2 were included in the combination 
with Raman as they showed better diagnostic performance than the remaining 
reflectance and fluorescence datasets. Figure 6.13 maps the prediction results for 
individual spectroscopic methods and combined methods. It was found that Raman, 
fluorescence and reflectance got in an agreement on predicting 70% of spectra, 
implying a potential improvement room for the diagnosis of cervical dysplasia. The 
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majority-determined was eventually excluded due to the unique prediction on four 
cases by three different datasets. The diagnostic accuracies achieved by 
product-determined, max-determined, mean-determined were 97.5% (78/80), 98.8% 
(79/80) and 97.5% (78/80), respectively, which were higher than either of Raman, 
fluorescence and reflectance alone. This demonstrates that combining the different 
spectroscopic techniques have the potential to further improve the diagnosis, of which 
max-determined prediction is the optimal one.  
Figure 6.13 Color coded prediction results by combining intrinsic fluorescence 2, 
normalized reflectance and Raman. column 1: histology prediction; column 2: 
fluorescence prediction; column 3: reflectance prediction; column 4: Raman prediction; 
column 5: product-determined prediction; column 6: max-determined prediction; column 
7: mean-determined prediction; column 8: majority-determined prediction; Blue: benign; 
Green: LGSILs; Brown: HGSILs; Orange: disagreement on predicting this case by 
fluorescence, reflectance and Raman. 





6.4 Discussion  
In this study, we evaluated the diagnostic capacities of three common spectroscopic 
techniques, including NIR Raman, UV/VIS fluorescence and reflectance spectroscopy, 
for cervical precancer and moreover explored the feasibility of further improving the 
diagnosis by combining these three techniques. Thus, NIR Raman, UV/VIS 
fluorescence and reflectance spectra were measured from the same set of cervical 
biopsied tissues, including three different types of pathologies (i.e., benign, LGSILs 
and HGSILs). This allowed us to make a direct pairwise comparison of diagnostic 
ability among Raman, fluorescence and reflectance as well as combine these three 
different techniques to optimize the diagnosis of cervical precancer. Good quality 
Raman, fluorescence and reflectance spectra were successfully acquired from cervical 
tissues. Significant spectral differences of Raman, fluorescence and reflectance were 
observed among benign, LGSILs and HGSILs. The diagnostic Raman spectral features 
have been discussed in detail in the section Discussions in Chapter 2. We discussed 
fluorescence and reflectance in detail in this chapter. 
Fluorescence spectra were mainly characterized by a single broad band centered at 486 
nm and two weak absorption dips at 542 and 576 nm as shown in Fig. 6.2(a). Note that 
fluorescence photon undergoes reabsorption and rescattering by those non-fluorescent 
absorbers and scatters in tissue. This can be illustrated in part by the two weak 
absorption dips. As a result, the measured tissue fluorescence spectrum is not the 
intrinsic fluorescence but the fluorescence distorted by tissue reabsorption and 
rescattering. This distortion may deteriorate the accuracy in predicting cervical 
dysplasia by fluorescence [261]. Besides, intrinsic fluorescence also facilitates the 
quantitative analysis of the concentration change of the fluorophores with tissue 
neoplastic transformation [138]. Therefore, it is desirable to investigate the diagnostic 
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ability exclusively of intrinsic fluorescence. In recent years, some methods have been 
proposed to retrieve intrinsic fluorescence from measured fluorescence by several 
groups [260, 262]. In this study, we employed a simple model to extract intrinsic 
fluorescence proposed by Diana et al [260]. The overall line shape of intrinsic 
fluorescence spectra remains similar to the measured fluorescence spectra, except the 
vanishing of the absorption dips, indicating the efficacy of this method on retrieving 
the intrinsic fluorescence from the measured fluorescence spectra.  
The tissue fluorescence spectra at 405-nm excitation can be mostly attributed to 
NADH, FAD, collagen and porphyrins, which have been proven to be fluorescent and 
diagnostically relevant to cancerous changes in various human organs [117, 134, 138, 
261, 263-265]. In particular for cervix, NADH and FAD dominate the epithelium 
fluorescence while collagen is the major contributor to stroma fluorescence [134, 137]. 
NADH is found to be increased while FAD is decreased in precancer tissues, which 
may be due to the increased metabolic activity associated with tissue premalignancy 
[117]. Collagen shows a decreased contribution to the tissue fluorescence in precancer 
tissues [117]. This may be explained by the increased collagenases which degrade the 
fluorescing collagen-crosslink in precancer tissues. This may also be partly due to the 
changes of tissue optical properties (e.g., thickening of epithelium) and morphologies 
(e.g., higher cellular density resulting from the increased nucleus to cytoplasm ratios) 
associated with dysplastic transformation. These changes above significantly attenuate 
the excitation light penetration and also obscure the tissue fluorescence photons 
emitted from the underlying stroma in precancer tissue as compared to normal cervical 
tissue [145, 192]. Our results show that HGSILs exhibited highly reduced fluorescence 
intensity. This may be due to the reduced FAD and collagen contribution. In 
comparison, fluorescence intensity above 600 nm was elevated in HGSILs as 
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compared to benign and LGSILs. This is probably attributed to the elevated porphyrins 
showing affinity with cancer cells, which is consistent with the reported finding in 
literature [115]. The classifications by PCA-LDA diagnostic models show that three 
groups of intrinsic fluorescence spectra yielded the same overall accuracy of 81.3% 
(65/80), which was higher than that achieved by measured fluorescence spectra (77.5% 
(62/80)). This indicates that intrinsic fluorescence has the potential to discriminate 
cervical dysplasia from benign tissues. The three-way ROC-VUS confirms its 
diagnostic potential and also suggests extracting intrinsic fluorescence with criterion 2 
is optimal for tissue discrimination.  
Reflectance spectra of three tissue groups (Fig. 6.7) were dominated by three 
prominent valleys, which were located in the vicinities of 418, 542 and 576 nm, 
respectively. These three valleys are recognized to result from the hemoglobin 
absorption and have been found in diffuse reflectance spectrum of a variety of human 
tissues [150, 151, 176, 260, 261, 266]. Moreover, the overall spectral intensity 
decreased continuously as the cervix tissue progresses from benign to HGSILs as 
shown in Fig. 6.7(a). This is consistent with the findings on cervix in the literature 
[150, 151]. This decrease in the reflectance of dysplasia can be accounted for by the 
increased hemoglobin absorption due to the fact that cancer tissue shows an increased 
angiogenesis with an increased microvessel density compared to normal or benign 
tissues [193]. In addition, the normalized reflectance spectrum (Fig. 6.7(b)) showed 
that the reflectance intensity increased in the region of 625~675 nm while decreased in 
the region of 450~500 nm with the progression of tissue from benign to HGSILs, 
indicating an increase in the spectrum slope. This slope change has been reported to be 
diagnostically valuable [151]. The reflectance spectral features above build a basis for 
reflectance spectroscopy coupled with multivariate statistical techniques (i.e., 
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PCA-LDA) as a diagnostic method for cervical precancer. The classification results 
show that PCA-LDA diagnostic model calculated from normalized data achieved 
almost the same overall accuracy (70/80) except one LGSILs case improvement 
compared to non-normalized data (69/80). However, the misclassification distribution 
was different, leading to various specificities in the diagnosis of each type of tissues. 
For instance, compared to non-normalized data, normalized data showed an increased 
sensitivity and specificity for LGSILs while the same sensitivity and a lower 
specificity for benign. Three-way ROC-VUS revealed the improvement extent by 
normalized data (0.78 vs 0.773) as compared to non-normalized data.     
Comparing the diagnostic accuracy and ROC-VUS calculated from Raman, 
fluorescence and reflectance, it was obvious that Raman outperformed fluorescence 
and reflectance in differentiating among benign, LGSILs and HGSILs while 
fluorescence showed the weakest diagnostic ability. The same diagnostic ranking of 
Raman, fluorescence and reflectance was reported on breast cancer [259]. The superior 
performance of Raman over fluorescence and reflectance may be explained as below. 
Raman spectroscopy is a molecular fingerprint technique and Raman spectrum of 
biological tissue contains many narrow Raman peaks which are assigned to different 
biomolecules. This allows Raman spectroscopy to probe the tissue biolomecular 
changes associated with tissue malignant transformation with high accuracy. In 
contrast, tissue fluorescence spectrum appears to be relatively broad, flat and 
featureless due to the overlap of the emission spectra from different fluorophores [175, 
259]. This may account for the less diagnostic information and consequently the 
inferior diagnostic performance compared to Raman. As for reflectance spectroscopy, 
it provides insight into tissue absorption (i.e., haemoglobin) and scattering properties 
(i.e., reduced scattering coefficient) related to tissue morphological structures [150, 
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151, 176]. Obviously, the diagnostic information contained in reflectance spectrum is 
very limited, especially compared to Raman spectrum, leading to the relatively weaker 
diagnostic ability. As for the comparison between fluorescence and reflectance, 
discrepancy is found in literature [144, 149, 259, 260].  
Furthermore, to our knowledge, we attempted to combine Raman, fluorescence and 
reflectance to improve the diagnosis of cervical dysplasia for the first time. Before this 
study, only fluorescence, diffuse reflectance and elastic scattering spectroscopy were 
included in the combination for improving the detection of cancer and precancer, [148, 
176, 259, 260]. Our previous study demonstrated that NIR Raman and 
autofluorescence are complementary rather than competitive in cancer diagnosis [175]. 
Therefore, we got Raman involved in the combination with fluorescence and 
reflectance for improving the diagnosis of cervical precancer. The combination of 
different spectroscopy methods can be achieved mainly in two different ways, which 
are combination of spectra for developing diagnostic algorithm and combination of 
classifier (i.e., use the majority of classifiers by different methods), respectively. The 
first one was reported to succeed in combining fluorescence and reflectance for 
improving breast tissue discrimination [259]. Meanwhile, the improvement by the 
second one is also reported in literature. For example, Georgakoudi et al succeeded in 
improving the diagnosis of esophageal dysplasia by combing fluorescence, reflectance 
and light-scattering spectroscopy with this method [176]. More recently, Veld et al 
attempted to use the maximum, product and mean of each case’s posterior probabilities 
yielded by fluorescence and reflectance to improve the diagnosis [260]. We used the 
same method to combine Raman, fluorescence and reflectance in our study. Our results 
demonstrated that combining Raman, fluorescence and reflectance has the potential to 
further improve the diagnosis of cervical dysplasia and max-determined prediction is 
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found to be the optimal combination strategy for improving the diagnosis of cervical 
dysplasia. The improvement resulting from the combination above can be accounted 
for by the fact that Raman, fluorescence and reflectance describe tissue in terms of 
different aspects of tissue as discussed above: Raman spectra provide the composition 
information of various biochemicals; fluorescence spectra probe a limited number of 
fluorophores and reflectance spectra provide the information about tissue morphology 
and architecture. 
6.5 Conclusion 
In this study, we evaluated the performance of NIR Raman, UV/VIS fluorescence and 
reflectance spectroscopy in the diagnosis of cervical dysplasia. The results showed that 
NIR Raman exhibited better diagnostic ability than UV/VIS fluorescence and 
reflectance, showing an overall diagnostic accuracy of 92.5% versus 81.3% 
(fluorescence) and 87.5% (reflectance). Then, we demonstrated that the diagnosis can 
be further improved by combining NIR Raman with UV/VIS fluorescence and 
reflectance with a significantly improved overall diagnostic accuracy of 98.8%. This 
implied that Raman, fluorescence and reflectance can provide complementary 
information for tissue diagnosis by providing different aspects of tissue 
pre-malignancy and malignancy. In addition, this combination can also create a more 
comprehensive understanding of the biochemical and morphological changes 
associated with tissue cancerous transformation, which may be helpful for treatment 
design. 
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Chapter 7 Conclusions and Future Work  
7.1 Conclusions 
The entire thesis is centered on NIR Raman spectroscopic diagnosis of the dysplasia in 
the cervix. The results and findings obtained from this thesis work demonstrate that 
NIR Raman spectroscopy has the potential to emerge as a promising technique for 
screening and diagnosing cervical dysplasia, and preventing cervical cancer.  
First of all, we explored the potential of NIR Raman spectroscopy for the detection of 
cervical precancer ex vivo. An in-house developed NIR Raman spectroscopy was 
employed and a novel data acquisition program was developed on LabVIEW platform 
for Raman measurement on biopsied cervical tissues. Significant spectral differences 
were observed among various tissue pathologies (i.e., benign, LGSILs and HGSILs). 
For instance, a significant decrease occurred on the intensity of Raman peaks at 849 
(C-C stretching of proline ring and ring breathing mode of tyrosine), 1125 (C-C 
stretching of lipid, C-N stretching of protein) and 1658 cm-1 (Amide I, C=O stretching 
mode of collagen and elastin) while an increased intensity for Raman peaks at 1004 
(phenylanaline), 1339 (nucleic acid) and 1449 cm-1 (phospholipids). Empirical analysis 
(i.e., intensity ratio of Raman peaks) and multivariate statistical techniques (i.e., 
PCA-LDA) were used to develop diagnostic algorithms. The PCA-LDA diagnostic 
model can make correct prediction for 92.5% of the tissues (i.e., benign, LGSILs and 
HGSILs). The volume under three-ways ROC surface was 0.815, indicating the total 
diagnostic accuracy. In addition, tissue spectral model revealed the major origins of 
biochemical changes with tissue precancerous transformation, such as the reduced 
contribution from collagen and glycogen and elevated contribution from lipids (i.e., 
cholesterol and oleic acid) and DNA. All the results above demonstrate that NIR 
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Raman spectroscopy has the potential for cervical precancer. 
The ex vivo study above encouraged an extension of our work to an in vivo study. A 
rapid portable NIR Raman spectroscopy system with a fiber-optic Raman probe was 
developed for the in vivo Raman measurement on the cervix. The fiber-optic Raman 
probe was coupled with a ball lens to enhance the detection of Raman signal 
originating from epithelial tissue, especially the epithelium. Monte Carlo method was 
employed to evaluate the performance of the ball lens Raman probe design. The Monte 
Carlo simulation results show that tissue Raman collection efficiency can be improved 
by properly selecting the refractive index and the diameter of the ball lens for the 
Raman probe design and the depth-selectivity of Raman measurements can also be 
improved by either increasing the refractive index or reducing the diameter of the ball 
lens. The simulation and experimental validation results demonstrate that this ball lens 
Raman probe design can facilitate the depth-selected Raman measurements of 
epithelial tissue in vivo. 
With the use of the in vivo Raman system we developed, we explored the feasibility of 
NIR Raman spectroscopy in the HW region (2800~3700 cm-1) for in vivo detection of 
cervical precancer as HW Raman is free of fiber optics’ interference and is more 
intense than Raman scattering in fingerprint region (800~1800 cm-1). Significant 
differences in Raman intensities of prominent Raman bands peaking at 2850 and 2885 
cm-1 (CH2 stretching of lipids), 2940 cm-1 (CH3 stretching of proteins), and the broad 
Raman band of water (peaking at 3400 cm-1 in the 3100-3700 cm-1 range) were 
observed in normal and dysplasia cervical tissue. A PCA-LDA diagnostic model 
calculated from the HW Raman data yielded a diagnostic sensitivity of 93.5% and 
specificity of 97.8% for dysplasia tissue, demonstrating the diagnostic ability of HW 
Raman spectroscopy for cervical dysplasia.  
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We also made efforts to improve the in vivo diagnosis of cervical dysplasia through 
combining NIR autofluorescence and Raman spectroscopy. Classification results 
obtained from the leave-one patient-out, cross-validation of the PCA-LDA model 
based on the three spectral datasets (i.e., Raman, NIR AF, and the combined NIR AF 
and Raman) yielded diagnostic sensitivities of 91.3%, 93.5%, 93.5%, specificities of 
95.7%, 87.0%, 95.7%, and accuracies of 93.5%, 90.2%, 94.6%, respectively, for 
precancer identification. Obviously, optimal discrimination was achieved by combined 
NIR AF and Raman, indicating NIR Raman and autofluorescence spectral features are 
complimentary rather than competitive in tissue diagnosis. The improvement in the 
diagnosis by combining NIR AF and Raman was further confirmed by ROC testing. 
The results above demonstrate that the integrated NIR autofluorescence and Raman 
spectroscopy has the potential to provide an effective and accurate diagnostic scheme 
for non-invasive, in vivo diagnosis and detection of precancer in the cervix.  
Alternatively, UV/VIS autofluorescence and diffuse reflectance were also combined 
with NIR Raman to optimize the optical diagnosis of cervical dysplasia. The diagnostic 
accuracy yielded by PCA-LDA models indicated that NIR Raman spectroscopy 
exhibited a better performance in differentiating cervical dysplasia than UV/VIS 
autofluorescence and diffuse reflectance spectroscopy. The optimal diagnosis was 
produced by combining Raman, fluorescence and reflectance with maximum rule 
which means the diagnostic decision is determined by the maximum of the posterior 
probabilities calculated from Raman, fluorescence and reflectance. The diagnostic 
accuracies were 100%, 97.1% and 100% for benign, LGSILs and HGSILs, respectively. 
This demonstrates the complementarity of Raman, fluorescence and reflectance in 
tissue diagnosis and the feasibility of improving clinic diagnosis with an integration of 
different optical screen modalities. 
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7.2 Future Directions 
In this study, we demonstrated that NIR Raman spectroscopy has the potential for 
cervical precancer detection and also exhibit higher diagnostic accuracy as compared 
conventional screening and diagnosis methods. However, further optimization is still 
desirable prior to being as a routine clinical screening and diagnosis program to 
prevent cervical cancer. Specifically, the future works to this thesis study are proposed 
as follows: 
1) Developing a robust spectroscopy program integrated with comprehensive 
functional modules, including data acquisition, data process and multivariate statistical 
analysis. The current Raman program built on LabVIEW platform only contains data 
acquisition and process modules. However, to achieve the true real-time tissue 
diagnosis and characterization, integration of diagnostic model is necessary. 
Meanwhile, prior to the on-line diagnosis in clinic, a large database must be built to 
validate the diagnostic model. 
2) Optimizing the diagnostic model by employing other multivariate statistic 
techniques. In this study, PCA-LDA was used for developing diagnostic algorithms 
throughout the whole thesis. Apart from PCA and LDA, there exist other multivariate 
statistic techniques which have been used for developing classification functions, such 
as support vector machine (SVM), artificial neural network (ANN), cluster analysis, 
recursive partition and random forest [9, 28, 46, 54, 65, 173, 267, 268]. For example, 
Widjaja et al used SVM to develop classification model for Raman spectra [28]. A 
pretty high accuracy of 99.9% was achieved in a multi-classification among normal, 
polyp and cancer colon tissues. Therefore, a proper selection of multivariate statistic 
techniques may be one of the choices of method to optimize the diagnostic algorithm 
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to optimize the diagnosis.  
3) Developing an in vivo optical diagnostic model integrated with NIR Raman, 
UV/VIS fluorescence and reflectance spectroscopy. In this thesis, the feasibility of 
combining these three different optical spectroscopic techniques to improve the 
diagnosis of cervical dysplasia was demonstrated ex vivo. In terms of clinical 
application, a multi-model suited for in vivo spectroscopic measurement is highly 
desired. Moreover, a higher efficacy in tissue diagnosis and identification may be 
achieved by adding the imaging mode into the multi-model system in addition to the 
spectroscopy mode. For instance, imaging mode can be used to rough the malignant 
tissue quickly and subsequently spectroscopy mode can further confirm the diagnosis 
and the tumor margin.  
4) Building an in vitro cervical tissue model to mimic live tissue at various 
histopathological conditions (i.e., normal, benign, LGSILs and HGSILs) for better 
understanding the biochemical changes accounting for Raman diagnosis. Although 
tissue classification is the primary goal of the diagnostic measurements in a clinical 
setting, understanding the underlying spectral differences is crucial for further 
validating and optimizing the methodology. In this study, we tentatively attributed the 
prominent Raman peaks to specific biochemicals and also used mathematical modeling 
(i.e., least squares fitting) to reconstruct the tissue spectrum with reference spectra of 
pure biochemicals. However, the accuracy of the former is limited by the overlap of 
different Raman bands; the latter one may be affected a lot by the selection of 
reference spectra and also does not consider the interaction among different 
biochemicals in tissue. Therefore, we propose to use organotypic culture method to 
build an in vitro tissue model to resemble the in vivo cervical neoplasia. Organotypic 
culture has been proven to be able to achieve the stratification and differentiation of 
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epithelial cells which are histopathologically similar to the epithelium in vivo in skin 
[269, 270], testis [271], ovary [272], stomach [273] and cervix [274, 275]. With this 
method, we can control and manipulate tissue components and culture conditions to 
build various tissue models for Raman study. Meanwhile, Raman study on individual 
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